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ABSTRACT
A Role for Endothelial Tissue-Nonspecific Alkaline Phosphatase in Blood-Tissue Barrier
Health and Disease
Allison L. Brichacek
Sepsis is a disorder that targets the microcirculation with significant effects at blood-tissue barriers
such as the blood-brain barrier (BBB) and gut-vascular barrier (GVB). Intestinal barrier
dysfunction is thought to be one of the most important contributors to multi-organ dysfunction in
sepsis. As a common site of infection, the impaired gut allows the dissemination of bacteria, which
exacerbates the disease pathophysiology, and can lead to long-term morbidity and mortality. The
mechanisms that influence altered barrier permeability in the GVB in sepsis and other
inflammatory disorders are not well understood. Tissue-nonspecific alkaline phosphatase (TNAP)
enzyme activity, which has been shown to be highly expressed on brain microvascular endothelial
cells (BMECs), is a viable therapeutic target. TNAP activity is recognized as generally antiinflammatory in sepsis-associated acute kidney injury (AKI) through mechanisms not well
understood, and its role in health and disease at various tissue barriers has yet to be explored.
One critical barrier to studying TNAP has been a lack of specific pharmacological and genetic
tools. Therefore, we first sought to examine the effects of pharmacological and genetic
manipulation of TNAP in experimental sepsis using novel techniques. Our central hypothesis
was that pharmacological or genetic depletion of TNAP enzyme activity would result in
exaggerated barrier permeability, increased inflammation, and impaired gut homeostasis in
experimental sepsis. Initially, a genetic mouse model with over-expression of TNAP on endothelial
cells (i.e., VE-cKO) revealed that TNAP-overexpression resulted in better clinical scores and
increased survival at 48-hours post-sepsis. Additionally, mice with genetic deletion of TNAP on
endothelial cells (i.e., VE-cKO) were used to determine a role for TNAP in GVB homeostasis. We
found that VE-cKO septic mice display increased bacterial burden and increased parameters of
gut dysbiosis at 8 days post-CLP, including a decreased Firmicutes:Bacteroidetes (F:B) ratio,
decreased relative antimicrobial expression, and, at 3 days post-CLP, decreased levels of shortchain fatty acids (SCFAs). At 24 hours post-CLP, permeability to molecules ranging from 625 Da
to 69 kDa is increased in VE-cKO ileum compared to Alplfl/fl littermate controls. The differences in
permeability between intestinal segments demonstrates that TNAP’s enzyme activity may impact
each region using different mechanisms. Ultimately, our results have shown that endothelial
TNAP is protective during sepsis via two potential mechanisms: (1) decreasing bacterial burden
and gut dysbiosis by 8 days post-CLP, and (2) decreasing intestinal permeability at 24 hours post-

CLP. This work demonstrates a protective role for endothelial TNAP against GVB dysfunction
which may be applicable to a number of inflammatory diseases.
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1. Overview
Sepsis is the body’s overwhelming response to infection that can result in tissue and organ
damage, and ultimately death [1,2]. The most severe effects of sepsis are a result of the host’s
exaggerated immune response, rather than the infection itself, which can result in widespread
inflammation, leaky blood vessels, abnormal blood clotting, and organ damage [2]. A continuum
of severity from sepsis to septic shock exists in which multi-organ dysfunction syndrome
eventually leads to death. According to the Global Sepsis Alliance sepsis remains a leading cause
of death in many third-world countries and results in higher mortality rates than heart attack or
cancer. The Agency for Healthcare Research and Quality reported that estimated medical costs
to treat sepsis patients and survivors exceeded more than $20 billion in 2011. With earlier
identification of sepsis and advanced treatments, this cost could be reduced by 1.5 billion and
save approximately 92,000 lives [3–7]. There are currently no FDA-approved drugs that
successfully suppress the exaggerated immune response without enhancing sepsis-associated
suppression [8]. In some cases of sepsis there are no long-term effects; however, patients
hospitalized due to sepsis have an increased risk of death and poor quality of life after discharge.
Many patients suffer from impaired physical or neurocognitive functioning, mood disorders, or gait
dysfunction [9]. Importantly, sepsis may also result in long-term effects on immune function such
that sepsis survivors are more vulnerable to infection and more likely to develop sepsis in the
future [10].
Sepsis is a disorder that targets the microcirculation with significant effects at tissuevascular barriers such as the blood-brain barrier (BBB) and gut-vascular barrier (GVB). Intestinal
barrier dysfunction is thought to be one of the most important contributors to multi-organ
dysfunction in sepsis [11]. The mechanisms that influence altered barrier permeability in the GVB
in sepsis and other inflammatory disorders are not well understood. The objective of this
dissertation is to understand how tissue-nonspecific alkaline phosphatase (TNAP) contributes to
the homeostasis of the GVB. TNAP is highly expressed by cerebral endothelial cells. While recent
studies from our laboratory and others support a critical role for TNAP in BBB homeostasis, the
role of TNAP in GVB homeostasis is less clear. Despite the absence of a clearly elucidated
mechanism for TNAP in brain endothelium, emerging data suggest that manipulation of AP
activity can influence disease outcomes. Preclinical studies using experimental autoimmune
encephalomyelitis (EAE) mice treated with bovine intestinal alkaline phosphatase (bIAP) show
reduced disease severity [12]. Human recombinant alkaline phosphatase (hrecAP) has been
shown to be a promising therapeutic candidate for a number of diseases, including
hypophosphatasia (HPP) and acute kidney injury, and some of these drugs are currently in clinical
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trials [13–15]. This dissertation will address the importance of endothelial cell TNAP at the GVB
in healthy mice and using a mouse model of experimental sepsis.
2. Sepsis
2.1 Sepsis Pathophysiology
The current definition from the Sepsis-3 consortium describes sepsis as a life-threatening
organ dysfunction caused by a dysregulated host response to an infection [16]. The most common
precipitating sites for sepsis are the respiratory system, genitourinary system, and the abdomen.
Sepsis may present as a combination of various non-descript signs and symptoms making early
diagnosis difficult. For example, patients may present with fever, cold, pain, delirium, increased
heart rate, shortness of breath, diarrhea, and/or low blood pressure. The diagnosis and
management of sepsis has changed dramatically over the last 30 years. The historical definition
of sepsis was focused primarily on inflammation and incorrectly portrayed sepsis as a sequential
process that eventually ends in septic shock. In 2016, Sepsis-2 criteria were revised to current
Sepsis-3 criteria to improve consistency in classification in epidemiological and clinical trials. The
revised Sepsis-3 classification focuses on accelerated recognition and management of sepsis
[17].
In recent years, the focus in clinical treatment has shifted to severe sepsis and septic
shock, which has increased survival in hospitalized patients diagnosed with severe sepsis and
critically ill patients with septic shock who have a higher risk of multi-organ failure complications
and death [18]. This heterogeneous presentation of clinical sepsis makes disease management
and appropriate therapeutic interventions difficult. Some challenges associated with the
management of sepsis include late diagnoses, poor prognoses, inadequate therapeutics, and
post-sepsis complications. These challenges stem from late recognition and difficulties
associated with differentiation of sepsis from other illnesses in its early stage. In the later stages
of sepsis, recognition becomes easier, yet sepsis is more difficult to treat and often coincides with
multi-organ failure [17–19]. Timing is an important factor to consider in the treatment of sepsis, as
the pathophysiology of sepsis is considered as an initial hyperinflammatory phase that lasts for
several days followed by a longer immunosuppressive phase that can last for several months to
several years, as shown in Figure 1.1 [20,21].
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Figure 1.1. Immune Response in Sepsis
Typical sepsis begins with a hyperinflammatory response that can lead to early death, recovery between
days 6-8 and return to homeostasis, immunosuppression between days 7-10, or long-term dysfunction and
possible mortality. While both the innate and adaptive immune responses are involved in sepsis
pathogenesis, these are altered to be hyperreactive or immunosuppressive. Hyperinflammation typically
leads to tissue damage, but immunosuppression can lead to secondary infections.

Most sepsis cases are hospital acquired and are often comorbid with prior injury, such as
stroke, trauma, or post-surgery. Most cases of hospital-acquired sepsis are treated in the
intensive care unit (ICU). However, ICU heterogeneity can make sepsis more common in one ICU
versus another. For example, there is a higher incidence of sepsis in a trauma ICU as opposed
to a surgical ICU [18]. Alternatively, a significant number of sepsis patients are admitted to the
hospital or directly to the ICU via the Emergency Department (ED); most of these patients present
with community-acquired sepsis from pneumonia or complications from other comorbid conditions
such as diabetes [22,23]. In addition to the patient setting, the development of sepsis often
depends on several risk factors, such as age, where a proportionate relationship exists between
increasing age and sepsis acquisition [24,25]. Male sex, non-white ethnicity, and preexisting
conditions such as Alzheimer disease (AD), human immunodeficiency virus (HIV), or cancer are
also risk factors for acquisition [18,25–27].
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2.2 Animal Models of Experimental Sepsis
Understanding the mechanisms involved in the pathophysiology of sepsis requires the use
of animal models that adequately reproduce several features of the human disorder, including
both inflammation and infection. The most common animal models are cecal ligation and puncture
(CLP), the colon ascendens stent peritonitis (CASP) model, endotoxin injection, and bacterial
infusion [28]. The CLP model is regarded as the gold standard for human-like sepsis progression
in animal models [29]. Execution of this model necessitates leakage of polymicrobial feces into
the peritoneum after the cecum is punctured with a needle. Disease severity is modeled by
controlling needle size and number of punctures; however, a major limitation of this model is the
failure to maintain continuous fecal leakage due to abscess formation and necrosis of the
punctured bowel. Some investigators also administer antibiotics either at the time of injury or at
intervals post injury. Although antibiotic administration is an additional feature which mimics the
treatment regimen in human patients, the use of different antibiotic classes and dosing paradigms
across laboratories may confound the interpretation of findings when results are compared
between laboratories [28,30]. The CASP model is a newer model recently introduced to counter
the flaws of the CLP model [28,31]. The model involves the insertion of a stent at the ascending
portion of the colon, allowing continual leakage of feces into the peritoneum [28,32]. Despite
resemblance to human-like sepsis progression, the drawbacks to this model include animal
variation in colon size, fecal content, and the volume of feces that leaks into the peritoneum
[28,33]. Although these two models have provided remarkable insights to understand the
pathophysiology of sepsis in humans, they fail to fully recapitulate the comprehensive clinical
progression of sepsis in humans [28].
Two alternative sepsis models involve injection or infusion of endotoxin or bacteria. The
endotoxin model typically involves injection of lipopolysaccharide (LPS) endotoxin, a component
of Gram-negative bacterial cell walls which signals most commonly through toll-like receptor-4
(TLR4). Administration of LPS via different routes (i.e., intraperitoneal, intravenous, or
intracerebroventricular) initiates a cytokine storm that results in the release of tumor necrosis
factor alpha (TNF-α) and numerous interleukins (ILs; IL-1, IL-6, and IL-10). Injection of LPS
mimics many classical signs and symptoms of sepsis-induced inflammation, thereby providing a
basic understanding of how inflammation activates the immune response in sepsis [28,34]. One
major limitation of the LPS model is the lack of integration of the infection component. A second
limitation is that very large endotoxin doses are required in many rodent models to mimic the
pathological profile of the clinical sepsis picture observed in humans [35]. Bacterial injection is a
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less widely used model involving infusion of a bacterium, usually Escherichia coli or
Staphylococcus aureus, to initiate both inflammation and infection [28,36,37]. Different bacterial
strains used for infection present a challenge in this model, as they will produce different patterns
of sepsis progression [38]. Thus, the characteristics of the sepsis model must be considered when
interpreting the effects of sepsis on the CNS and other organ systems.
2.3 Current Pharmaceutical Interventions in Sepsis
There is a current shift in the literature regarding specific pathogens that play a role in the
inflammatory response associated with sepsis. Knowing the microbe implicated in sepsis best
dictates which appropriate antibiotic or other type of treatment is required. Whereas older studies
implicate Gram-negative bacteria necessitating antibiotic intervention in sepsis, newer studies
have begun to reveal that other pathogens like Gram-positive bacteria, fungi, and viruses can
also stimulate the inflammatory response associated with sepsis. According to recent
epidemiologic studies, Gram-positive bacteria cause approximately 50,000 more cases of sepsis
every year in the United States compared with Gram-negative bacteria [18,26,39]. Because
factors such as the type of inciting pathogen and the site of infection are good predictors of patient
mortality, it is essential that the antimicrobial agent be used to effectively treat the disease as well
as any subsequent side effects such as neurological impairment. Currently, this is often difficult
and impractical in the hospital, as the time from diagnosis to initiation of treatment is critical. In
addition, the sepsis field has faced many difficulties in developing effective therapeutics to treat
sepsis. Currently, there are no Food and Drug Administration (FDA)-approved drugs used to treat
sepsis as there have been numerous clinical trial failures over the past 15 years [40–43]. This
difficulty stems from our incomplete knowledge about the mechanisms that underlie the disease
pathology associated with sepsis. Initial suspicion of sepsis necessitates the use of non-specific
broad-spectrum antibiotics against Gram-positive (e.g., vancomycin) and Gram-negative (e.g.,
imipenem) bacteria before blood cultures become available. Following pathogen identification,
the initial antibiotic regimen is often narrowed to a single agent [44,45].
The acute phase of sepsis is embodied by a diminished production of immunoglobulin G
(IgG) because the immune system takes 1 to 2 weeks to generate sufficient IgG levels needed to
respond to an infection [46]. Therefore, the observed reduction in IgG levels has warranted the
use of immunomodulatory intravenous immunoglobulins (IVIgs) in sepsis patients [46,47]. The
mechanisms by which IVIg operates are complex and remain unclear [48,49]. However, it has
been proposed that the IVIg polyclonal IgG domains exert an immunomodulatory function by
binding Fc receptors (FcγRs) found on many immune cell types (i.e., microglia, endothelial,
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leukocyte). IVIg binding is thought to neutralize endotoxins/cytokines, inhibit complement
activation, and block leukocyte adhesion molecule binding [50–52]. Several studies have
demonstrated the efficacy of IVIg treatment in sepsis. Esen et al. showed that the administration
of IVIg enriched with IgA and IgM improved BBB permeability, reduced sickness behavior, and
improved mortality in CLP-induced rats [51]. Further investigations by the same group revealed
that the improvement in BBB integrity, neuronal destruction, and amelioration of septic
encephalopathy is mediated by the inhibition of complement 5a (C5a) [50]. A small number of
clinical meta-analytical studies have reported a decrease in mortality of sepsis patients
administered IVIg; this finding complements the results observed by Esen et al [51,53–55]. In
contrast, a larger double-blinded randomized control trial conducted in the International Neonatal
Immunotherapy Study (INIS) showed no significant differences in mortality following IVIg
administration [52,56]. Note that the studies included in the meta-analysis showing a decrease in
mortality after IVIg administration consisted of relatively small patient populations, which suggests
that these studies may not have been sufficiently powered to detect meaningful differences in
mortality [49,52,57,58]. Taken together, the apparent effects of IVIg in sepsis treatment appear to
be promising yet inconclusive. The high cost of treatment combined with unknown mechanism(s)
of action and limited efficacy in a number of publications have made it difficult for organizations
like the FDA and the Surviving Sepsis Campaign Guidelines (SSCG) to recommend IVIg as an
adjuvant in sepsis treatment [46,48,52].
3. Alkaline Phosphatases
3.1 Genetics and Cell Biology
Alkaline phosphatase (AP) was first discovered in 1923, when Dr. Robert Robison
described the presence of an enzyme abundant in animal bone that rapidly hydrolyzed
hexosemonophosphoric acid into phosphoric acid [59]. AP has since been shown to play a
significant role in human bone mineralization, confirmed by many cases of hypophosphatasia, a
rare metabolic inherited disease caused by a mutation in the ALPL gene [60–62]. There are four
isoenzymes of AP in humans, i.e. intestinal (IAP), placental (PLAP), germinal (GCAP), and tissue
nonspecific (TNAP) [63–66], which can be reviewed in [67,68]. The first three isoenzymes are
expressed in the tissues for which they are named and each is encoded by a unique homologous
gene loci in humans: ALPI, ALPP, ALPPL2, and ALPL [68,69]. The TNAP protein, also known as
bone/liver/kidney AP, is expressed by a variety of tissues including multiple cell types in the brain.
TNAP is the most abundant isoenzyme collected from blood, where approximately 50-60% is
derived from bone, 30% from the intestines, and 10-20% from the liver [70]. APs belong to the
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ectophosphatase enzyme family and are localized in multiple mammalian cells and tissues
[67,71–75]. This class of enzymes is anchored on the cell plasma membrane surface by a
glycosylphosphatidylinositol (GPI) moiety which allows them to act on substrates in the
extracellular space. APs can be localized in the lipid rafts of the plasma membrane outer leaflet
via the C-terminus to the GPI, found as a soluble protein in the serum, or as a vesicle-associated
protein in the extracellular space. GPI-anchored AP proteins can be shed from the plasma
membrane by cleavage from phosphatidylinositol-phospholipases to take on the soluble form in
blood [76,77].
Abnormal levels of AP can result in hypophosphatasia [78–80]. Thus, AP has a wellcharacterized role in skeletal mineralization, and speculation into other physiological function(s)
of AP enzymes has generated the most interest with regard to host defense. The role in
inflammation is due, in part, to its ability to neutralize endotoxins through dephosphorylation of
the lipid-A moiety converting it to the non-toxic monophosphoryl product, and it may target
bacterial components like CpG DNA and flagellin [81–83]. Similarly, AP also deactivates ATP,
which when upregulated can act as an immunological danger signal, while maintaining
homeostasis of gut bacteria [82,84,85]. Figure 1.2 summarizes AP’s actions in the periphery.

Figure 1.2. Role of Alkaline Phosphatase Isoenzymes in the Periphery
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AP plays an important role in the physiology and pathophysiology of many organ systems. AP’s actions in
the gastrointestinal, immune, and cardiovascular systems are most relevant to the systemic immune
response in ischemic stroke. A.) In the gastrointestinal system, both TNAP and intestinal AP play an
important anti-inflammatory role by neutralizing gut microbes. B.) Immune system: Numerous peptides,
lipids, and other molecules are recognized by antigen-presenting cells (APC) to activate T-cells in the
periphery. During T-cell activation adenosine triphosphate (ATP) is released, contributing to the
inflammatory environment. TNAP can convert ATP to the anti-inflammatory molecule adenosine through
stepwise conversion of ATP to adenosine diphosphate (ADP) and adenosine monophosphate (AMP). C.)
Cardiovascular system: An excess of bone AP contributes to vascular calcification, leading to stiff muscle
walls and, eventually, atherosclerosis. This figure was published in: Brichacek, AL., & Brown, CM. Alkaline
Phosphatase: A Potential Biomarker for Stroke and Implications for Treatment. Metabolic Brain Disease.
(2019) 34:3-19. doi: 10.1007/s11011-018-0322-3.

Another complication of abnormal AP serum levels in Akp2 (mouse TNAP gene) null mice
is epilepsy. Nearly three decades after its initial discovery, Shimizu showed histochemical
evidence of TNAP in the nervous system of several animal models [86]. However, the roles of
TNAP in neurological disorders remains poorly understood. Since TNAP has been shown to
interact with multiple substrates and molecules, it is highly likely that TNAP exhibits multiple
functions in the brain [78,87,88]. Depending on the cell type, TNAP can be transiently or
constitutively expressed within the central nervous system, which suggests multiple mechanisms
of gene expression across the many cell types in the brain and spinal cord [89–92]. Some data
suggest that TNAP may play a role in neurotransmitter metabolism [91,93,94], and Hanics et al.
used TNAP null mice to show that TNAP deficiency leads to decreased brain myelination and
synaptogenesis. These findings suggest that TNAP plays an important role in brain development
and that TNAP deficiency can contribute to many forms of neurological dysfunction, including
epilepsy [95]. Figure 1.3 depicts numerous presumed functions of AP in the CNS.
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Figure 1.3. Role of TNAP in the Central Nervous System
TNAP is expressed in neurons, microglia, astrocytes, oligodendrocytes, and is highly expressed
in brain endothelial cells. TNAP is localized in the lipid rafts of the plasma membrane outer leaflet
via its C-terminus to the GPI. It can also be found as a soluble protein in the serum or as a vesicleassociated protein in the extracellular space. TNAP may have a role in BBB breakdown,
neuroinflammation, and vascular dysfunction in stroke and other neurological disorders.
Inflammatory mediators such as reactive oxygen species (ROS), proteases, and inflammatory
cytokines, promote the breakdown of junctional proteins at the BBB. The loss of junctional
proteins weakens the BBB and allows activated T-cells, antigen-presenting cells (APC), other
leukocytes, and pro-inflammatory mediators to traverse the BBB, with bidirectional movement
between the brain parenchyma and cerebral circulation. These mechanisms play an important
role in the pathophysiology of ischemic stroke and other neuroinflammatory disorders. This figure
was published in: Brichacek, AL., & Brown, CM. Alkaline Phosphatase: A Potential Biomarker for
Stroke and Implications for Treatment. Metabolic Brain Disease. (2019) 34:3-19. doi:
10.1007/s11011-018-0322-3.

3.2 TNAP Global Gene Expression and Enzyme Activity
The identification of unexplored membrane proteins may be key to better understanding
the specific barrier functions of the intestine in various disease states. In turn, this knowledge may
provide novel therapeutic targets. One potential intestinal therapeutic target localized to the
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surface of intestinal epithelial and endothelial cells is AP. AP has been shown to play an integral
role in the regulation of inflammation and can be found either as a soluble form in the peripheral
circulation or in cell membranes. There are four distinct forms of AP in humans, encoded by four
separate genes: intestinal (IAP; ALPI), placental, germinal, and tissue-nonspecific alkaline
phosphatase (TNAP; ALP) [68]. TNAP, also known as bone/liver/kidney AP, is the most abundant
type within the human body, and accounts for ~70% of the soluble AP [70]. TNAP knock-out (Alpl/-

) mice are only viable for a few days post-natal, and there are very few specific pharmacological

inhibitors available, which make studying TNAP challenging. Therefore, many researchers are
turning to genetic models where TNAP is only conditionally knocked-out in one cell-type.
Although TNAP protein is present in all mammals and in most tissues, its gene (ALPL in
humans, Alpl or Akp2 in mice) expression varies among different tissues [96]. In the first of its 12
exons, the 5’-untranslated region (UTR) contains either exon 1A or 1B by alternative transcription
initiation [97]. Exon 1A is preferentially driven in osteoblasts, while exon 1B is more often initiated
by the liver and kidney [98–100]. Using marmosets, the TNAP isoform found in brain has been
shown to use the same promotor as bone; however, exon 1B is preferentially transcribed by
mouse neurons [96]. TNAP activity is also important during mouse embryo development and
appears to be the predominant AP seen in 7- to 14-day-old embryos and primordial germ cells
[101]. As of May 2021, there are 411 mutations reported in the ALPL gene mutations database
(http://alplmutationdatabase.hypophosphatasie.com/) (Access on: 13 May 2021), the majority of
which are pathogenic loss-of-function mutations that result in HPP. In addition to deficits in bone
and teeth development, the depleted TNAP activity in HPP also results in impaired neuronal
function that manifests most commonly as seizures [102–104]. Conversely, abnormally high
levels of TNAP activity in neurons can also result in seizures and neurological dysfunction
[102,105,106]. This paradox presents an interesting dynamic where TNAP activity levels must be
sustained within a specific range in order to maintain homeostasis within the nervous system.
3.3 TNAP on Endothelium: What We Know from Brain Microvascular Endothelial Cells
Most of what is known about endothelial TNAP comes from information at the BBB, as
TNAP is the only isoenzyme of AP detected in the human brain and has long been used as a
marker of brain endothelium [96,107]. The BBB’s unique structure is primarily comprised of
endothelial cells, joined my tight junctions, and surrounded by astrocyte end-feet and pericytes,
similarly to the recently described GVB. Infectious or inflammatory diseases, like sepsis, can
cause BBB permeability, and consequently induce neuroinflammation [108]. Others have
described changes in barrier permeability [109], and our lab has shown that TNAP enzyme activity
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is decreased in experimental sepsis [110]. Suppression of TNAP activity using levamisole, a
nonspecific AP inhibitor, increased brain endothelial cell permeability [107]. The mechanisms
underlying TNAP’s functional role in brain endothelium is unclear; however, data across several
species strongly suggest that TNAP plays a role in transport of specific classes of compounds
across the BBB [111], and we speculate that it may have a similar function at the GVB.
Two different TNAP isoforms, commonly described as bone TNAP and liver TNAP, are
expressed in the brain. The bone-type TNAP transcript is expressed in human and mouse brain
microvascular endothelial cells (BMECs) [96]. During development, TNAP activity in murine
cerebral microvessels is delayed and not seen until postnatal day 10. In comparison, TNAP
activity has been detected as early as embryonic day 15 in rats [96] and at 28 weeks of gestation
in humans [112]. In addition, TNAP enzymatic activity in the brain parenchyma compared to
cerebral microvessels differs from one species to another. For example, TNAP activity is weaker
in the brain parenchyma compared to cerebral microvessels in humans, monkeys, rodents,
guinea pigs, and cats [86,113–115]. Conversely, TNAP activity in cerebral microvessels is
stronger in the brain parenchyma and weaker in rabbits, frogs, and chickens [86,116].
Furthermore, there are significant differences between TNAP activity in cerebral microvessels
compared to peripheral microvessels. A comparative study assessing the TNAP activity in BMECs
compared to peripheral endothelial cells from the aorta showed that TNAP activity in BMECs is
highly elevated compared to peripheral endothelial cells [117]. In addition, Vorbrodt et al. showed
that TNAP in the endothelial cells of the liver sinusoids was absent, while skeletal endothelial cells
revealed a strong TNAP activity that was discontinuous or irregularly scattered across the plasma
membrane compared to BMECs, which showed a continuous and uniform layer of strong TNAP
enzyme activity [118]. Given these observations, species-specific and developmental differences
in TNAP protein expression and enzyme activity need to be taken into account when elucidating
the function of BMEC TNAP in animal models prior to translating these findings to human BMEC
TNAP function. Additionally, other cell types that comprise the BBB such as astrocyte end-feet
processes and pericytes also exhibit moderate TNAP activity [74,119,120]. Co-culture of BMECs
with mixed glial cells/co-cultures in vitro has been shown to drastically increase TNAP protein,
activity, and mRNA expression in BMECs compared to solo-cultures [107,121,122]. In another
study, Tio et al. used a conditioned medium from astrocytes to demonstrate that secreted
products from astrocytes were also capable of inducing an increase in TNAP activity in endothelial
cells [123].
The cellular and molecular mechanisms underlying TNAP’s functional role in brain
endothelium and BBB are unclear; however, results from numerous studies across several

12

species strongly suggest that TNAP plays a role in the transport of specific classes of compounds
across the BBB [111]. Brain endothelial cell TNAP protein may also help facilitate crosstalk
between the BBB and other cell types; in addition, a number of molecules, including cyclic
adenosine monophosphate (cAMP) and IL-6, have been shown to modulate TNAP expression.
Deracinois et al found that TNAP expression was increased in brain endothelial cells, and that
the inhibition of AP activity using levamisole, a non-specific AP inhibitor, increased brain
endothelial cell permeability [107]. We speculate that TNAP’s regulatory phosphatase activity on
a number of BBB endothelial proteins may play an important role in maintaining BBB integrity,
thereby alleviating septic encephalopathy or long-term brain dysfunction. TNAP enzyme activity
appears to be downregulated in CLP-injured mice compared with their sham-injured counterparts
[110,124]. However, the mechanistic function of TNAP in the BBB remains to be elucidated in
sepsis and is currently being investigated in our lab.
Other brain-specific functions of TNAP have been described as having a role in
proliferation and migration in the developing nervous system, control of axonal growth formation
and maturation of synapse, and dephosphorylation of extracellular phospho-tau in AD
[89,95,96,125]. Despite the absence of a clearly elucidated mechanism for TNAP in brain
endothelium and neurons, emerging data suggest that the manipulation of the AP activity can
influence disease outcomes. For example, pretreatment of EAE mice with bovine intestinal AP
reduced the disease severity through a mechanism that caused a reduction in neuroinflammation
and autoreactive T regulatory cell proliferation [12]. Increased levels of AP have also been
detected in blood of epileptic patients, suggesting its applicability as a potential biomarker for
many neurological diseases [79].
3.4 The Problem: Lack of TNAP-Specific Models is a Critical Barrier to Progress
3.4.1 Pharmacological Tools and Pharmaceuticals for TNAP
There are several commercially available TNAP inhibitors currently on the market. Lhomoarginine (hArg) and levamisole are two of the oldest inhibitors; however, these inhibitors
lack selectivity for specific isoenzymes and offer weak binding to TNAP [126,127]. Recent studies
have shown that although hArg had no effect on TNAP levels in TNAP-overexpressing mice, it
did offer some protection from myocardial remodeling through mechanisms unrelated to TNAP
inhibition [128]. Although levamisole has been used in several studies to help identify the role that
TNAP plays in health and disease [111,121,129], it is a reversible inhibitor, so cells treated with
this drug rapidly regain TNAP activity [130]. In order to identify small molecule inhibitors to target
specific AP isoforms, Millan and colleagues employed high-throughput screening approaches and
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identified several small molecule aryl sulfonamides as potent and selective TNAP inhibitors [129].
The most potent inhibitor identified in this study was 2,5-dimethoxy-N-(quinoline-3-yl)
benzenesulfonamide, or MLS-0038949. This molecule is commercially available for purchase and
most commonly referred to as TNAP inhibitor (TNAPi); this molecule is also targeted primarily for
in vitro studies (personal communication, Dr. Jose Luis Millan). Further screening for additional
candidates with higher selectivity and potency identified a second inhibitor, SBI-425, which is
more appropriate for in vivo applications [131]. SBI-425 has been used in several studies related
to vascular calcification [126,132,133], and this work shows its applicability for studying TNAP’s
role in the brain.
To date, there are few pharmaceuticals available for exogenous treatment to restore AP
activity. Enzyme replacement therapy using asfotase alfa (brand name: STRENSIQ) is the first
and only, thus-far, FDA-approved medication for patients with perinatal-, infantile-, and juvenileonset HPP [134,135]. This drug works through the cleavage of inorganic pyrophosphate (PPi) to
phosphate (Pi) so that Pi may bind with calcium to form hydroxyapatite crystals needed for healthy
bones [136–138]. Overall, this treatment has helped improve physical function and health-related
quality of life in adults with pediatric-onset HPP [133]. Recombinant human TNAP (rhTNAP)
purified from rabbit transgenic milk samples and administered to LPS-infected mice resulted in
increased survival [139]. Clinical trials using bIAP have shown functional improvement in patients
with sepsis and ulcerative colitis [137,138,140,141]. However, due to side-effects, a human
recombinant AP (recAP), which encompasses the stability afforded from placental AP and
catalytic viability of IAP, was created and has been promising in clinical trials [142,143]. In
preclinical studies recAP did not affect pulmonary inflammation or endothelial and epithelial
dysfunction in rats [144]. In a Phase II clinical trial, recAP failed to improve short-term kidney
function in patients with sepsis-associated acute kidney injury (sepsis-AKI), although an
exploratory finding showed lower mortality in patients who received recAP compared to those
who received a placebo [145]. A Phase III clinical trial is now in progress in North America and
Europe to test recAP in a larger group of patients with sepsis-AKI.

3.4.2 Mouse Models to Study TNAP
The life expectancy of mice with a global genetic deletion of the Alpl gene (Alpl-/-) averages
3–5 weeks due to HPP and neurological deficits such as seizures [78,146]. The pathophysiology
of HPP is described in a recent review that provides an excellent overview of mouse models
where Alpl is either genetically or chemically depleted [147]. Due to the side-effects from the HPP
phenotype, Alpl null mice are inadequate models to study molecular or cellular functions
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associated with TNAP beyond young adulthood. Alternatively, other researchers have employed
adult heterozygous transgenic mice (Alpl+/-) to explore the consequences of reduced TNAP
activity [148–150]. Injection of a recombinant mineral-targeted TNAP lentivirus into neonatal mice
has been shown to increase AP levels up to 60 days and reduced craniosynostosis [151,152].
Due to the wide and variable expression of TNAP in various cell types, TNAP-expressing cells
can also be targeted using the Cre-Lox system. For example, using mice with tamoxifen-inducible
inactivation of transforming growth factor ß (TGF-ß) in TNAP-expressing cells (Tnapcre;Tgfßr2fl/fl),
researchers have shown that TNAP mitigates TGF-ß-dependent cardiac and skeletal muscle
fibrosis through inactivation of SMAD2/3 transcription factors [153].
The majority of research in this field has focused on overexpression of TNAP in peripheral
endothelial cells to study vascular calcification. The cell-specific mouse models generated thus
far using Cre recombinase transgenic mice and manipulation of the TNAP gene are described in
Table 1.1. Conditional TNAP overexpression has been achieved using an HprtALPL knock-in
mouse, which is described in [154]. Briefly, this model contains a floxed “stop cassette” and
human ALPL cDNA is inserted into the hypoxanthine phosphoribosyltransferase (Hprt) locus on
the X chromosome. Cross-breeding of the HprtALPL with Cre-expressing mice results in deletion
of the stop cassette and constitutive ALPL expression within the target cell type. Because of the
nature of this X-linked system, both homozygous (HprtALPL/ALPL) and heterozygous (HprtALPL/-)
females are considered to be over-expressors, however HprtALPL/- females typically show a milder
phenotype. For example, female TagIn-Cre+/-;HprtALPL/- mice showed a much milder medial
vascular calcification (MVC) phenotype compared to male hemizygous TagIn-Cre+/-;HprtALPL/Y
mice; however, the effects in female TagInCre+/-;HprtALPL/ALPL mice were not described [154].
More recently, Alplfl/fl mice were developed; these mice possess a floxed Alpl allele,
allowing for cell-specific conditional knock-down of TNAP when crossed with Cre recombinase
transgenic mice. The authors showed that targeted deletion of TNAP on osteoblasts and selected
dental cells (Col1a1-cKO) or deletion in chondrocytes, osteoblasts, and craniofacial mesenchyme
(Prx1-cKO) mimicked the skeletal and dental manifestations of late-onset HPP [132]. These novel
genetic tools can provide much-needed clarification on the tissue- or cell-specific functions of
TNAP in health and disease, as well as provide more insight to therapeutic interventions involving
TNAP.
Table 1.1. Cell-specific In vivo mouse models for TNAP
Mouse Model
Cre-Mediated
Preclinical Outcomes
Type
Target Cell
Vascular smooth
Mice had increased AP enzyme activity,
TNAP OE
muscle cells
increased systolic blood pressure, and
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Ref.
[154]

(Tagln-Cre or
SM22-Cre)

TNAP OE

Endothelial cells
(Tie2-Cre)

TNAP OE
with “wicked
high
cholesterol”
(C57BL/6JLdlrHlb301/J)

Endothelial cells
(Tie2-Cre)

TNAP KO

Osteoblasts and
odontoblasts
(Col1a1-Cre); Early
limb bud
mesenchyme and a
subset of
craniofacial
mesenchyme
(Prx1-Cre)

increased vascular calcification. Male
TNAP-OE mice lifespan was shorter than
WT controls, as all died by 5 months of
age.
Increased AP activity was localized to the
luminal side of the aorta and vascular
networks of heart, lung, kidney, liver,
small intestine, and pancreas. No skeletal
abnormalities were detected, however in
the heart, kidney, mesentery, pancreas,
spleen, and lung parenchyma there were
calcified lesions in adult mice.
Mice displayed increased AP activity in
endothelial cells and increased subendothelial calcification nodules in their
coronary arteries, which recapitulates
murine atherosclerosis.
While both Cre recombinase drivers result
in similar phenotypes with regards to
skeletal defects in cortical and trabecular
bone, Prx1-cKO mouse long bones
appeared more severely affected. Both
models resulted in increased osteoclast
numbers on alveolar bone surfaces and
reduced alveolar bone height. Both
models resulted in cementum and
periodontal ligament defects, consistent
with periodontal disease.

[155]

[128,156]

[132]

4. Intestine
4.1 Intestine Anatomy, Physiology, and Function
The small and large intestine are a continuous tube that stretches from the stomach to
anus. The small and large intestine differ in size, with the small intestine in humans stretching 67 meters (m) in length, while the large intestine/colon is wider and shorter in length, averaging 1.5
m. The small intestine begins at the pylorus and ends at the ileocaecal valve; it is divided into
three main segments: the duodenum (closest to the stomach), jejunum, and ileum (closest to the
cecum). Each segment contains finger-like projections that create optimal surface area, known
as villi, that extend out into the intestinal lumen and participate in nutrient absorption. Intestinal
epithelial cells are continuously renewed, and extruded every 4-5 days, by stem cells arising from
the crypts of Lieberkuhn, which mature into enterocytes, Paneth cells, goblet cells, and
neuroendocrine cells. Local immune cells must also adapt to function in this ever-changing
environment. Most of the intestinal immunological processes take place in the mucosa, which
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consists of the epithelium, lamina propria and muscularis mucosa layers. Within the lamina
propria, the layer of loosely packed connective tissue that forms scaffolding for the villus, rests
the blood supply, lymph system, and nervous supply for the mucosa. Despite the close proximity
of the lamina propria and epithelium, they form very district immunological compartments [157].
While the three segments of the small intestine are mostly similar to the naked eye, they
have differing physiological functions. The epithelial cells of the duodenum and jejunum are
covered in a layer of microvilli, which further increase surface area and are embedded along with
the enzymes needed for digestion. In diseases that cause damage to the upper small intestine,
severe malabsorption, protein leakage, and malnutrition are common. Because the ileum
contributes less to nutrient absorption, the villi are shorter and contains lower levels of brush
border enzymes. The colon has little to no digestive function, and its main roles include the
reabsorption of water and elimination of waste. For a thorough review on the regional differences
of intestinal epithelial cells and lymphocytes, the reader is referred to [157]. Regional immunity is
thought to be shaped by homing molecules [158–165], as well as environmental factors, including
retinoic acid [166,167] and short-chain fatty acids [168]. The intestinal lumen contains trillions of
bacteria, whose concentration increases as you move down the length of the intestine [157,169].
Originally, the host and its commensal bacteria were thought to live fairly independent of each
other; however, it has become apparent that both influence each other and this relationship plays
a critical role in acute and chronic disease [170,171].
4.2 The Intestine in Sepsis
Sepsis is characterized by systemic bacterial infection and translocation, which are
believed to be driven by changes in the intestinal mucosa, including: increased epithelial cell
damage and hyperpermeability, increased inflammatory signaling, and alterations in the mucus
layer. During sepsis, the gut must combat these pathogens and navigate food antigens while
avoiding inflammatory responses to commensal bacteria that form the microbiome to maintain
homeostasis [172]. Critically ill patients who present with three or more gastrointestinal signs of
distress on day one in an ICU, or who have elevated levels of intestinal distress markers, have
an increased risk of mortality [173–175]. Sepsis induces intestinal barrier dysfunction and
hyperpermeability, which allows bacteria and bacterial products to move from the lumen into
intestinal tissue and enter circulation [11,176–178]. In preclinical models of sepsis, changes in
the expression of tight junction proteins occurs as early as 1 hour, and intestinal hyperpermeability
persists for at least 48 hours, after sepsis [11]. Intestinal epithelial apoptosis is increased in clinical
and preclinical models of sepsis through activation of death-receptor and mitochondrial pathways
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[179]. In sepsis, the intestinal bacteria shift from a state of commensal to pathogenic microbes,
which amplifies the effects of permeability and apoptosis. Additionally, clinical therapies used to
alleviate sepsis, including the use of antibiotics, proton-pump inhibitors, and parenteral nutrition
aids in further depletion or alteration of the natural microbiota. In general, this transition from a
healthy intestinal microenvironment to one that is more pathogenic, is termed “dysbiosis” [180].
This term encompasses features involved in the loss of microbial diversity, dominance of
pathogenic organisms, and alterations in bacteria to appear more virulent [181,182]. The
mechanisms involved in this transition have not been completely elucidated, but it is clear that its
understanding is important for determining host outcome. While the intestine itself is perturbed
after sepsis, it is important to emphasize that crosstalk between the intestinal microenvironment
and extra-intestinal tissues, such as the vasculature and the brain, impacts cells and tissues
outside of its local environment [169].
4.3 Alkaline Phosphatases in the Intestine
Originally, the small intestine of adult mice was thought to express IAP exclusively [183],
although TNAP was transiently expressed in the fetal stage [184]. Today, it has been shown that
while IAP is expressed on the brush border of epithelial cells, TNAP is expressed by leukocytes,
endothelial cells, and other cell types that make up intestinal tissue.
4.3.1 Intestinal Alkaline Phosphatase
IAP has become one of the best-characterized AP isoforms, and has classically been
assumed to participate in nutrient absorption due to its location. Besides controlling lipid
absorption [185], IAP has roles in intestinal homeostasis involving bicarbonate secretion
[186,187], controlling inflammation and infection [81,84,188,189], and limiting bacterial
translocation across the mucosal barrier [190–192]. Malnourishment and starvation can lower the
synthesis of new IAP. IAP-KO (Akp3-/-) mice have increased gut permeability using 4 kDa- and
10 kDa-dextran-FITC extravasation into the serum; this is accompanied by reduced mRNA
expression of Cldn1, Ocln, and ZO-1 [193]. IAP supplementation reduces age-induced barrier
dysfunction, metabolic dysfunction, and increases mouse life-span [194]. In CLP-induced sepsis,
IAP treatment had no effect on clinical outcomes, but reduced small intestine permeability by 50%
[192]. Because of the proximity of immune and endothelial cells within the lamina propria to
epithelial cells and the commensal bacteria, it’s possible that TNAP within the intestine has some
redundant roles to IAP. A study using WAG/RjjCmcr rats showed that following radiation-induced
intestinal injury, IAP mRNA is reduced, while TNAP mRNA is upregulated [195].
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4.3.2 Tissue-Nonspecific Alkaline Phosphatase
TNAP knock-out (Alpl-/-) mice are not viable and usually only survive for 2-3 weeks postbirth [78,146]. TNAP haplodeficient (Alpl+/-) mice can live to adulthood and are indistinguishable
in appearance and behavior from their control counterparts. Interestingly, in these mice mRNA
expression is decreased in all organs examined, including the duodenum, jejunum, ileum, and
colon by approximately 50%, however enzymatic activity was only significantly decreased in the
ileum [148]. Similarly, gene knockdown in adipocytes results in largely reduced mRNA (85-97%
abolition), but only somewhat reduced AP activity (15-47%) [196]. This suggests that AP enzyme
activity, typically measured using p-nitrophenylphosphate (pNPP) as substrate, is largely
insensitive to the TNAP ‘gene dose’ [148]. The intestine of Alpl-/- mice appear proportional to their
body in length, but contain large amounts of gas, while Alpl+/- littermates have normal amounts of
gas [197]. This gaseous distention in the small intestine is likely due to a low proportion of enteric
neurons in the submucosa and muscular layer. Microscopically, Alpl-/- mucosa of the small
intestines and colon appears thinner. It is important to note, however, that due to severe skeletal
and dental malformations, and seizures, Alpl-/- mice appear malnourished, which would affect the
health of both their neurons and intestines [198]. Unfortunately, these general knock-out models
do not allow for easy identification of cell-specific TNAP functions in vivo.
In inflammatory bowel disease, it’s been shown that an increase in colonic TNAP is due
to both an influx of leukocytes into the inflamed colon, as well as enhanced expression in epithelial
cells [199–201]. While TNAP is expressed on lymphocytes with low baseline levels, it appears to
have a role in the differentiation of B and T lymphocytes. TNAP activity is upregulated on activated
B cells and correlates with antibody secretion; this likely relates to its general mechanism, allowing
TNAP to control the proliferation-differentiation ratio by dephosphorylation [202,203]. Others have
shown that T cells from Alpl+/- mice exhibit a reduced response to stimuli in vitro and in vivo,
suggesting TNAP is needed for complete stimulation of T cells [148]. TNAP is also expressed by
neutrophils and macrophages, although it’s possible functions remain unclear [199,204].
5. Blood-Tissue Barriers
Specialized compartments in the body act as gatekeepers to strictly control the movement
of solutes and cells between the blood and tissue [205]. This concept was discovered over a
century ago, when experiments administering dyes to laboratory animals failed to stain the brain
and testes [206–208]. This dissertation will discuss a role for endothelial TNAP at the gut-vascular
barrier (GVB), while a role has been previously established in the blood-brain barrier (BBB) by
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our lab. Figure 1.4 shows an overview of the similarities of the BBB and GVB, where TNAP is
expressed by endothelial cells at both barriers.
5.1 The Blood-Brain Barrier (BBB)
The concept of the BBB arose from studies by Paul Ehrlich through observations that dyes
injected intravenously in the periphery did not penetrate the brain [206]. Later studies by Reese
and Karnovsky revealed that the inability of the dye to penetrate the brain from the periphery was
due to the modifications of the CNS capillary components in the brain compared to other organs.
These modifications include lack of fenestrations and the presence of tight junction (TJ) proteins
between adjacent brain endothelial cells [209]. Subsequent studies revealed that the construct
observed by Reese and Karnosky also included astrocyte end feet processes, pericytes that
ensheath the basement membrane, and brain capillary endothelial cells; cooperation among
these cell types is critically important for the regulation and the movement of most substances
from the periphery into the brain parenchyma. This vascular interface is known as the BBB, and
it is required for maintenance of precise cerebral homeostasis [210,211]. The concept of the
neurovascular unit (NVU) emphasizes the continual crosstalk and interactions between the BBB,
other resident CNS cells such as neurons, microglia, and oligodendrocytes, and peripheral
immune cells. Thus, BBB-NVU interactions form a network in which all cells are under constant
surveillance and adapt their behavior to accommodate both healthy and disease states [211].
Readers are referred to several excellent reviews on the BBB and NVU [211–214].
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Figure 1.4. Tissue-Nonspecific Alkaline Phosphatase (TNAP) at the BBB and GVB
The BBB and GVB are specialized compartments that strictly regulate the flow of molecules and
cells into and out of circulation and tissues. Amongst other cell types, TNAP is expressed by the
endothelial cell of the blood-brain and gut-vascular barriers. TNAP is bound to the cell membrane
by a GPI anchor, and can become soluble to enter the circulation or tissue when cleaved.
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The infiltration of immune cells from the periphery into the brain is a central indication that
other components of the BBB such as TJ proteins and cytoskeletal proteins may be dysfunctional.
Loss of BBB integrity is well documented in neuropathologies like multiple sclerosis (MS), AD,
epilepsy, traumatic brain injury (TBI), and stroke [215,216]. At the onset of inflammation,
peripheral leukocytes migrate through the tightly regulated BBB and enter myriad CNS
compartments, including, but not restricted to, the cerebrospinal fluid (CSF), choroid plexus [217],
meninges, perivascular spaces, and eventually into the cerebral parenchyma [218]. Migration of
leukocytes across the BBB during inflammation is a multi-step process. Two distinct pathways of
leukocyte trans-endothelial migration (TEM) have been described in the literature. Paracellular
diapedesis involves the trafficking of leukocytes via adjacent endothelial cell junctions, while
transcellular diapedesis occurs via the formation of pore-like structures in endothelial cells that
fosters an active protrusion of leukocytes pseudopods into the endothelial cell body [219,220].
Although paracellular diapedesis is a favored mechanism for leukocyte extravasation in periphery
tissues, the complexity and intricacies of brain endothelial cells allow certain immune cell types
to favor transcellular diapedesis over paracellular diapedesis [219]. Extravasation of leukocytes
across the BBB has been implicated in many neurological diseases such as MS, stroke, and lifethreatening infections like sepsis [221–223].
Numerous studies have shown reduced expression of TJ proteins (occludin and claudin5) and the upregulation of metalloproteinases (MMPs) in human brain microvascular endothelial
cells after treatment with the serum of MS patients [224–227]. Furthermore, the reorganization of
BBB actin cytoskeleton via proinflammatory cytokines in MS patients contributes to the decreased
expression of TJ proteins [228,229]. Likewise, oxidative stress at the BBB during the ischemic
and reperfusion phases in stroke may also induce BBB dysfunction. In vitro oxygen-glucose
deprivation and in vivo middle cerebral artery occlusion (MCAO) experiments conducted by Liu
et al. showed that TJ proteins are decreased and redistributed along with an associated increase
in MMP-2 [230]. These findings demonstrate the importance of the BBB in cerebral homeostasis
and highlight the changes that occur when BBB integrity is perturbed.

5.2 The Gut-Vascular Barrier (GVB)
The intestine has historically been thought to comprise three main components: 1) a single
cell epithelial layer, 2) the microbes that live within the gut lumen, 3) and the host immune system
which closely monitors the existence of these commensal bacteria. While the intestinal epithelium
has several vital roles in human health, including being the primary location for food absorption,
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aiding in the secretion of hormones, providing a semi-permeable barrier for separation between
the host and gut lumen, and aiding in host defense against invading microorganisms [169], recent
studies have shown that this is not the only gut barrier that needs breached for dissemination of
bacteria in sepsis. The existence of a GVB has recently been characterized as an equally
important endothelial intestinal barrier. Arguably, the most critical feature of an endothelial cell
barrier is to control paracellular trafficking and the movement of solutes and fluids through a
complex system of TJ and adherens junction (AJ) proteins. Several of these proteins identified to
be expressed by enteric endothelial cells include occludin, zonula occludens-1 (ZO-1), cingulin,
junctional adhesion molecule-A (JAM-A), vascular endothelial cadherin (VE-cadherin), and ßcatenin. Most importantly, the authors showed that the ability of nonpathogenic bacteria to cross
the epithelial barrier was not sufficient for dissemination of the bacteria to the liver or spleen [231].
This suggests that an intact endothelial barrier is also critical for the maintenance of a healthy
intestinal microenvironment.
5.3 Tissue-Gut-Microbiota Axes: Using the Blood-Brain Barrier as a Model to Study the
Gut Vascular Barrier
The BBB acts as a nexus between the brain and the gut. Ischemic stroke, MS, mood
disorders (anxiety and depression), and neurodegenerative disorders such as AD and
Parkinson’s disease (PD) have all been linked to dysfunctional bidirectional communication within
the gut-brain-microbiota axis [232–237]. Furthermore, the gut microbiome also plays an important
role in the development of tissue barriers, metabolism, and immunity in the CNS [217,238,239].
For example, the importance of the gut microbiome in early development of the BBB was
demonstrated by Braniste et al. (2014) in germ-free (GF) mice. This group showed that GF mice
(i.e., mice that have had no exposure to microbes after birth and during adulthood) had increased
BBB permeability and reduced expression of TJ proteins occludin and claudin-5 compared to
specific pathogen-free (SPF) mice, i.e., mice reared in an environment free of monitored mouse
pathogens. The authors also found that fecal transfer of bacteria that produce short-chain fatty
acids (SCFAs) from SPF mice into GF mice decreased the permeability of the BBB [239]. These
findings suggest that the products of the gut microbiome, which are primarily SCFAs, may
generate numerous responses at the BBB. The SCFA propionate has also been shown to protect
the BBB from oxidative stress via nuclear factor erythroid 2-related factor 2 (NRF2) signaling
[240]. Other studies have shown that bacterial muramyl peptides produced in the gut are found
in the brain and have been shown to be important in promoting sleep [241–243].
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Neurodegenerative diseases are also associated with alterations in the gut microbiome.
Beneficial effects of gut bacteria have been reported in several studies. Ma et al. (2018) showed
that the administration of ketogenic diet in young healthy mice shifted the gut microbiota from
proinflammatory, harmful bacteria taxa (i.e., Desulfovibrio and Turicibacter) to beneficial bacterial
taxa (i.e., Akkermansia and Lactobacillus). Beyond alterations in the gut microbiota, these mice
showed significant increases in cerebral blood flow (CBF) and Pgp transporters on the BBB that
facilitated the clearance of beta-amyloid, the primary component of extracellular plaques in AD
[244]. Other studies have also shown a protective effect of the gut microbe Clostridium butyricum
on decreasing BBB permeability via glucagon-like peptide-1 (GLP-1) in a model of TBI [245].
Although these previous studies demonstrate a beneficial effect of the gut microbiome on
maintaining BBB integrity, other studies suggest that the gut microbiome may also have
deleterious effects. A notable instance of the microbiome causing BBB dysfunction is in the
context of sepsis, a life-threatening systemic inflammatory condition. Studies that address the role
of the gut microbiome in preclinical models of sepsis have shown that shifts in the gut microbiome
are associated with an impairment in BBB function, as evidenced by increased leukocyte
infiltration, upregulation of adhesion molecules, degradation of TJ proteins, and increased
expression of toll-like receptors (TLRs) on the brain endothelium [243,246–249]. Taken together,
these findings support an emerging important role for the gut-brain-microbiota axis in BBB
integrity and cerebral homeostasis.
6. Summary: Dissertation Objectives and Specific Aims
6.1 Objectives
The goal of this project was to determine a novel role for endothelial TNAP at the gutvascular barrier (GVB). The existence of a GVB with similar qualities to that of the blood-brain
barrier (BBB), has recently been characterized. This barrier, in concordance with the intestinal
epithelial barrier, controls the movements of nutrients and microorganisms into and out of the
blood; so an intact GVB is crucial for maintenance of a healthy intestinal microenvironment. In
diseases like sepsis, homeostasis is perturbed leading to increased inflammation, permeability,
and bacterial translocation from the gut. To better understand the mechanisms important for
intestine barrier function, it is critical that we understand the various proteins which reside within
these barriers, and how they can be manipulated for therapeutic purposes. Tissue-nonspecific
alkaline phosphatase (TNAP), has been historically used as a brain endothelial marker for its
abundant expression in the vasculature, yet its mechanisms of action remain largely
undetermined. Our objective was to determine a role for TNAP in the intestinal vasculature, which
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may ultimately lead to improved understanding of TNAP’s beneficial role in inflammation.
Inflammation and gut permeability in sepsis leads to increased extravasation of solutes, immune
cells, and bacteria to both systemic and local locations. Thus, our central hypothesis was that
pharmacological or genetic depletion of TNAP enzyme activity would result in exaggerated barrier
permeability, increased inflammation, and impaired microbial homeostasis in experimental
sepsis.
6.2 Specific Aims
Aim 1: Determine if pharmacological inhibition or genetic manipulation of TNAP activity is
more informative for the determination of TNAP function in healthy and septic mice.
Clinical outcome and survival were assessed in separate studies using pharmacological inhibition
or genetic manipulation of TNAP enzyme activity. Confirmation of AP manipulation was assessed
using a biochemical assay and plasma/tissue lysates.
Aim 2: Determine if endothelial TNAP activity regulates gut bacterial load, inflammation,
and gut homeostasis in healthy and septic mice.
During sepsis, there is a shift in an environment mostly of commensal microbes to those that are
pathogenic. These bacteria infiltrate the tissue and cause increased immune responses to
bacteria and bacterial products. We hypothesized that deletion of endothelial TNAP on endothelial
cells would result in increased bacterial load and dissemination after sepsis. Gut bacterial load
and translocation was assessed by comparing the quantification of culturable bacteria on brainheart-infusion agar. Additionally, the Firmicutes to Bacteroidetes ratio, fecal short-chain fatty acid
composition, and relative levels of anti-microbial genes were quantified.
Aim 3: Determine if endothelial TNAP activity regulates sepsis-associated gut-vascular
barrier permeability.
Hyperpermeability during sepsis allows solutes, bacteria, and bacterial products to escape the
intestine lumen and move into the blood stream. We hypothesized that deletion of endothelial
TNAP on endothelial cells would result in exaggerated intestinal permeability after sepsis. Gut
permeability was assessed following the injection of fluorescent molecules of various sizes, and
fluorescent intensity was quantified in whole tissue lysate and frozen tissue sections.
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6.3 Impact
This is the first study to explore a role for TNAP at the GVB. We expected to see worsened
pathological outcomes in mice that have reduced endothelial cell TNAP activity and predicted that
this would result in increased intestinal barrier permeability, perturbed homeostasis, and
increased bacterial load and bacterial translocation from the gut after sepsis. The translational
impact of this project will help to delineate novel roles for TNAP at the GVB and how TNAP plays
a critical role in the maintenance of intestinal homeostasis. Elucidating these mechanisms will
provide important insights for understanding how manipulation of TNAP can be employed to treat
dysfunction of the GVB in sepsis.
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ABSTRACT
Tissue-nonspecific alkaline phosphatase (TNAP) is a ubiquitous enzyme present in many cells
and tissues, including the central nervous system. Yet its functions at the brain-immune axis
remain unclear. The goal of this study was to use a novel small molecular inhibitor of TNAP, SBI425, to interrogate the function of TNAP in neuroimmune disorders. Following intraperitoneal (IP)
administration of SBI-425, mass spectrometry analysis revealed that the SBI-425 does not cross
the blood-brain barrier (BBB) in healthy mice. To elucidate the role of TNAP at the brain-immune
axis, mice were subjected to experimental sepsis and received either vehicle or SBI-425 (25
mg/kg, IP) daily for 7 days. While SBI-425 administration did not affect clinical severity outcomes,
we found that SBI-425 administration suppressed CD4+Foxp3+CD25- and CD8+Foxp3+CD25splenocyte T-cell populations compared to controls. Further evaluation of SBI-425’s effects in the
brain revealed that TNAP activity was suppressed in the brain parenchyma of SBI-425-treated
mice compared to controls. When primary brain endothelial cells were treated with a
proinflammatory stimulus the addition of SBI-425 treatment potentiated the loss of barrier function
in BBB endothelial cells. To further demonstrate a protective role for TNAP at endothelial barriers
within this axis, transgenic mice with a conditional overexpression of TNAP were subjected to
experimental sepsis and found to have increased survival and decreased clinical severity scores
compared to controls. Taken together, these results demonstrate a novel role for TNAP activity in
shaping the dynamic interactions within the brain-immune axis.
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Introduction
Inflammation is a vital part of the immune response and a primary component in host
defense and in the resolution of disease; it exhibits both positive and negative consequences in
the brain or in the periphery depending on the timing, location, and underlying mechanisms of
infection, injury, or disease. The mechanisms underlying brain-immune communication are
unique due, in part, to the blood-brain barrier (BBB). The BBB is a regulatory interface between
the brain and systemic circulation consisting of a network of cerebral endothelial cells linked
together by junctional adhesion molecules and surrounded by astrocytes, pericytes, and other
supportive cells. A compromised BBB due to injury or disease commonly initiates a series of
inflammatory signaling pathways which collectively result in neuroinflammation. An important
component of the neuroinflammatory response is the activation of astrocytes and microglia. While
a transient level of neuroinflammation is necessary for an appropriate immune response,
sustained and chronic levels of inflammation lead to neurological dysfunction and disease.
There are numerous proteins that work together to orchestrate an appropriate
inflammatory response in peripheral tissues and throughout the brain. Several lines of evidence
suggest that the alkaline phosphatase (AP) family of enzymes may play an important role in the
regulation of immunity. In an alkaline environment, AP catalyzes the hydrolysis of phosphate
groups from a number of substrates [250,251]. Three of the four human AP isoenzymes are tissue
specific, while the fourth and most abundant member of the family is tissue-nonspecific (i.e.,
TNAP). TNAP, also known as liver/bone/kidney AP, is ubiquitously expressed in numerous cell
types [70]. Genetic ablation or over-expression of TNAP in humans (gene: ALPL) or mice (gene:
Alpl or Akp2) demonstrates a defined role in bone and teeth mineralization as well as vascular
calcification [68,154–156]. Additionally, TNAP assists with lipopolysaccharide (LPS) and
nucleotide detoxification, and emerging evidence suggests an immunoregulatory role for TNAP
throughout the immune system [81,252]. TNAP activity is abundant within endothelial cells and
neurons of the central nervous system (CNS), and has historically been used as a marker of
cerebral microvessels [112,115,253–257]. TNAP is the only isozyme found in the brain, and
changes in TNAP activity in injured or diseased brains suggest a putative role in the regulation of
neuroinflammation [88,92,258,259].
Although APs were discovered nearly a century ago, surprisingly little is known about their
function and mechanisms due to a lack of genetic and pharmacologic tools [59]. Alpl null mice
only survive for approximately 10 days due to problems associated with hypophosphatasia and
epileptic seizures, thus limiting studies of TNAP function to the postnatal period [197]. Alpl-floxed
mice were recently used to confirm the importance of TNAP in mineralization of teeth and bone
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[132]. Previously, most pharmacological inhibitors used to interrogate TNAP function were either
non-specific for TNAP isozymes or limited to in vitro applications, thus highlighting the need for
specific inhibitors of TNAP with both in vivo and in vitro activity. 5-((5-chloro-2methoxyphenyl)sulfonamide) nicotinamide, or SBI-425, is a novel, highly specific TNAP inhibitor
[131,154]. In vivo studies demonstrate that SBI-425 suppresses aortic calcification in mice that
overexpress TNAP in smooth muscle cells, which results in reduced aortic calcification and
increased life-span [131,154]. Although the role of TNAP in the cardiac vasculature is welldescribed, a defined role for TNAP in the central nervous system and the immune system remains
unclear.
The goal of this study was to elucidate unknown functions of TNAP at the brain-immune
interface via pharmacological inhibition of the enzyme. We therefore sought to characterize the
effect of SBI-425 on inhibition of murine brain TNAP enzyme activity through pharmacological,
biochemical, histological, and behavioral approaches. In the first set of studies, we optimized a
bioassay to measure brain AP activity using ex vivo and in vivo methods of SBI-425
administration. In the second set of studies, we investigated the in vivo activity of SBI-425 during
acute systemic inflammation by using a cecal ligation and puncture model of experimental sepsis.
We hypothesized that SBI-425 administration to septic mice would suppress brain TNAP activity,
enhance neuroinflammation, and promote peripheral immunosuppression in the later stages of
sepsis. The results obtained from in vivo and in vitro pharmacological inhibition of TNAP
enzymatic activity with SBI-425 demonstrate that the loss of TNAP’s activity during systemic
proinflammatory states, i.e., sepsis, enhances disruption of the brain-immune axis. In turn, the
conditional overexpression of TNAP in brain endothelial cells improves sepsis outcomes.
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Results
In vivo SBI-425 administration does not cross the blood-brain barrier (BBB) in healthy mice
Since TNAP is highly expressed in cerebral microvessels, we sought to determine whether
SBI-425 was capable of passing through the BBB. As a preliminary analysis, we used mass
spectrometry to quantify the amount of SBI-425 detected two and eight hours following a 10 mg/kg
IP injection into healthy male C57BL/6 mice. This analysis revealed low SBI-425 concentrations
in plasma and homogenized brain tissue. At 2 hr post-injection the plasma level of SBI-425 was
21.6 µM and the brain level was 0.17 µM (brain:plasma<0.01); and at 8 hr post-injection the
plasma level of SBI-425 was 1.26 µM and the brain level was <0.014 µM (brain:plasma<0.01)
(Table 2.1). Low brain:plasma ratios at 2 hr and 8 hr post SBI-425 injection strongly suggests that
SBI-425 does not cross the BBB under normal physiological conditions.
The next set of experiments addressed whether SBI-425 could inhibit brain AP activity in
vitro. We collected plasma, brain, and bone tissue from healthy male C57BL/6 mice following
saline perfusion. Plasma and supernatants from tissue homogenates were spiked with 40 µM
SBI-425, 100 µM of an early TNAP inhibitor (TNAPi), or vehicle (DMSO) and AP activity was
kinetically read for 5 hours. TNAPi has been previously described; the in vitro efficacy is similar
to SBI-425 but due to its biochemical properties it cannot be used in vivo [129,131]. There was a
significant decrease in AP activity in all TNAPi- and SBI-425-treated samples compared to vehicle
(Figure 2.1). This decrease in TNAP activity was highest in bone (Figure 2.1c/f) compared to
significant reductions in brain homogenate and plasma (Figure 2.1a/d and 2.1b/e), thus
indicating that SBI-425 is a potent TNAP inhibitor in vitro.
SBI-425 displays in vivo TNAP inhibitory activity in plasma and brain
Given that our results showed that SBI-425 was able to inhibit brain TNAP activity in vitro,
but unable to cross the BBB in vivo, we then tested whether SBI-425 treatment could inhibit TNAP
activity in vivo via different routes. We administered a single dose of SBI-425 or vehicle solution
(10% DMSO, 10% Tween-80, 80% water) to healthy C57BL/6J mice by either intraperitoneal (IP)
or retro-orbital (IV) injection. One group of mice were injected IP with a 25 mg/kg dose of SBI-425
or vehicle, followed by plasma and brain tissue harvest at 1-, 4-, or 6-hours post-injection. A
second group of mice were injected IV with a 5 mg/kg dose of SBI-425, followed by plasma and
brain harvest at 10-, 30-, or 60-mins post-injection. Timepoints for tissue collection were different
between the two groups since we reasoned that IV injected SBI-425 would require less time to
reach the brain than IP administered SBI-425. Our results show that TNAP activity is inhibited by
SBI-425 in plasma at all time-points for both IP (Figure 2.2a-b) and IV injections (Figure 2.2c-d).
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However, IP-injection of SBI-425 inhibited TNAP activity in brain homogenate at 6 h post-injection
(Figure 2.2e-f), while IV-injection of SBI-425 exhibited a time-dependent inhibition of TNAP
activity (Figure 2.2g-h).
TNAP inhibition does not alter survival or behavioral outcomes in experimental sepsis
To determine SBI-425’s effects on the brain-immune axis in vivo, female C57BL/6 mice
were subjected to cecal ligation and puncture (CLP), a mouse model of experimental sepsis. Each
mouse received SBI-425 (25 mg/kg, IP) or vehicle injections one-hour post-CLP surgery. SBI-425
or vehicle injections continued once daily for a total of 7 days, followed by plasma and tissue
collection 24 hr after the final vehicle or SBI-425 injection. No differences were observed in plasma
or bone AP activity levels, but there was a significant increase in brain AP activity in SBI-425treated mice (Figure 2.3).
Next, due to TNAP’s role in LPS and nucleotide detoxification, we hypothesized that SBI425 administration would increase mortality and worsen clinical severity. Daily observations of all
mice showed that there were no significant differences in mortality (Figure 2.4a) or weight loss
(Figure 2.4b) in vehicle and SBI-425 treated mice over 7 days. Sepsis clinical severity scores,
obtained using a murine sepsis severity scoring paradigm, decreased over time (Figure 2.4c).
Likewise, no differences in locomotor activity were observed between vehicle or SBI-425 treated
mice (Table 2.2). These results demonstrate that SBI-425 administration did not potentiate any
effects of CLP injury for these clinical outcomes.
TNAP inhibition during experimental sepsis suppresses splenic Foxp3+ T-cells
To determine whether inhibition of TNAP affects the immune response in late sepsis,
splenocytes were isolated from each mouse and immunophenotyped using flow cytometry.
Murine splenocytes were gated using the strategy shown in Supplementary Figure 2.1 and the
median fluorescent intensity (MFI) of staining for each marker was calculated. Vehicle- and SBI425-treated mice had similar staining intensities for CD4+ T cells (Figure 2.5a), while SBI-425
splenocytes had a lower staining intensity for CD8+ T cells than vehicle splenocytes (Figure 2.5b).
To determine whether SBI-425 altered regulatory T cell populations (Tregs) in late sepsis, CD4+
and CD8+ T cells were gated for CD25 and Foxp3, which are two prototypical markers for Tregs
[260,261]. All CD4+ and CD8+ T cells isolated from splenocytes were CD25- and Foxp3+. SBI-425
decreased the MFI of Foxp3+ T cell subsets. Both CD4+Foxp3+ (Figure 2.5c) and CD8+Foxp3+
(Figure 2.5d) T cell subsets were significantly decreased in splenocytes from SBI-425-treated
mice compared to their vehicle counterparts.
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SBI-425 suppresses alkaline phosphatase enzyme activity in brain parenchyma
To determine whether SBI-425 decreased in vivo brain TNAP activity, AP enzyme activity
assays were performed on brain tissue sections harvested at day 7 from the same set of vehicleand SBI-425-treated mice. Areas of detectable AP enzyme activity were denoted by the presence
of a blue-purple stain. AP enzyme activity was localized to blood vessels and parenchymal
neuronal fibers in the brains of septic mice treated with vehicle or SBI-425 (Figure 2.6). Sepsis
resulted in intense dark blue staining of the neuropil (Figure 2.6a) compared to mice treated with
SBI-425 (Figure 2.6b). The maximal staining intensity of blood vessel was similar in both
treatment groups; however, regions of lighter staining were observed in all sections of both
treatments (arrow in b). High-magnification microscopy revealed the cell bodies of neurons
appear relatively unstained while processes can be identified traveling through the parenchyma
and white matter (arrow in Figure 2.6c). Quantification of AP cortical enzyme activity revealed a
significant reduction in parenchymal AP staining intensity in SBI-425-treated septic mice
compared to septic mice who received vehicle (Figure 2.6d).
TNAP inhibition does not alter astrocyte or microglial activation
Since SBI-425 administration suppressed TNAP activity in the brain parenchyma and
TNAP has an emerging role in the immune system, the next set of histological studies addressed
whether SBI-425 treatment increased indices of sepsis-associated neuroinflammation. Astrocyte
(GFAP) and microglial (Iba-1) activation were quantified as indices of neuroinflammation.
Astrocytes responded to sepsis with an increase in GFAP immunoreactivity in the hippocampus
and primary white matter tracts (Figure 2.7). The morphology of reactive astrocytes was different
for protoplasmic and fibrous glia. Gray matter (protoplasmic) astrocytes displayed intense
immunoreactivity in the cell body and several short, thick processes (Figure 2.7a and 2.7b), while
other processes were thinner and lightly stained. Reactive astrocytes were observed extending
processes to blood vessels. In white matter (fibrous) astrocytes of the cingulum, astrocyte cell
bodies were also intensely stained, but processes appeared thicker and more restricted to the
region proximal to the cell body (Figure 2.7c and 2.7d). Glial-wrapped blood vessels were seen
less frequently in white matter. Both types of reactive astrocytes contained small, clear vesicles
in the processes (arrow in a, c). Double-staining with immunohistochemistry and TNAP enzyme
activity revealed co-localization of some, but not all, cerebral vessels (Figure 2.7e and 2.7f).
Many regions of vessels displayed high levels of enzyme activity and intense astrocyte
immunoreactivity (large arrowheads in e, f), while other regions displayed either enzyme activity
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or GFAP immunoreactivity (small arrowheads in e, f). No differences in double-staining were
observed following treatment with SBI-425. Densitometric analysis of GFAP immunoreactivity
revealed similar intensities of immunoreactivity in hippocampus (Figure 2.7g) and cingulate
cortex (Figure 2.7h). In spite of the changes in astrocyte morphology and TNAP activity in
cerebral microvessels, SBI-425 treatment had no further effect on changes in GFAP
immunoreactivity induced by sepsis.
Similar results were observed for microglial activation. Microglia in most brain regions of
both treatment groups appeared in the surveillance state (Figure 2.8). These cells had a round
to oval cell body with long, thin processes that twisted through the neural parenchyma (Figure
2.8a and 2.8b). In larger diameter blood vessels, however, sepsis-induced activation of microglia
was persistently observed (Figure 2.8c). These cells appeared round with a few short, thick
processes, and contained phagocytic debris. The quantity of microglial cells was evaluated in
images of medial orbital cortex in septic mice treated with vehicle or SBI-425. No differences in
microglial number were observed between treatment groups (Figure 2.8d).
SBI-425 suppresses BBB integrity in brain microvascular endothelial cells
The reduction of AP activity in brain parenchyma suggested that SBI-425 is able to cross
the BBB during systemic pro-inflammatory disease states (e.g., sepsis) when its integrity is
compromised. Therefore, the next set of experiments addressed whether SBI-425 potentiates the
effects of a proinflammatory stimulus on barrier function in murine brain microvascular endothelial
cells (BMECs). To test this, real-time changes in barrier function were quantified in primary
BMECs by measuring changes in cellular impedance, denoted as the cell index (CI). After
reaching confluency, BMECs were treated with vehicle (DMSO) alone, SBI-425 alone, the
inflammatory stimuli interferon-g (IFNg) combined with tumor necrosis factor-a (TNFa), or SBI425 in combination with IFNg and TNFa (IFNg+TNFa). In a separate set of experiments, we
confirmed that treatment with SBI-425, IFNg+TNFa, or the combination of both treatments did not
result in any significant differences in cytotoxicity (data not shown). Normalized CI was
continuously recorded for ~100 hours post-treatment (Figure 2.9a). Changes in the CI slope over
four consecutive 24-hour intervals (i.e., four days) showed that early treatment (day 1) with SBI425 decreased barrier function either alone or in combination with IFNg+TNFa treatment. Smaller
decreases in barrier function persisted through day 2, followed by recovery of barrier function in
SBI-425 only treated cells over days 3 and 4. In contrast, the detrimental effects of IFNg+TNFa
alone or IFNg+TNFa in combination with SBI-425 persisted until day 4 (Figure 2.9b).
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Overexpression of TNAP in brain endothelial cells improves sepsis outcomes
The final set of experiments addressed the effects of sepsis on TNAP expression and
enzyme activity. Since TNAP is expressed in multiple cell types within the brain, we first tested
the mRNA expression of Alpl in primary BMECs. Cells were treated with a vehicle (DMSO),
lipopolysaccharide (LPS, 100 ng/ml), TNAP inhibitor (TNAPi, 100 µM), or a combination of
LPS+TNAPi. The effects of a 100 µM dose of TNAPi on barrier function were identical to SBI-425
(data not shown.) Alpl expression was quantified at 3, 6, and 24 hr after treatment and was found
to be elevated with LPS+TNAPi treatment at all timepoints (Supplemental Figure 2.2).
To determine the impact of increased TNAP expression on the neuroimmune axis in vivo,
we utilized a transgenic mouse model with VE-cadherin-Cre driven conditional overexpression of
TNAP in endothelial cells, or VE-cOE mice. The high expression of TNAP in brain endothelial
cells compared to other endothelial cell populations allowed us to focus on the neuroimmune axis.
In sham-injured animals, TNAP enzyme activity exhibited a trending increase toward significance
in brain tissue (Figure 2.10a) and was significantly increased in plasma (Figure 2.10b) in VEcOE mice compared to controls. Next, VE-cOE mice and their controls were subjected to CLP
and euthanized 48 hours later. VE-cOE mice had 100% survival (Figure 2.10c) and lower clinical
scores (Figure 2.10d) compared to wild-type controls. Assessment of locomotor activity one day
after CLP showed that both VE-cOE and wild-type mice exhibited similar levels of horizonal
movement during the first 20 minutes of testing, while significant differences in movement
emerged during the final 10 minutes of testing (Figure 2.10e). Activity during this period was
significantly greater in VE-cOE mice compared to negligible movement in controls (Figure 2.10f).
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Discussion
In this study, we investigated a novel immunoregulatory role for TNAP in a mouse model
of experimental sepsis. Our results highlight a novel and important role for sustained TNAP
enzyme activity at the brain-immune axis. First, we confirmed that SBI-425 does not cross an
intact BBB in healthy mice. Second, we found that SBI-425 administration does not affect survival
or behavioral outcomes after experimental sepsis. Third, we identified a critical role for TNAP in
splenic T cells as we found that SBI-425 downregulates Foxp3+CD25- populations of CD4+ and
CD8+ T cells. Fourth, our results demonstrate that SBI-425 can traverse a compromised BBB as
shown by reduced in vivo brain TNAP activity following experimental sepsis. Fifth, we showed
that SBI-425 potentiates the inflammation-induced loss of barrier function in brain endothelial cells
– the cells which interface with the systemic circulation at the BBB. Finally, we demonstrated that
overexpression of TNAP in endothelial cells improves survival, clinical scores, and behavioral
outcomes associated with early sepsis.
The translational implications of our results are summarized in Figure 2.11. Under normal
conditions, TNAP serves a critical role in immune surveillance by maintaining the integrity of the
BBB. Under sepsis and other systemic inflammatory conditions, TNAP protects against the loss
of BBB permeability as demonstrated using both in vivo and in vitro inhibition of TNAP via SBI425 treatment in the current study. Additionally, many other studies have also shown that TNAP
dephosphorylates LPS into a nontoxic form [81,82], which inhibits LPS binding to the toll-like 4
receptor (TLR4) and prevents signaling of TLR4-mediated pro-inflammatory signaling pathways
[262,263]. Therefore, TNAP serves a role that is two-fold with regard to endotoxins by: 1)
dephosphorylating LPS and 2) preventing the movement of LPS across the endothelium and into
the brain parenchyma. Collectively, our results underscore a beneficial role for TNAP within the
neuroimmune axis.
The finding that SBI-425 does not cross the BBB in healthy mice is largely supported by
the LC/MS/MS result of low SBI-425 brain:plasma ratios following SBI-425 IP administration.
Although we did observe decreased AP activity following SBI-425 in some experiments, this
decrease may be due to inhibition of AP on the apical side of the BBB rather than in the neural
parenchyma. Because SBI-425 binds in a reversible manner, homogenization of brain tissue
could release bound inhibitor which could subsequently interact with AP from the parenchyma.
Since our methods require homogenization of brain tissue, we were not able to distinguish the
cerebrovascular origin of AP from other brain cell types that also express functional TNAP
enzymes, which may include neurons, astrocytes, microglia, pericytes, and brain-resident
macrophages such as perivascular macrophages. Taken together, this also suggests that SBI-
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425 may be a valuable pharmacological tool to study TNAP function located on the apical, or
luminal, side of the BBB.
At seven days post-sepsis, we measured a significant increase in AP activity in brain
homogenate of SBI-425-treated mice and no significant changes between vehicle or SBI-425
treatment in plasma and bone. There are several explanations for this observation. The final SBI425 IP injection occurred ~18-20 h prior to termination. The half-life of an orally administered 10
mg/kg dose of SBI-425 is 2.3 hr [154], so the IP-administered SBI-425 in our study should have
been metabolized in plasma and bone by 18 hr. In contrast, the increase in brain AP activity may
have been caused by a potential positive-feedback mechanism causing an increase in AP protein
and/or an increase in activity within specific brain regions when the enzyme is inhibited. Since the
entire brain was homogenized, we were unable to address brain region specific alterations in AP
activity. However, histological experiments showed a decrease in TNAP activity in brain
parenchyma from cortical tissue sections. We focused on the cortex because brain AP activity
levels have been characterized in this region [91,93,96,264]. Specific physiological functions and
mechanistic pathways that regulate TNAP activity remain poorly understood in many organs,
including the brain. Brain-localized TNAP has been suggested to aid in proliferation and migration
of the developing nervous system [89,265], promote axonal growth [125], and regulate the
formation and maturation of synapse [264,266]. Additional studies suggest that changes in brain
TNAP expression may contribute to Alzheimer’s disease (AD) [267] and epilepsy [78,268]. TNAP
has varied levels of expression in the brain [115,264], and the amount of total TNAP protein and
catalytically active enzyme activity are not equal [107]. Therefore, it is important to quantify the
amount of active enzyme and not just the amount of TNAP protein in the brain.
Sepsis is characterized by a hyper-inflammatory, elevated immune response during early
sepsis followed by the transition to a hypo-inflammatory, immunosuppressive period in late sepsis
prior to restoration of homeostasis [269]. While the innate immune response predominates during
early sepsis, the innate and adaptive immune responses function in parallel during later sepsis to
reduce immunosuppression and restore immune homeostasis. The immune imbalance can lead
to lessened cytokine production and reduced T cell proliferation [270,271]. TNAP is expressed on
immune cells, including neutrophils and T lymphocytes, where it plays a role in B cell
differentiation, so it is often upregulated at the site of inflammation [202,203,272,273]. TNAP has
also been shown to modulate T cell function in a heterozygous TNAP+/- mouse model of colitis
[148]. We assessed differences in T-cell splenocyte populations at seven days post-sepsis from
mice who received either SBI-425 or vehicle treatment. Our flow cytometry data revealed that
inhibition of TNAP resulted in differential expression of splenocyte T-cell populations following
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sepsis. We found decreased mean fluorescence intensity of both CD4+ and CD8+ T-cell subsets
in SBI-425-treated compared to vehicle-treated animals. Sepsis is associated with T-cell
dysfunction, and our results suggest that TNAP inhibition may enhance T-cell mediated
immunosuppression in late sepsis [274,275]. The increase in CD4+Foxp3+ and CD8+Foxp3+
Tregs in vehicle- compared to SBI-425- treated mice is consistent with previous findings which
show that elevated Tregs are associated with increased survival and improved sepsis outcomes
[276].
Histological analyses of septic mice treated with vehicle or the TNAP enzyme inhibitor,
SBI-425, revealed decreased enzyme activity in the neural parenchyma of treated mice. Neuronal
processes coursing through the parenchyma appeared more affected by SBI-425 than enzyme
activity localized to blood vessels. Regions of blood vessels were intensely stained in both
treatment groups; however, distal regions of the same vessel could be either lightly stained, or
not apparent in the enzyme stain. The reasons for these differences are not well understood but
may reflect differences in regional exposure to blood products produced by the sepsis surgery, or
whether levels of the inhibitor were sufficient to downregulate TNAP enzyme activity. Doublestaining for TNAP enzyme activity and GFAP immunoreactivity revealed regions of vessels that
were co-stained, adjacent to regions that were singly stained for TNAP activity or GFAP. The
mechanisms regulating differential staining are not known. However, the loss of barrier function
in murine primary brain endothelial cells treated with SBI-425 demonstrates a significant role for
the preservation of TNAP enzyme activity in cerebral microvessels. The BBB-like properties of
brain endothelial cells were diminished in the presence of SBI-425 on day 1 compared to
IFNg+TNFa treated counterparts. SBI-425 treatment also potentiated the long-term effects of an
IFNg+TNFa inflammatory stimulus, suggesting that inhibition of TNAP enzyme activity during
acute pro-inflammatory conditions may have highly detrimental effect. These results are
supported by previous work which demonstrates a loss of brain endothelial cell permeability in
cells treated with levamisole, a pan-AP inhibitor [107,111].
Glial reactivity of astrocytes and microglia reflected a residual sepsis effect. Although there
were no significant differences between vehicle and SBI-425 treatment, these results have
important implications for elucidating a neuroinflammatory role for TNAP in both early and late
sepsis. The seven-day time course of experimental sepsis and tissue harvest occurred after the
typical early peak response of microglia, but prior to the relatively late peak response of
astrocytes. During the stage of late sepsis examined in this study, most microglia displayed
surveillance morphology. In contrast, activated, phagocytic cells were observed in the vicinity of
blood vessels, where interaction with residual blood components from the sepsis surgery could
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still manifest. Likewise, astrocytes displayed an activated morphology with elevated levels of
GFAP, but no effect of the inhibitor was observed. High-magnification microscopy also revealed
the presence of small, clear vesicles in the processes of astrocytes. These vesicles are presumed
to be exocytic vesicles prior to release that represent chemical communication between
astrocytes and neighboring cells. Astrocytic release of extracellular vesicles has recently emerged
as a major mechanism of communication in neuroinflammation and neurodegeneration and may
contribute to bidirectional communication within the neuroimmune axis [277,278].
Results from the in vivo model of experimental sepsis suggest that SBI-425 may disrupt
barrier function under physiological conditions when BBB integrity is compromised. This finding
was corroborated by in vitro barrier function studies in murine BMECs. Although we did not
observe changes in locomotor activity in experimental sepsis, SBI-425 could affect and potentiate
behavioral changes in other domains associated with sepsis including: learning and memory,
nociception, or depression. In contrast, we observed that overexpression of TNAP in endothelial
cells improved neurobehavioral outcomes. These results are important because altered mental
status is one of the most common and severe symptoms associated with sepsis and its underlying
origins have been linked to BBB dysfunction [279,280].
In summary, our results show that the highly-specific TNAP inhibitor, SBI-425, is unlikely
to cross an intact BBB in the absence of injury or disease. In contrast, in vivo and in vitro results
demonstrate that SBI-425 can traverse the BBB and disrupt TNAP activity in the brain
parenchyma during injury or disease. However, the long-term consequences, if any, of a shortterm disruption of brain TNAP activity are unclear and will be investigated in future studies. This
is important because short-term perturbations in cerebrovascular function have been
hypothesized to have long-term implications for neurological function. Thus, the short-term loss
of TNAP activity in brain endothelial cells during sepsis may be one reason for diminished
neurological function observed in sepsis survivors. As SBI-425 is currently under investigation as
a therapeutic agent to treat vascular calcification [156], caution may be warranted when
individuals undergoing SBI-425 therapy experience co-morbid pathological conditions associated
with the loss of BBB integrity. Individuals with ischemic stroke, traumatic brain injury, sepsis, and
Alzheimer’s disease represent populations where SBI-425 could easily cross the BBB
[221,281,282]. TNAP has many unexplored important physiological roles in the nervous system
and the immune system which rely on the tightly controlled regulation of its enzymatic activity in
different cells and tissues. Thus, the availability of a novel and highly-specific pharmacological
compound such as SBI-425 provides a valuable tool to elucidate novel, in vivo roles for TNAP
within the brain-immune axis.
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Materials and Methods
Animals: Male and female C57BL/6J mice were obtained from The Jackson Laboratory (Bar
Harbor, ME, USA) and bred in the West Virginia University Office of Laboratory Animal Resource
(OLAR) facility. B6.FVB-Tg(Cdh5-cre)7Mlia/J mice expressing Cre recombinase under the control
of the endothelial cell-specific Cdh5 promoter (also known as VE-Cadherin-Cre or VE-Cre) were
obtained from The Jackson Laboratory (Bar Harbor, ME, USA; stock 006137) [283–285]. HprtALPL
knock-in mice were previously described [154]. VE-Cre male mice were bred with homozygous
female HprtALPL mice to create mice with elevated expression, i.e., overexpression, of TNAP in
endothelial cells (i.e., VE-cOE). Animals were genotyped by PCR using DNA extracted from ear
snips using the Purelink Genomic DNA Mini Kit (Invitrogen, Carlsbad, CA, USA), then a Veriti 96well Thermal Cycler (Applied Biosystems). VE-Cre specificity was determined using forward and
reverse primers GAACCTGATGGACATGTTCAGG / AGTGCGTTCGAACGCTAGAGCCTGT;
and PCR conditions 94°C for 1 min, [(94°C for 30 sec, 60°C for 30 sec, 72°C for 45 sec) x 40
cycles], then 72°C for 1 min (band length 320 kb). TNAP overexpression-specificity was
determined using two sets of forward and reverse primers: AATGCCCAGGTCCCTGACAGC /
GGTTCCAGATGAAGTGGGAGT (presence of 505 kb band indicating overexpression) and
TGTCCTTAGAAAACACATATCCAGGG / CTGGCTTAAAGACAACATCTGGGAGA (presence of
345 kb band indicating wild-type gene); and PCR conditions 94°C for 1 min, [(94°C for 30 sec,
68°C for 30 sec, 72°C for 45 sec) x 40 cycles], then 72°C for 1 min. Wild-type mice of the same
genetic background strains (VE-Cre and HprtALPL) were used as control animals. All mice used
were aged 2-4 months. All animal studies were approved by the Institutional Animal Care and
Use Committee of West Virginia University and were in compliance with the National Institutes of
Health guidelines for the humane treatment of animals.
SBI-425 preparation: SBI-425 was synthesized as previously described [131]. SBI-425 powder
was dissolved using heat and sonification in 100% dimethyl sulfoxide (DMSO, Sigma-Aldrich,
Milwaukee, WI) to make a 12.5 mg/ml stock solution stored at -80°C. For in vivo administration of
SBI-425, the stock was diluted to 1 mg/ml in a vehicle solution comprised of: 10% DMSO, 10%
Tween-80 (Sigma-Aldrich), and 80% water. All control mice were injected with a volume of vehicle
solution equivalent to the largest volume of SBI-425 administered to all mice in that cohort.
Sample collection for biochemical studies: Mice were anesthetized with isoflurane and
euthanized by cardiac perfusion with 0.9% saline. Plasma was collected by cardiac puncture into
Microvette tubes coated with lithium-heparin (Sarstdet; Nümbrecht, Germany), centrifuged at
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10,000 x g for 5 mins, aliquoted, and stored at -80°C until analysis. Brain cortices (excluding
olfactory bulbs and cerebellum) and bone (femur and/or tibia) tissues were collected following
saline perfusion, homogenized in AP buffer (comprised of: 1 M Tris-HCl (Tris Base: Fisher
Scientific, Pittsburg, PA; Hydrochloric acid: Sigma-Aldrich, Milwaukee, WI), 1 M MgCl2 (Fisher
Scientific), 50 mM ZnCl2 (Acros Organics, NJ), and deionized water) without the substrate, and
stored at -80°C for further analysis. Samples were spiked with 40 µM SBI-425 (equivalent to a 10
mg/kg dose), 100 µM of an unoptimized TNAP inhibitor (TNAPI; MLS-0038949, Cat #: 613810,
Millipore-Sigma, Burlington, MA [129]), or vehicle (DMSO) and AP activity was detected using the
methods described below.
Dosing and sample collection for in vivo studies: Mice were weighed immediately prior to
treatment injections to ensure accurate dosing of each animal, and sacrificed 1-, 4-, and 6-hours
post-treatment for 25 mg/kg intraperitoneal (IP) administration, or 10-, 30-, and 60-minutes posttreatment for 5 mg/kg intravenous (IV) injection via retro-orbital administration. Vehicle-treated
animals were sacrificed at the latest time-point (6 hours post IP injection and 1-hour post IV
injection). Mice were anesthetized with isoflurane and euthanized by cardiac perfusion with 0.9%
saline. Plasma was collected by cardiac puncture into Microvette tubes coated with lithiumheparin, centrifuged at 10,000 x g for 5 mins, aliquoted, and stored at -80°C until analysis. Organ
tissues were collected following saline perfusion, homogenized in AP buffer without the substrate,
and stored at -80°C.
Detection of alkaline phosphatase (AP) activity: AP activity assays were adapted from a
previously published protocol and performed in a 384-well plate [286]. Briefly, plasma and tissue
homogenates were centrifuged to remove insoluble material, diluted if necessary, and then mixed
with a buffer comprised of 1 M Tris-HCl (Tris Base: Fisher Scientific, Pittsburg, PA; Hydrochloric
acid: Sigma-Aldrich, Milwaukee, WI), 1 M MgCl2 (Fisher Scientific), 50 mM ZnCl2 (Acros Organics,
NJ), deionized water, and 13.5 mM para-nitrophenylphosphate (pNPP; Millipore Sigma, Billerica,
MA) solutions. Brain homogenates were diluted 1:10 using AP buffer with pNPP omitted. Each
sample was plated in duplicate and matched to a background control using a control buffer
containing 5% of a 200 mM sodium orthovanadate (BeanTown Chemical, Hudson, NH) solution.
AP activity levels were read kinetically every 5-10 mins at O.D. 380 nm for 5 hours on a Synergy
H1 Hybrid Reader and absorbance was acquired with Gen5 Version 2.01.14 software (BioTek
Instruments, Inc., Winooski, VT). The area under the curve (AUC) was calculated to determine
TNAP activity levels in each sample.
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Liquid chromatography tandem mass spectrometry (LC/MS/MS): Mass spectrometry
analysis was performed on SBI-425 (10 mg/kg IP dose; n=3 per group) in plasma and
homogenized brain of male C57BL/6 mice harvested at 2 hr and 8 hr after injection. For plasma
preparation, an aliquot of 60 µL sample was protein precipitated with 480 µL internal standard
solution, vortexed for 1 min, and centrifuged at 13000 rpm for 15 min. Brain homogenate was
prepared by homogenizing brain with 4 volumes (w:v) of homogenizing solution (deionized water).
An aliquot of 60 µL sample was protein precipitated with 480 µL internal standard solution, the
mixture was vortex-mixed for 1 min and centrifuged at 13000 rpm for 15 min. 5 µL supernatant
was injected for analysis using the Linear Ion Trap Quadrupole LC/MS/MS Mass Spectrometer
(AB Sciex Instruments, Model #1004229, API 4000). Internal standards of 100 ng/mL
dexamethasone, 100 ng/mL diclofenac, and 100 ng/mL tolbutamide in acetonitrile were used.
Cecal ligation and puncture: A sublethal model of experimental sepsis was induced by cecal
ligation and puncture (CLP) as previously described [287]. Briefly, on day 0 C57BL/6J female
mice (n=25) were anesthetized with isoflurane in normal air (3% induction, 1% maintenance),
numbed with a topical 2% lidocaine hydrochloride solution (Pheonix, St. Joseph, MO) applied to
the peritoneum, and subjected to CLP surgery. CLP surgery was completed by tying off two-thirds
of the cecum using a silk thread suture (Look Surgical Specialties, Reading, PA), poking two holes
into the cecum with a 22-gauge needle and squeezing a small amount of fecal matter up to the
tissue surface. The cecum was returned to the abdominal cavity, and the incision was closed
using 6-0 (peritoneum) and 5-0 (skin) monofilament (Unify PGA Surgical Sutures, Sunnyvale,
CA). After completion of the surgery, mice were given 1 ml subcutaneous normal saline for
rehydration. One hour following surgery, and once daily for 7 days total, mice were IP injected
with 25 mg/kg SBI-425 (n=10) or vehicle (n=12); this SBI-245 dose is similar to previously reported
values in other published studies [154,288]. Weights, temperatures, and clinical assessments
were performed daily between 9:00 am and 12:00 pm. Clinical assessments were performed by
a blinded investigator and calculated based on a modified murine sepsis scoring system with a
range of 0 (no pathology) – 36 (probable death); mice with a score ³ 24 were euthanized
[289,290]. On day 7 post-surgery (24 hr following the last SBI-425 or vehicle treatment), mice
were harvested for plasma and tissues.
Open field testing: On day 2 post-CLP, mice underwent open field testing to assess locomotor
activity using individual 16 x 16 x 15 chambers (Photobeam Activity System, San Diego
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Instruments, San Diego, CA) measured as the number of beam breaks. Parameters included 5minute interval assessments of a 60-minute total trial using 3 x 3 periphery.
Tissue harvest and processing: Mice were deeply anesthetized with isoflurane and were
perfused transcardially with a perfusion pump (Masterflex 7524-10, Cole-Parmer, Vernon Hills,
IL) set to 5.0 ml/min. Blood was removed with 10 ml 0.9% saline and tissues were fixed with 50
ml of 4% cold paraformaldehyde (Fisher Scientific, Pittsburgh, PA). Brains were removed from
the skull, bisected, and post-fixed in 4% paraformaldehyde overnight at 4°C. The following day,
the hemispheres were rinsed in 0.01 M phosphate buffered saline (PBS) and incubated
sequentially in 10%, 20%, and 30% sucrose in PBS for 24 hr each.
Splenocyte isolation: Perfused spleens were collected in 10 ml cold isolation buffer containing
RPMI-1640 (Corning, Manassas, VA) supplemented with 1.5% fetal bovine serum (FBS, Gemini
Bio-Products, West Sacramento, CA) and processed immediately to obtain a single cell
suspension. Briefly, spleens were meshed gently using the back of a plunger and filtered through
a 70 µm cell strainer (Fisher Scientific). Cells were collected by centrifugation at 300 x g for 10
min at 4°C. Red blood cells were lysed with 4 ml of ACK Lysis Buffer (Lonza, Portsmouth, NH)
per spleen, incubated for 2-3 min at room temperature (RT) and washed as previously described
[287]. Viability and total splenocyte yield were determined by trypan blue (Life Technologies,
Eugene, OR) exclusion. Splenocytes were re-suspended to a final concentration of 2.5-3 × 106
cells/ml with FACS buffer (1X PBS, 5 mM EDTA, 2% FBS) for flow cytometry.
Flow cytometry: Immunophenotyping of splenocytes was performed by flow cytometry. Briefly,
cells were washed twice in sodium azide- and protein-free cold PBS and stained with fixable
viability dye eFluor780 (Cat. #65-0865; Thermo Fisher Scientific, Waltham, MA) for 30 min at 4°C
in the dark. Cells were then briefly washed with FACS buffer and blocked with Ultra-Leaf purified
anti-mouse CD16/32 (Clone: 93; Cat. #101330; BioLegend, San Diego, CA) for at least 20 mins.
Following non-specific blocking, cells were stained with monoclonal antibodies for CD45-PE
(Clone: REA737; Cat #: 130-110-659), CD11b-VioBlue (Cat #: 130-097-336), CD11c-PerCpVio700 (Cat #: 130-103-806), Ly6G-APC (Order #130-107-914), Ly6C-PE-Vio770 (Cat #: 130103-046) from Miltenyi Biotec (Auburn, CA USA) or anti CD4-FITC (Clone: RM4-5; Cat #: 110042-82), CD25-PE (Clone: PC61.5; Cat #: 12-0251-82), CD19-PerCp-Cy5.5 (Clone: 1D3; Cat.
#:45-0193-80) and CD8a-eFluor450 (Clone: 53-6.7; Cat#: 48-0081-82) from Thermo Fisher
Scientific for 10 min at 4°C. Appropriate single stained controls were prepared for fluorophore
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compensation using compensation beads (Invitrogen, Carlsbad, CA). For intracellular FOXP3
detection, after staining the surface markers (CD4 or CD25), cells were fixed/permeabilized using
Mouse regulatory T cell staining kit according to manufactory’s instruction (Invitrogen) and stained
with anti-FOXP3-PE-Cy5 (Clone: FJK-16s; Cat #:15-5773-82). Fluorescent assessment was
carried out with BD LSR Fortessa using FACS Diva software (BD Biosciences, San Jose, CA).
Single cells were identified by forward scatter and side scatter, and viable cells were gated. Cells
were gated for CD45 positive populations then divided into lymphoid cells, which included B cells
(CD11c-CD19+), T-helper cells (CD3+CD4+), cytotoxic T cells (CD3+CD8+), T-regulatory cells
(CD4+CD25+Foxp3+); and myeloid cells, which included neutrophils (Ly6G+), monocytes
(Ly6C+), and dendritic cells (CD11c+). All data were compensated and spectral overlap was
minimized using the automatic compensation feature in BD FACSDiva software (BD Biosciences).
The gating strategy for lymphocytes is shown in Supplemental Figure 2.1.
Embedding and sectioning: Hemispheres were co-embedded into a 15% gelatin matrix in
groups of nine for simultaneous sectioning. The gelatin block was processed sequentially through
4% paraformaldehyde for 24 hr, 15% sucrose for 24 hr, and 30% sucrose for 48 hr. The block
was trimmed and quick frozen in dry ice/isopentane for three min. Sectioning was performed in
the coronal plane at 40 µm on a sliding microtome (HM 450, ThermoFisher Scientific) equipped
with a 3 x 3 freezing stage (BFS-40MPA, Physitemp, Clifton, NJ) at -20oC. Sections were collected
into a series of six cups filled with PBS + sodium azide (0.6 g sodium azide/1 L PBS). Adjacent
cups were used for sequential stains or immunostains.
Antibodies and immunohistochemistry: The following antibodies were used (antibody names,
registry numbers, and dilutions): glial fibrillary acidic protein (GFAP) - 10013382 (Z0334,
Dako/Agilent; 1:10,000 primary, 1:10,000 secondary); Iba-1 - 839509 (019-19741, Wako; 1:2,000
primary, 1:1,000 secondary). Sections were stained free-floating using a modified ABC procedure
(Vector Laboratories, Burlingame, CA). Sections were treated with 10% methanol, 10% hydrogen
peroxide in Dulbecco’s modified phosphate buffered saline (DPBS; 136 mM NaCl, 8 mM
Na2HPO4, 2.6 mM KCl, 1.5 mM KH2PO4) for 15 min to quench endogenous peroxidase. Following
three rinses in DPBS for five min each, sections were incubated in a permeabilizing solution (1.8%
L-lysine, 4% normal horse serum, 0.2% Triton X-100 in DPBS) for 30 min at room temperature.
Sections were transferred directly to primary antibody solution in DPBS + 4% normal horse serum
and were incubated overnight at room temperature. The following day, sections were rinsed three
times in DPBS for five min each and transferred to secondary antibody solution in DPBS + 4%
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normal horse serum for two hours at room temperature. Following three rinses in DPBS for five
min each, sections were incubated in Avidin D-HRP (1:1000 in DPBS, Vector Laboratories,
Burlingame, CA) for 1 h at room temperature, rinsed three times in DPBS for five min each, and
incubated with chromogen solution (3-3’ diaminobenzidine, 50 mg in 100 ml DPBS + 50 µl 30%
hydrogen peroxide, Electron Microscopy Sciences, Hatfield, PA) for five min. Sections were rinsed
three times in DPBS for five min each, mounted onto microscope slides (Unifrost+, Azer Scientific,
Morgantown, PA), air-dried overnight, dehydrated through a standard dehydration series, and
cover slipped with Permount (Fisher Scientific). A subseries of sections was double-stained for
GFAP by immunohistochemistry and subsequently for TNAP enzyme activity.
Microscopy and image analysis: Slides were viewed on a Leica DM6B microscope and images
were captured using Leica LASX software. Images of GFAP immunoreactivity were captured at
40X extended depth of field (EDOF) in CA1 of hippocampus. Images of ALPL enzyme staining
and Iba-1 immunoreactivity were captured at 20X EDOF in medial orbital cortex. For GFAP,
images were captured from CA1 in hippocampus of three adjacent sections at 40X. A batch
processing file was programmed in Photoshop with the following steps:1) convert to grayscale; 2)
invert; 3) threshold = 144; 4) select All; 5) record measurement – mean gray scale. Mean intensity
values were collected and analyzed by unpaired t-test. For Iba-1, images were captured from
medial orbital cortex of three adjacent sections at 20X. A batch processing file was programmed
in Photoshop with the following steps: 1) convert to grayscale; 2) invert; 3) threshold = 164. Cell
bodies were counted manually using the count tool and were recorded and analyzed in Prism 7.0.
Alkaline phosphatase enzyme activity histology and image analysis: Brains were evaluated
for alkaline phosphatase enzyme activity by staining free-floating with a BCIP/NBT substrate kit
as described (SK-5400, Vector Laboratories, Burlingame, CA). Sections were rinsed in DPBS
twice for 5 min each, once in 0.1 M Tris-HCl (pH = 9.5) for 5 min, and incubated in the staining
solution for 24 hr. Following three rinses in Tris-HCl, the sections were mounted onto microscope
slides (Unifrost+, Azer Scientific, Morgantown, PA), air-dried overnight, dehydrated through a
standard dehydration series, and cover slipped with Permount. Images were viewed and analyzed
in Photoshop CC19.0 (Adobe Systems Inc., San Jose, CA). The density of ALPL enzyme staining
was measured from the blue channel. A 2.0 x 2.0 cm square was drawn and moved to ten random
positions in between the vasculature of three adjacent sections. The mean intensity of the blue
channel was captured from the histogram, and recorded in Excel (Microsoft Corp., Redmond,
WA). Density values were subtracted from 255 (the maximum bright level) to reconcile the inverse
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relationship between reduced staining and increased brightness. The average staining density
was calculated for each animal and differences in mean staining intensity were evaluated between
treatment groups.
Brain endothelial cell primary culture: Brain microvascular endothelial cells (BMECs) were
cultured based on published protocols with minor modifications [291]. Briefly, five adult male mice
(3-4 months) were perfused with ice-cold phosphate-buffered saline. Cortices were dissected and
homogenized, followed by tissue digestion in papain and DNase I (both from Worthington
Biochemical Corp, Lakewood, NJ) at 37°C for 1 hr. Following trituration, the homogenate was
centrifuged (1360 x g) for 10 minutes, followed by myelin removal. The cell pellet was
resuspended in endothelial cell growth medium (ECGM: F12 medium with 10% fetal bovine serum
(FBS), endothelial growth supplement, ascorbate (2.5 µg/ml), L-glutamine (4 mM), and heparin
(10 µg/ml)), and plated into four collagen-coated wells (calf skin collagen, Sigma-Aldrich) of a sixwell plate. Cultures were treated with fresh ECGM medium the next day followed by treatment
with puromycin hydrochloride (4 µg/ml) with EGCM+FBS for 2.5 days. Cultures reached
confluency after 5-7 days, after which they were detached with Accutase (Innovative Cell
Technologies, San Diego, CA) and seeded onto 3 separate collagen-coated 16-well E-Plate 16
PET arrays (Acea Biosciences, San Diego CA) at a concentration of 30,000 cells/well and loaded,
in parallel, onto an xCelligence RTCA DP system (ACEA Biosciences) enclosed in a tissue culture
incubator. A subset of primary BMECs from each preparation was assessed for purity and found
to be >99% as assessed CD31 immunolabeling (data not shown; CD31 goat polyclonal 1:250,
Santa Cruz Biotechnology, Santa Cruz, CA).
Brain endothelial cell barrier function assays: The barrier function of primary BMECs was
quantified by continuous recording of impedance in each well, which was recorded at 15-minute
intervals and reported as cell index (CI). Cells reached confluence, indicated by a plateau in CI,
which was ~25 hours after seeding. At this time, all arrays were removed from the xCelligence
RTCA DP system (ACEA Bioscience, San Diego, CA) and duplicate wells in each array were
treated with 200 µl of the following: vehicle (DMSO, 0.3%), SBI-425 (100 µM), tumor necrosis
factor-a (TNFa, 10 ng/ml) and interferon-g (IFNg, 10 ng/ml), or SBI-425 in combination with
TNFa+IFNg; the concentration of DMSO vehicle was equivalent to the highest final concentration
of DMSO in all other treatments of SBI-425. The concentration of SBI-425 was selected based on
dose-response curves (1 µM to 500 µM) to test the effects of SBI-425 and TNAPI on barrier
function. CI was recorded continuously for ~96 hours at 15 min intervals and analyzed with RTCA
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Software 2.0 (ACEA Bioscience). At the completion of the data collection period, the CI for all
wells was normalized to a single timepoint, i.e., ~1 h after treatment (~26 hr total), and calculated
over the 96 hr duration of treatment. To calculate the slope of the normalized CI over a 96-hr
period, results were divided into 4-separate 24 hr, i.e., 1 day, intervals, and the slope was
calculated by RTCA Software using the equation: CI = slope*time + intercept.
Primary BMEC Treatment Conditions and Reverse-transcriptase PCR: BMECs were plated
in collagen-coated 24-well dishes and allowed to reach confluence. Following stimulation for 24
hours with the treatments described above, total RNA was isolated using Qiagen RNAeasy Mini
Kit (Qiagen, Germantown, MD) using the manufacturer’s instructions. Total RNA was quantified
using a NanoDrop 2000 spectrophotometer (Thermo Scientific, Waltham, MA). 10 ng of total RNA
was used to quantify Alpl expression using a one-step quantitative real time PCR reaction
consisting of Taqman Universal Master Mix II, no uracil-N-glycosylase (UNG), MuLV Reverse
Transcriptase, RNase inhibitor, and Taqman Expression Assays for: mouse Alpl (Assay ID:
Mm03024075_m1) and 18S (Assay ID: Hs99999901_s1); 18S was used as a housekeeping
gene. Quantitative real time PCR was performed in a 96-well reaction plate (Applied Biosystems)
by using a StepOne Plus real time PCR instrument (Applied Biosystems) under the following
conditions: reverse transcription: 45°C for 30 minutes followed by 95°C for 5 minutes; reverse
transcription was followed immediately by 40 cycles of PCR amplification (95°C for 10 seconds
and 60°C for 1 min). Fold changes in Alpl gene expression were calculated using the 2-ΔΔCt method
and results for treatment groups were expressed as the fold change compared to vehicle-treated
(control) cells as previously described [292].
Statistical analysis: All results were reported as means ± SEM unless otherwise noted and were
analyzed with Student’s unpaired t-test for two comparisons or one-way ANOVA for three or more
comparisons, followed by Dunnett’s test for comparisons made to a control group or Tukey’s test
for comparisons made between all groups. Survival curve analysis was performed by using log
rank (Mantel-Cox) test. Longitudinal analyses for weight change and clinical score were analyzed
by using a mixed effects model (restricted maximum likelihood, REML) followed by Dunnett’s
multiple comparisons test. Each experiment was performed with a minimum of n=3 mice for in
vivo studies or n=3 technical replicates for in vitro studies. Specific details for each experiment
are provided in the figure legends. All data were analyzed using GraphPad Prism 8.0 software
(GraphPad Inc., La Jolla, CA) with alpha set to 0.05 as the significance threshold. Significance
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determined from post hoc testing was designated by *P≤0.05; **P≤0.01; ***P≤0.001; and
****P≤0.0001.
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Tables

2h post SBI-425
mean

SD

CV

n

7356.667

2281.235

31.0

3

Brain (ng/g)

57.200

21.884

38.3

3

B/P ratio

0.0077

0.0009

11.5

3

Plasma (ng/mL)

8h post SBI-425
mean

SD

CV

n

432.000

148.162

34.3

3

Brain (ng/g)

1.783

3.089

173.2

3

B/P ratio

0.0031

0.0054

173.2

3

Plasma (ng/mL)

B/P = brain/plasma ratio
Table 2.1. SBI-425 concentrations in plasma and brain
Healthy C57BL/6J mice received IP injections of SBI-425 followed by harvest of plasma and brain
at 2 hours (n=3) and 8 hours (n=3). SBI-425 levels in plasma and brain homogenates were
quantified by liquid chromatography tandem mass spectrometry (LC/MS/MS). SD=standard
deviation and CV=coefficient of variation.
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Total horizontal

Vehicle Beam Breaks

SBI-425 Beam Breaks

P value

(mean ± SEM)

(mean ± SEM)

1968 ± 471

1933 ± 407

0.96

1519 ± 360

1335 ± 351

0.79

449 ±121

598 ± 88

0.40

72 ± 24

54 ± 30

0.64

movements
Total peripheral
movements
Total central
movements
Total rearing
movements

Table 2.2. Open field behavior in CLP-injured mice treated with vehicle or SBI-425
Surviving CLP-injured mice treated with vehicle (n=6) or SBI-425 (n=4) underwent open field
behavior testing on day 2 post-surgery. Movements were recorded in each plane based on the
number of infrared beam breaks. No significant differences were seen in total horizontal,
peripheral, central, or rearing movements between vehicle and SBI-425 treated mice.
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Figures

Figure 2.1. SBI-425 inhibition of TNAP activity in mouse plasma, brain, and bone
homogenates
Kinetic absorbance (O.D. 380 nm) measurements were recorded over 5 hours to quantify AP
enzyme activity. Plasma, brain, and bone samples were spiked with 40 µM SBI-425, 100 µM
TNAP inhibitor (TNAPi), or vehicle. Curves illustrating mean absorbance from (a) plasma, (b)
brain, and (c) bone samples are shown. The area under the curve (AUC) was calculated to
determine the level of TNAP activity in each sample. Spike-in of TNAPi or SBI-425 in all samples
equally inhibited TNAP activity in (d) plasma (P<0.0001), (e) brain (P=0.0001), and (f) bone
(P<0.0001). Data represent mean ± SEM and were analyzed with one-way ANOVA followed by
Dunnett’s multiple comparisons tests showing treatment results compared to vehicle; n=4–12
samples from individual mice per group. Asterisks represent multiple comparisons: *P≤0.05;
**P≤0.01; ***P≤0.001; and ****P≤0.0001.

52

53

Figure 2.2. SBI-425 kinetics in plasma and brain via intraperitoneal and intravenous
administration
Male and female C57BL/6J were randomly assigned to intraperitoneal (IP; 25 mg/kg; n=34/group) or intravenous (IV; 5 mg/kg; n=2-3/group) injection groups prior to administration of
vehicle or SBI-425. IP-injected mice were harvested at 1-, 4-, or 6-hours following treatment and
IV-injected mice were harvested 10-, 30-, or 60-minutes following treatment. Kinetic absorbance
measurements were recorded at O.D. 380 nm and curves (mean absorbance) are shown for each
dosing paradigm: (a) plasma IP, (b) plasma IV, (c) brain IP, and (d) brain IV. TNAP activity was
calculated from the area under the curve (AUC, mean ± SEM) for (e) plasma IP (P<0.0001), (f)
plasma IV (P<0.0001), (g) brain IP (P=0.0019), and (h) brain IV (P<0.0001). Results were
analyzed with one-way ANOVA followed by Dunnett’s test with all comparisons made to vehicle
treatment. Asterisks represent multiple comparisons: *P≤0.05; **P≤0.01; ***P≤0.001; and
****P≤0.0001.
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Figure 2.3. SBI-425-mediated inhibition of plasma, brain, and bone TNAP activity in
murine experimental sepsis
Kinetic absorbance (O.D. 380 nm) measurements of TNAP activity are depicted in curves
(showing mean absorbance) for (a) plasma, (b) brain, and (c) bone harvested from mice that were
subjected to cecal ligation and puncture (CLP) and treated with either vehicle (n=5) or SBI-425
(n=3) every 24 hours for 7 days. TNAP activity levels between vehicle and SBI-425 groups were
compared measuring area under the curve (AUC), reported as means ± SEM, and analyzed by
Student’s t-test in (d) plasma, (e) brain (p=0.0002), and (f) bone; ***P≤0.001.
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Figure 2.4. Pharmacological inhibition of TNAP does not alter survival, weight loss, or
clinical severity scores in experimental sepsis
Mice were subjected to cecal ligation and puncture (CLP) and were randomly assigned to
treatment with either vehicle (n=12) or SBI-425 group (n=10) on day 0. (a) Survival, (b) weight
change, and (c) clinical scores were assessed daily following CLP surgery. Mice were treated
once daily with 25 mg/kg (IP) SBI-425 or equivalent volume of vehicle for 7 days. Survival analysis
was performed by the log rank Mantel-Cox test. Weight change and clinical severity scores were
analyzed by mixed effects model followed by Dunnett’s test. Clinical scores showed an overall
interaction between time and SBI-425 treatment (P=0.0035) and a main effect of time (P=0.001),
while post hoc analyses showed that clinical scores at days 4,5 and 6 were significantly different
compared to day 1 for SBI-425-treated mice; # represents P≤0.05 compared to the SBI-425 score
at day 1. Data represent means ± SEM.
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Figure 2.5. SBI-425 treatment suppressed Foxp3 expression in CD4+ and CD8+ T cells in
splenocytes from CLP-injured mice
Spleens were harvested on day 7 post-CLP, followed by isolation and purification of splenocytes.
Splenocyte populations in vehicle (n=5) and SBI-425 (n=3) treated mice were immunophenotyped
by flow cytometry and reported as median fluorescent intensity (MFI). (a) CD4+ T cell MFI did not
differ between vehicle and SBI-425 splenocytes (P=0.28), while (b) CD8+ T cell MFI was lower in
splenocytes from SBI-425- than vehicle-treated mice (P=0.017). Foxp3+ MFI was also lower in
(c) CD4+Foxp3+CD25- (P=0.0027) and (d) CD8+Foxp3+CD25- (P=0.010) T cell populations from
SBI-425-treated mice compared to vehicle-treated mice. Data were analyzed by Student’s t-test
and represent means ± SEM; **P≤0.01.
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Figure 2.6. Alkaline phosphatase enzyme activity in the brains of septic mice treated with
vehicle or SBI-425
Sepsis increased TNAP enzyme activity in the (a) parenchyma of vehicle treated mice (n=5) that
was inhibited by (b) SBI-425 treatment (n=3). The maximal intensity of blood vessel staining was
similar in both groups although vessels with lighter staining were observed in both treatment
groups (arrow in b). Detailed examination of the neural parenchyma reveals enzyme activity in
the processes of neurons (arrow in c) but not the cell body. (d) Graphical analysis of mean staining
intensity analyzed by Student’s t-test revealed significant differences in parenchymal staining
between treatment groups (P<0.0001). Scale bar in a, b = 80µm. Scale bar in c = 40µm. Data
represent means ± SEM; ****P≤0.0001.
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Figure 2.7. Astrocyte immunoreactivity is affected by sepsis but not SBI-425 treatment
(a-d) Astrocytes in both gray and white matter displayed morphology of activation following
sepsis. (a, b) Protoplasmic astrocytes displayed intense immunoreactivity in the cell body and
several processes while other processes remained thin and lightly stained. These astrocytes were
more often seen in apposition to blood vessels. (c, d) Fibrous astrocytes were intensely stained,
but cell processes were more restricted to the proximal vicinity of the cell body. Sepsis treatment
also resulted in the appearance of small, clear vesicles in the processes of reactive glia (arrows
in a, c). (e, f) Double-staining of sections with GFAP immunohistochemistry and TNAP enzyme
activity revealed co-localization of astrocyte immunoreactivity and alkaline phosphatase enzyme
activity on regions of blood vessels (large arrowheads), while other vessels displayed staining for
either GFAP or TNAP enzyme activity (small arrowheads). No differences in double-staining were
observed following vehicle (n=5) or SBI-425 (n=3) treatment. Student’s t-test revealed similar
levels of immunoreactivity and no differences in GFAP staining density between vehicle and SBI425 treatment groups in the (g) hippocampus or (h) cingulate cortex. Scale bar in a – f = 40µm.
Data represent means ± SEM.
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Figure 2.8. Microglial immunoreactivity is affected by sepsis but not SBI-425 treatment
The microglial response to sepsis surgery and SBI-425 treatment was largely resolved by the
time-point of sacrifice. (a) Microglia displayed a surveillance-type morphology with a round to
slightly oval cell body and many long, thin twisted processes (arrow). (b) Treatment with SBI-425
had no effect on microglial activation status. (c) Residual pathology was observed in the vicinity
of blood vessels, where microglia had a round cell body with few and thicker processes that
contained spheroids. Phagocytic debris was observed in microglial processes in the parenchyma
proximal to and within the walls of blood vessels (arrow). (d) Microglial number was quantified
from sections of both treatment groups and Student’s t-test revealed no significant differences in
the number of glial cell bodies in the cortex between vehicle (n=5) and SBI-425 (n=3) treated
mice. Scale bar a-c = 40µm. Data represent means ± SEM.
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Figure 2.9. SBI-425 treatment decreases barrier function in murine brain microvascular
endothelial cells (BMECs)
Normalized cell index (CI) is an impedance-based measure of barrier function. (a) Primary murine
BMECs were treated with either vehicle, IFNg (10ng/ml) + TNFa (10ng/ml), SBI-425 (100 µM) or
SBI-425 in combination with IFNg+TNFa. Representative traces depicting the normalized CI (set
to 1.0) at the time of treatment (25 hr after seeding cells) and recorded until the end of the
experiment (125 hr after seeding cells). Each representative trace depicts means ± SD and is
separated into four consecutive 24 hr intervals, designated 1-4. (b) Changes in the slope, which
represents change in CI over each 24 hr interval, are shown over a four-day period. Data
represent means ± SD and were analyzed by one-way ANOVA followed by Tukey’s test with
P≤0.001 as significant where “a” indicates significance compared to vehicle; “b” indicates
significance compared to IFNg+TNFa; “c” indicates significance compared to SBI-425.
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Figure 2.10. Genetic over-expression of TNAP on endothelial cells reduces morbidity and
mortality after sepsis
Sham-injured VE-cOE mice have increased AP activity compared to sham-injured control animals
in (a) brain (n=2 per group) and (b) plasma (n=3-4 per group). (c) Survival is increased up to 48
hr after sepsis in VE-cOE mice (survival in 6 of 6 mice) compared to controls (survival in 3 of 5
mice). (d) Clinical severity scores were decreased in VE-cOE mice 24 hr after sepsis (n=6 mice
per group). (e-f) Open field testing shows that there is increased voluntary movement by septic
VE-cOE mice (n=6) compared to controls (n=4) in the last ten minutes of the test. Data represent
means ± SEM and were analyzed using Student’s unpaired t-test, where p<0.05 is significant.
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Figure 2.11. Proposed mechanism of action of TNAP enzyme activity and its inhibition in
sepsis
In healthy brain endothelium (left) TNAP performs a role in immune surveillance and the
maintenance of BBB permeability. The brain endothelial cells that form the BBB maintain a tight
barrier via intact junctional and cytoskeletal proteins which keep toxins and extracellular
molecules from entering the brain parenchyma. In sepsis (right), release of systemic cytokines
and activation of pro-inflammatory pathways increases brain endothelial cell permeability. In
systemic bacterial infections, lipopolysaccharide (LPS) binds to toll-like receptors (primarily TLR4)
and initiates a pro-inflammatory innate immune response. One of TNAP’s physiological roles is
to dephosphorylate LPS, which converts the molecule from a toxic form to nontoxic form to help
reduce inflammation. When TNAP’s enzyme activity is inhibited using SBI-425, more LPS is
available to bind to its receptors as well as diffuse across the brain endothelium to activate TLRs
on brain resident cells such as microglia and astrocytes.
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Supplemental Figure 2.1. Gating strategy for murine splenocytes
(a) Murine splenocyte CD45+ cells were first gated as CD3+ cells. (b) CD3+ cells were then gated
for T-helper cells (CD3+CD4+) and cytotoxic T cells (CD3+CD8+). (c) CD4+ cells were further
gated as: regulatory T cells (Tregs: CD3+CD4+Foxp3+CD25+), Foxp3+ T cells
(CD3+CD4+Foxp3+CD25-), CD25+ T cells (CD3+CD4+CD25+Foxp3-/low), and non-Tregs or
naïve/resting T cells that did not express any CD25+Foxp3+ markers (CD3+CD4+CD25-Foxp3). (d) The same strategy was applied to CD8+ T cells to gate for CD8+ Tregs.
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Supplemental Figure 2.2. Relative expression of TNAP in murine BMECs
C57BL/6 mouse (6-8 weeks old) primary BMECs showed increased TNAP (Alpl) mRNA
expression by 3 to 24 hrs post-stimulation with a combination treatment of LPS and TNAPi. Data
were analyzed using two-way ANOVA followed by Tukey’s multiple comparisons test.
Significance is compared to the control group, where **p=0.002 and ****p<0.0001.
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SUMMARY
The vascular system and gastrointestinal tract are two of the most severely impacted
organ systems in sepsis. The gut is also one of the most common sources of infection in sepsis.
Unlike the gut-epithelial barrier, the mechanisms underlying the leakage of bacteria from the gut
into the bloodstream through the gut-vascular barrier are not well understood. The gut consists of
several layers of protection which keep harmful bacteria from freely entering into the circulation.
Two of the cell types which comprise these protective layers in the gut are epithelial cells and
endothelial cells. Both cell types express an isoform of alkaline phosphatase (AP), a ubiquitous
enzyme best known for its role in bone mineralization. Intestinal alkaline phosphatase (IAP) is
expressed by the epithelial cells that form the gut-epithelial barrier; this enzyme has been shown
to play a role in gut permeability, bacterial homeostasis, and mitigating LPS toxicity and
inflammation. In contrast, the mechanisms underlying the permeability of the gut-vascular barrier,
the second layer that must be breached for bacteria to enter the systemic circulation, are not well
understood. Tissue-nonspecific alkaline phosphatase (TNAP) is expressed by endothelial cells
within the gut-vascular barrier, and may perform complementary or redundant functions with IAP.
Our lab has shown that that TNAP activity is suppressed in brain endothelial cells during sepsis,
and that pharmacological inhibition of TNAP results in diminished brain endothelial cell barrier
integrity. Based on our preliminary findings in brain endothelial cells, we addressed the hypothesis
that TNAP protects against the loss of gut-vascular barrier integrity by decreasing endothelial
permeability and minimizing gut dysbiosis. To address this, we generated mice with a conditional
deletion of TNAP in endothelial cells, i.e. VE-cKO mice, and investigated TNAP's role in both
sham and septic adult (11-12 mo) mice from both sexes. We have found that VE-cKO septic mice
display an increased bacterial burden and increased parameters of gut dysbiosis at 8 days postCLP, including a decreased Firmicutes:Bacteroidetes (F:B) ratio, decreased relative expression
of antimicrobial proteins, and, at 3 days post-CLP, decreased levels of short-chain fatty acids
(SCFAs). At 24 hours post-CLP, permeability to molecules ranging from 625 Da to 69 kDa is
increased in VE-cKO ileum compared to Alplfl/fl littermate controls. The differences in permeability
between intestinal segments also demonstrates that TNAP’s enzyme activity may impact each
region using different mechanisms. Overall, these results demonstrate a protective role for
endothelial cell TNAP against gut-vascular barrier dysfunction and dysbiosis in healthy and
injured mice.
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INTRODUCTION
The gut-vascular barrier (GVB) has been recognized as an important component of gut
homeostasis. Similar to the blood-brain barrier (BBB), under normal physiological conditions the
GVB is impenetrable to commensal bacteria, which are limited to the intestinal lumen and confer
many symbiotic advantages to the host. However, in disease or injury an elevated immune
response increases GVB permeability and more readily allows the passage of bacteria, ect. into
the circulation [231]. In order to better understand the mechanisms behind these vascular
changes, it is important to evaluate the endothelial surface components that may have a role in
regulating these changes. Tissue-nonspecific alkaline phosphatase (TNAP) is one such enzyme
that is highly expressed on endothelial cells, including those that comprise the BBB and GVB.
The enzyme activity afforded by alkaline phosphatases (APs) has been recognized for
over a century, yet, until recently, little was known about its physiological function in health and
disease outside of bone and mineral metabolism. In humans, there are four main isoenzymes of
alkaline phosphatases transcribed by different genes; three are tissue-specific (intestinal alkaline
phosphatase, IAP; germ cell alkaline phosphatase, GCAP; and placental alkaline phosphatase,
PLAP), and one that is tissue-nonspecific (TNAP) [68]. The four isoenzymes differ in their glycidic
residues and linkage to the protein [67]. The gene that encodes TNAP is ALPL in humans and
Alpl or Akp2 in mice. TNAP gene expression in bone, driven by exon 1A, differs from that
expressed by liver and kidney, which are both driven by exon 1B, at the mRNA level; however
the first exon is untranslated so the isoforms are identical at the protein level [99]. The reader is
referred to a recent review for additional information on the molecular genetics of AP isoenzymes
[147]. In addition to its widely studied expression in bone and teeth, TNAP is expressed by a
variety of cell types, including immune cells, neurons, and endothelial cells. In its membranebound form, TNAP is bound to the cell by a glycosylphosphatidylinositol (GPI) anchor, which
allows it to act on substrates in the extracellular space. TNAP can also be shed from the cell by
phosphatidylinositol-phospholipases, which cleave it to a soluble form, where its enzyme activity
can be detected in blood [76,77].
A role for TNAP has been well-established in the promotion of bone and teeth
mineralization through its enzymatic conversion of pyrophosphate (PPi) to monophosphate (Pi),
resulting in the creation of hydroxyapatite (HA) and interference with apatite crystallization
[293,294]. In addition, the TNAP enzyme is capable of converting ATP stepwise to adenosine,
which suggests a role for TNAP in purinergic signaling [147,295]. In the blood, brain, and spinal
cord, TNAP is inferred to limit inflammation by converting ATP to adenosine [296–298]. Two
independent genetic models of Akp2 total depletion (Alpltm1Sor/Tnap¯ (MGI ID: 1857124) and

70

Alpltm1Jlm/Akp2¯ (MGI ID: 2183411)) mimic severe infantile hypophosphatasia (HPP) and exhibit
symptoms that include bone and teeth malformations, seizures, and ultimately result in death by
approximately postnatal day 10 [78,103,197,299]. In contrast, too much TNAP enzyme activity
can promote vascular calcification, which mimics atherosclerosis, through mechanisms related to
abnormal osteogenic differentiation of vascular smooth muscle cells (VSMCs), VSMC death,
elevated levels of inorganic phosphate, and chronic inflammation [300–302]. These various
scenarios in health and disease suggest that generation of TNAP protein and the regulation of
TNAP enzymatic activity may represent a complex physiological mechanism in multiple tissues.
It also highlights the importance of knowledge needed in relation to the tissue- and cell-specific
roles of TNAP.
To test the contributions of endothelial-specific TNAP, and the effects of its loss in gut
barrier function, we bred Alpl-floxed (Alplfl/fl) mice with VE-cadherin Cre (Cdh5-Cre) mice to create
mice with a genetic deletion of TNAP on their endothelium (i.e., VE-cKO mice). To identify effects
related to disease and inflammation, we employed the cecal ligation and puncture (CLP) model
of experimental sepsis to examine differences in bacterial load, permeability, and inflammation in
VE-cKO mice compared to their littermate controls. Interestingly, loss of endothelial TNAP results
in widely-spread gut dysbiosis, not limited to the intestinal lamina propria. We found that VE-cKO
mice had a sustained increase in bacterial load, increased permeability, and a dysregulated
response to inflammation post-sepsis compared to littermate controls. Taken together, our results
have uncovered a previously unexplored, yet important, role for endothelial TNAP in gut
homeostasis.
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METHODS
Animals
All experiments were completed according to the National Institutes of Health Guide for the Care
and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use
Committee at West Virginia University. B6.FVB-Tg(Cdh5-cre)7Mlia/J (VE-Cadherin Cre, Cat. #
006137) mice were purchased from Jackson Labs (Bar Harbor, ME), and have been
characterized in [283]. To confirm Cre specificity, VE-cadherin Cre (Cdh5-Cre) mice were bred
with B6.Cg-Gt(ROSA)26Sor (Ai9, Jackson Labs, Cat. # 007909) mice (provided by Dr. Eric Tucker
in the Department of Neuroscience at West Virginia University), which express a red-fluorescent
protein variant, tdTomato, following Cre-mediated recombination. Alpl-floxed (Alplfl/fl) mice,
originally described in [132], were bred with VE-cadherin Cre mice for three generations to create
mice with a conditional deletion of TNAP on endothelial cells (i.e. VE-cKO mice) and their
littermate controls (Alplfl/fl mice). Mice were bred and aged in environmentally controlled conditions
with a reverse light cycle (12:12 h light:dark cycle) with food and water supplied ad libitum. Naïve
male Alplfl/fl and VE-cKO mice, aged 2-4 months were used for AP assay and tissue staining
experiments in Figure 3.1. For the remaining sepsis experiments, mice, aged 11-12 months, were
group-housed by genotype, treatment, and sex.
Genotyping
Animal genotypes were confirmed using DNA extracted from ear snips using the Purelink
Genomic DNA Mini Kit (Invitrogen, Carlsbad, CA). PCR products were amplified on a Veriti 96well Thermal Cycler (Applied Biosystems, ThermoFisher Scientific, Waltham, MA), ran under the
following conditions: 94°C for 1 min, [(94°C for 30 sec, 60°C for 30 sec, 72°C for 45 sec) × 40
cycles], then 72°C for 1 min. VE-Cadherin Cre presence was determined by the visualization of a
700 bp product using the following primers; ACRE_F: 5’- GAACCTGATGGACATGTTCAGGGA 3’ and ACRE_R: 5’- CAGAGTCATCCTTAGCGCCGTAAA -3’ [283]. Confirmation of floxed Alpl
sites was determined by the presence of a 263 bp product using the following primer set; Alplflox_F:
5’-

GTTGCGATGTGTGAAGATGTCCTCG

-3’

and

Alplflox_R:

5’-

CTTGGGCTTGCTGTCGCCAGTAAC -3’.
Study 1 general design
Study 1 was designed to assess survival post-sepsis for up to 8 days (Figure 3.2A). On day 0 of
the study, VE-cKO and Alplfl/fl mice underwent cecal ligation and puncture (CLP) or sham surgery
to produce the experimental groups with the following sample sizes: Alplfl/fl sham (n=10), Alplfl/fl
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CLP (n=14), VE-cKO sham (n=10), VE-cKO CLP (n=16). At baseline and day 3 post-surgery,
fecal boli were collected for short-chain fatty acid (SCFA) analysis. Mice were monitored daily
post-surgery for survival, weights, and assigned a diarrhea score. On day 8 post-surgery, blood
and tissues were harvested for further analysis.
Study 2 general design
Study 2 was designed to assess intestinal permeability at 24 hours post-sepsis (Figure 3.6A).
Mice received either CLP or sham surgery to produce experimental groups with the following
sample sizes: Alplfl/fl sham (n=16), Alplfl/fl CLP (n=23), VE-cKO sham (n=15), VE-cKO CLP (n=20).
Approximately 24 hours post-surgery, a mixture of fluorescently labeled molecules was injected
retro-orbitally into the bloodstream and allowed to circulate for 1 hour. Following circulation, mice
were deeply anesthetized with isoflurane, and blood and tissues were harvested for analysis.
Cecal Ligation and Puncture (CLP)
The cecal ligation and puncture (CLP) model of polymicrobial experimental sepsis was performed
as previously described by our laboratory [110,124]. Briefly, animals are anesthetized with 3-5%
isoflurane, then an abdominal incision is made to remove the mouse cecum. After ligation of
approximately 70% of the cecum, the ligated cecum is punctured twice, through and through, with
a 22-gauge needle. The cecum is squeezed gently until feces can be visualized, after which the
cecum is returned to the abdominal cavity, the abdomen and skin are sutured shut, and the animal
is monitored until awoken from anesthesia. Sham-operated mice also underwent isoflurane
anesthetization and received an abdominal incision, but the cecum was returned to the peritoneal
cavity free of ligation or puncturing.
Blood and tissue collection and processing
Fecal pellets for short-chain fatty acid (SCFA) analysis, collected at baseline and on day 3 postCLP, were collected on ice then stored at -80°C until analysis. Mice were deeply anesthetized
with isoflurane and blood collected transcardially into microvette tubes lined with lithium-heparin
(Sarstdet; Nümbrecht, Germany). Plasma was separated according to manufacturer’s instructions
and stored at -80°C. Mice were then transcardially perfused at 5 ml/min with sterile 0.9% saline
or 1X phosphate buffered saline (PBS). Prior to collection, intestine tissue for any assay was
flushed with 0.9% saline to remove feces. Tissues collected for AP activity assays, bacterial CFU
quantification, permeability assays, or ELISAs were weighed, homogenized for 1 min at max
speed in 500 ul sterile 0.9% saline or 1X PBS, aliquoted, and immediately plated for bacterial load
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quantification, or stored at -80°C. Tissue collected for RNA extraction were stored in RNAlater
(Invitrogen, Carlsbad, CA) at -20°C. Tissues collected for sectioning on a cryostat were flashfrozen for approximately 20 sec in a solution of cold isopentane, then stored at -20°C. Tissues
collected for immunohistochemical staining were fixed in cold 10% formalin and stored at 4°C.
Alkaline Phosphatase (AP) Enzyme Activity Assay
AP enzyme activity was detected as previously described [124] with some modifications. Briefly,
tissue homogenates were diluted 1:20 for duodenum and 1:10 for ileum using AP assay buffer
without para-nitrophenylphosphate (pNPP). Samples were plated in duplicate and mixed with AP
assay reaction buffer (1 M Tris-HCl (Tris Base: Fisher Scientific, Pittsburg, PA; Hydrochloric acid:
Sigma-Aldrich, Milwaukee, WI), 1 M MgCl2 (Fisher Scientific), 50 mM ZnCl2 (Acros Organics, NJ),
deionized water, and 13.5 mM pNPP (Millipore Sigma, Billerica, MA)). Additionally, a single
background control well was matched to each sample using AP assay control buffer (AP assay
reaction buffer with the addition of 5% sodium orthovanadate (BeanTown Chemical, Hudson,
NH)). A second set of sample and control wells were included with the addition of 50 mM LPhenylalanine (PA; Fisher, Cat. # BP391-100) in order to differentiate between activity produced
from TNAP vs. IAP, as performed by [192]. AP enzyme activity were normalized to protein
concentration using BCA Protein Assay Kit (Thermo Scientific, Cat. # 23225, Rockford, IL),
performed according to manufacturer’s instructions. AP enzyme activity levels were read
kinetically every 10 mins at O.D. 380 nm for 5 hours on a Synergy H1 Hybrid Reader and
absorbance was acquired with Gen5 Version 2.01.14 software (BioTek Instruments, Inc.,
Winooski, VT). Enzyme activity levels were compared between groups at the peaks of enzyme
activity, which were approximately 60 mins for duodenum and 260 mins for ileum.
Tissue Embedding and Sectioning
Tissues were fixed in 10% formalin at 4°C, then incubated sequentially in 10%, 20%, and 30%
sucrose in PBS for 24 hrs each at 4°C. Tissues were co-embedded into a 15% gelatin matrix for
simultaneous sectioning and staining. The gelatin block was processed sequentially through 10%
formalin, 15% sucrose, and 30% sucrose for 24 hrs at 4°C. Blocks were trimmed and frozen by
incubating them at -80°C for 1 hr. Sectioning was performed at 35 μm on a sliding microtome (HM
450, ThermoFisher Scientific) equipped with a 3 x 3 freezing stage (BFS-40MPA, Physitemp,
Clifton, NJ) at −20 °C. Sections were collected into a series of cups filled with 1X PBS + sodium
azide (0.6 g sodium azide/1 L PBS). Flash-frozen tissues were assembled in a block of optimal
cutting temperature compound (OCT, Tissue-TeK, Ref # 4583). Tissues were sectioned at 5 μm
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on a cryostat (Leica CM30505 Cryostat) onto microscope slides Unifrost+, Azer Scientific,
Morgantown, PA) and stored at -20°C until imaging.
Immunohistochemistry
The following antibodies were used (antibody information and dilutions): Endothelial cells (CD31)
- (RnD Systems (1:500), AB_1026192, Minneapolis, MN) and TNAP protein (Alpl) - (RnD Systems
(1:500), AF2909, Minneapolis, MN). Tissue immunostaining was performed as previously
described with modifications [110,124]. Briefly, tissue sections were washed 3 times in 0.01 M
(1X) PBS for 5 mins each and blocked with 10% methanol + 3% hydrogen peroxide in 1X PBS
for 15 min on a shaker to quench endogenous peroxidase. Sections were washed 3 times in 1X
PBS for 5 mins each and permeabilized (4% normal horse serum, 0.2% Triton X-100 in PBS) for
30 mins on a shaker. Sections were washed once in 1X PBS for 5 mins, then incubated overnight
with primary antibody in 1X PBS + 4% normal horse serum. The next day, sections were washed
3 times in 1X PBS for 5 mins each on a shaker, then transferred to secondary antibody in 1X PBS
+ 4% normal horse serum for 2 hrs on a shaker at room temperature. Sections were washed with
1X PBS 3 times for 5 mins each. Sections were then incubated in DAB (Vector Laboratories,
Burlingame, CA, Ref # SK-4100), prepared according to the manufacturer’s instructions, for 3
mins on a shaker. Sections were washed 3 times with 1X PBS for 5 mins on a shaker, mounted
onto slides (Unifrost+, Azer Scientific, Morgantown, PA), then allowed to dry. Once slides were
completely dry, they were dehydrated through a series of alcohols (once with 95% alcohol, and
twice each with 100% alcohol and xylene) for 5 mins each, and cover slipped with Permount
(Fisher Scientific, Pittsburgh, PA). The same steps were carried out for immunofluorescence
staining; however, the hydrogen peroxide/methanol blocking, DAB, and dehydration steps were
excluded. Fluorescent sections were mounted onto slides and cover slipped with antifade
mounting medium (Vector Laboratories, Burlingame, CA, Ref # H-1000-10).
TNAP Enzyme Activity Histochemistry
TNAP enzyme activity was evaluated from tissue sections using the BCIP/NBT substrate kit (SK5400, Vector Laboratories, Burlingame, CA) as previously described [110,124]. Briefly, tissue
sections were rinsed 3 times in 0.1M Tris-HCl (pH = 9.5) for 5 min and incubated in BCIP/NBT
staining solution + 50 mM PA for 3 or 6 hr at room temperature. Following incubation, sections
were rinsed in 1X PBS, mounted onto microscope slides, and airdried overnight. The next day,
slides were taken through a standard dehydration series and cover slipped with Permount.
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Image Analysis
Fixed and frozen tissue sections were imaged on a Leica DM6B microscope (Leica Camera,
Allendale, NJ) captured using Leica LASX software (Leica Microsystems, Buffalo Grove, IL).
Images were captured at 10X, 20X or 40X, as indicated in the figure legend. For quantification of
fluorescent images, a minimum of 3 fields from 2 sections per animal were collected and images
were quantified using FIJI/Image J version 2.0 software.
Percent weight change and diarrhea score
Mouse weights were recorded at baseline and once daily in the morning post-CLP. Baseline
weight was changed to 100%, and percent weight change was calculated using the following
formula: 100 – (((baseline weight – new weight) / baseline weight)*100). Diarrhea scoring was
completed using a portion of the validated modified murine sepsis severity score (MMSS) system
used by our lab [110]. The scoring system is as follows: 0 = normal; 1 = mild, small increase
compared to normal amount of feces; 2 = moderate, significant increase compared to normal
amount of feces; 3 = severe compared to normal amount of feces, includes sticky or loose stool;
4 = severe and sticky/impacted loose stool, which may require removal by the investigator.
Bacterial burden quantification
Serial dilutions of blood or tissue homogenate were performed using 1X PBS in a 96-well plate.
10 µl of sample was plated in triplicate on brain-heart infusion (BHI) agar and incubated at 37°C
under either aerobic or anaerobic conditions, as indicated. After 24 hr incubation, the number of
colony-forming units (CFUs) of bacteria were recorded from the countable dilution and normalized
to tissue weight.
Nucleic acid isolation and quantitative reverse transcriptase polymerase chain reaction (qRTPCR)
Intestine tissue RNA was isolated using TRIzol (Ambion, Carlsbad, CA) and the RNeasy Mini Kit
(Qiagen, Germantown, MD) following the protocol listed in the RNeasy Lipid Tissue Mini
Handbook (Qiagen), with a slight modification. In place of the TissueRuptor II or TissueLyser II, a
Mini-Beadbeater (Biospec Products, Bartlesville, OK) was used with the settings on max speed
for 2 mins. Liver and lung tissue RNA was isolated using the RNeasy Mini Kit. Generation of cDNA
was performed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Foster City, CA). PCR amplification was performed with Bio-Rad SsoAdvanced Universal SYBR
Green Supermix on a C1000 Touch Thermal Cycler with a CFX384 system (Bio-Rad, Hercules,
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CA) under the following conditions: 95°C for 2 mins, then 95°C for 5 sec and 60°C for 30 sec for
39 cycles. Relative gene expression was quantified using the following validated primer sets
purchased from Integrated DNA Technologies (IDT, Coralville, IA): mucin-2 (Muc2,
Mm.PT.58.29496069.g) and -4 (Muc4, Mm.PT.56a.7498123), regenerating islet-derived protein
3-beta (Reg3β, Mm.PT.58.6726650) and -gamma (Reg3γ, Mm.PT.58.12757535), plasmalemma
vesicle associated protein (Plvap, Mm.PT.58.28447797), mucosal vascular addressin cell
adhesion

molecule

1

(MADCAM1,

Mm.PT.58.28611018),

E-selectin

(Sele,

Mm.PT.58.29497526), P-selectin (Selp, Mm.PT.58.42554288), vascular cell adhesion molecule1

(VCAM1,

Mm.PT.58.9687546),

intracellular

adhesion

molecule-1

(ICAM1,

Mm.PT.58.43714327), claudin 5 (Cldn5, Mm.PT.58.33394738.g), claudin 12 (Cldn12,
Mm.PT.58.41535303), occludin (Ocln, Mm.PT.58.30118962), zonula occludens-1 (ZO-1, Tjp1,
Mm.PT.58.12952721), glucose transporter 1 (Glut1, Slc2a1, Mm.PT.58.7590689), and Pglycoprotein (P-gp, Abcb1b, Mm.PT.58.5959129), which were all normalized to housekeeping
gene cyclase associated actin cytoskeleton regulatory protein 1 (Cap1, Mm.PT.58.44007407).
Bacterial DNA was isolated from tissue using the DNeasy Blood & Tissue Kit (Qiagen,
Germantown, MD). Previously validated primers for amplification of Firmicutes, Bacteroidetes,
Actinobacteria, and the 16S rRNA gene [303] were obtained from IDT and PCR reactions
performed as described above.
Short-chain fatty acid (SCFA) analysis
Fecal boli collected for SCFA analysis were packed on dry ice and shipped overnight to
Microbiome Insights (Vancouver, BC, Canada). All samples were tested at the same time. The
SCFA extraction procedure was similar to that of [304]. Briefly, fecal samples were resuspended
in MilliQ-grade water and homogenized using MP Bio FastPrep for 1 min at 4 m/s. 5M HCl was
added to acidify the fecal suspensions to a final pH of 2. Acidified fecal suspensions were
incubated and centrifuged at 10,000 RPM to separate the supernatant. Fecal supernatants were
spiked with 2-Ethylbutyric acid for a final concentration of 1 mM. Extracted SCFA supernatants
were stored in 2 ml GC vials with glass inserts. SCFAs were detected using gas chromatography
(Thermo Trace 1310), coupled to a flame ionization detector (Thermo), using a SCFA column
(Thermo TG-WAXMS A GC Column, 30 m, 0.32 mm, 0.25 um). SCFA detection was performed
under the conditions listed below. SCFA standards from Fisher: Acetic Acid (Glacial, ACS-Pur
Cat. # 351271-212), and Sigma Aldrich: Propionic Acid (Cat. # 94425-5ML-F), Isobutryic Acid
(Cat. # I1754-100ML), Butyric Acid (Cat. # B103500-100ML), Isovaleric Acid (Cat. # 129542100ML), Valeric Acid (Cat. #240370-5ML), Hexanoic Acid (Cat. # 153745-100G), Heptanoic Acid
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(Cat. # 75190-100ML), and 2-Ethylbutyric Acid (Cat. # 109959-100ML) were used to generate
standard curves for SCFA quantification. Concentrations were normalized to the amount of input
material (mmol SCFA / kg fecal boli).
Whole tissue permeability assay
A mixture of the following fluorescently-labeled molecules from Life Technologies (Carlsbad, CA)
were used for permeability size analysis post-CLP: Rhodamine 123 (FluoroPure Grade, 380 Da,
Cat. # R22420), Texas Red (Sulforhodamine 101, 625 Da, Cat. # S359), Cascade blue-3 kDa
dextran (Anionic, Lysine Fixable, Cat. # D7132), and Albumin from Bovine Serum (BSA, Alexa
Fluor 647 conjugate, 69 kDa; Cat. # A34785). The dyes were injected retro-orbitally into the
circulation at a concentration of 2 mM, and allowed to circulate for 1 hour. After blood collection,
mice were deeply anesthetized and perfused transcardially with 1X PBS to remove blood from
tissue. Tissues collected for analysis were weighed, homogenized in 500 ul of 1X PBS, and
centrifuged at 15,000 g for 20 mins at 4°C. Supernatants were transferred to a new
microcentrifuge tube. Duodenum samples were diluted 1:100 and lung samples were diluted 1:20.
Samples were plated in duplicate into a black 96-well plate and fluorescence read on a plate
reader (BioTek, Winooski, VT) using the following respective excitation/emission filters:
Rhodamine (488/525 nm), Texas red (561/605 nm), cascade blue-3 kDa dextran (360/450 nm)
and Albumin (640/670 nm).
Enzyme-linked Immunosorbent assay (ELISA)
Detection of IgA (Invitrogen, Cat. # 88-50450-88, Carlsbad, CA), IL-6 (Invitrogen, Cat. # 88-706488, Carlsbad, CA), IL-1b (Invitrogen, Cat. # 88-7013-88, Carlsbad, CA), and IL-18 (Abcam, Cat.
# ab216165, Cambridge, MA) were conducted using standard ELISA kits according to the
manufacturer’s instructions.
Statistics
Student’s unpaired t-test was performed to compare one independent variable between two
groups. Two-way ANOVA was used to assess data with two independent variables. Three-way
ANOVA was used to assess data with three independent variables. Post-hoc testing was used to
compare differences between groups following ANOVA. Details for individual experiments are
described in the figure legends. Outliers were eliminated using the ROUT method (Q=1%) prior
to additional statistical analyses. All statistical analyses were performed in GraphPad Prism 9.0
(GraphPad Software, Inc. La Jolla, CA) with p£0.05 as significant. Statistical significance is
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indicated by the following annotations: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. All results
are expressed as means ± SEM.
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RESULTS
Alkaline phosphatase activity in VE-cKO and Alplfl/fl intestine
This is the first study examining how deletion of endothelial TNAP affects the GVB,
therefore we first sought to verify our mouse model (i.e., VE-cKO mice) at the level of the intestine.
Supplementary Figure 3.1 shows that the Cdh5(VE)-Cre mice, when crossed with a
Ai9(tdTomato)-Reporter mouse, target endothelial cells. We also verified that vascular endothelial
cells of the intestine in adult mice have AP enzyme activity (Figure 3.1A). Using whole tissue
lysates of duodenum and ileum tissue, we determined there was an overall depletion of TNAP
activity in the duodenum, but not the ileum (Figure 3.1B). However, deletion of endothelial TNAP
in both segments was confirmed using intestine tissue sections and an AP enzyme activity stain
(Figure 3.1C).
Deletion of endothelial TNAP increases bacterial burden in males and diminishes survival
in female mice post-CLP
Naïve VE-cKO mice appear healthy and do not have any obvious physical or behavioral
defects compared to Alplfl/fl littermate control mice; therefore, we wanted to determine if their
responses to a model of inflammation and infection differed from that of controls. To determine if
deletion of endothelial TNAP had an effect on sepsis survival, we employed the cecal ligation and
puncture (CLP) model of experimental sepsis. Baseline weights and fecal boli were collected prior
to surgery, then animals were assigned either CLP or sham surgery on day 0 of the study. Animals
were monitored daily for up to day 7 post-CLP, with an additional fecal boli collection on day 3,
then tissues were harvested for analysis on day 8 (Figure 3.2A). While Alplfl/fl CLP males
experienced higher mortality than VE-cKO CLP males, it was the opposite in females, where
female VE-cKO CLP mice had 56% survival compared to 86% in their Alplfl/fl CLP counterparts
(Figure 3.2B). VE-cKO and Alplfl/fl mice experienced similar depletions in weight (Figure 3.2C),
while VE-cKO mice had higher diarrhea scores early after sepsis onset compared to controls
(Figure 3.2D). Bacterial burden was enhanced in VE-cKO male duodenum, ileum, and lung postCLP (Figure 3.2E-I).
Deletion of endothelial TNAP enhances gut dysbiosis post-CLP
Firmicutes, Bacteroides, and Actinobacteria are three of the most abundant bacterial phyla
in humans and mice, and the ratio of Firmicutes to Bacteroidetes has been used as a determinant
of health outcome [305,306]. Also, proportions of bacteria post-sepsis are shifted as the gut takes
on an overall more pathogenic phenotype. Therefore, we measured the relative expression of
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these phyla in the intestine and distal organs at 8 days post-CLP (Supplementary Figure 3.2).
Overall, the upper intestine (duodenum and jejunum) of VE-cKO CLP mice had greater increases
in Actinobacteria compared to their Alplfl/fl CLP counterparts. Also, there was a genotype x CLP
effect (p=0.0386) in the ileum, where it appears that VE-cKO CLP mouse Firmicutes are
decreased at 8 days after CLP, while Alplfl/fl CLP Firmicutes are not. This shift led to a diminished
F:B ratio in the ileum of VE-cKO CLP female mice (Figure 3.3C). Meanwhile, there was an effect
of genotype in the jejunum (Figure 3.3B, p=0.0440), and an effect of CLP in the duodenum
(Figure 3.3A, p=0.0106), liver (Figure 3.3E, p<0.0001), and lung (Figure 3.3F, p=0.0002), with
no effects on this ratio observed in the colon (Figure 3.3D).
Shifts in the composition of bacteria also typically result in changes in the types of soluble
bacterial products, including short-chain fatty acids (SCFAs). We measured baseline levels of
fecal SCFAs and observed an effect of genotype x sex (p=0.0207) for acetic acid, where it was
slightly lower in male and slightly higher in female VE-cKO mice compared to controls
(Supplementary Figure 3.3A). By 3 days post-CLP, butyric acid (Figure 3.3H) and propionic
acid (Figure 3I) appeared depleted in VE-cKO CLP females, while there was a main effect of CLP
(p=0.0532) on acetic acid levels (Figure 3.3G). There were also no differences in isobutyric acid,
and a CLP-dependent depletion (p=0.0008) of isovaleric acid in both genotypes (Supplementary
3.3B). Mucus and antimicrobial proteins help tame luminal bacteria and keep it separated from
intestinal tissue. During sepsis, the mucosal layer becomes thinner as damage to the epithelial
layer diminishes its ability to maintain a healthy barrier. Therefore, we examined relative
expression of some of these important antimicrobial genes using qRT-PCR. We observed that
relative expression of Muc2 was diminished in VE-cKO female duodenum and ileum post-CLP,
but not in the lung (Figure 3.3J-K). There were no changes in Muc4 expression in the duodenum,
but there was an overall increase in Muc4 in the ileum after CLP (p=0.0328) (Supplementary
Figure 3.4D-E). There was also a depletion in Reg3g expression in VE-cKO male ileum after CLP
(Figure 3.3N), meanwhile there were main effects of CLP in the duodenum (Figure 3.3M,
p=0.0273) and lung (Figure 3.3O, p=0.0085) in both genotypes. Overall, Reg3b was increased
in the duodenum (p=0.0092), but decreased in the ileum (p=0.0054) and lung (p=0.0017) after
CLP (Supplementary Figure 3.4G-I).
Relative expression of selectin adhesion molecules is reduced in VE-cKO male ileum
In sepsis, leukocyte activation and recruitment into host tissues play a critical part in
causing the breakdown of vascular endothelium [307,308]. These events can be triggered from
soluble mediators including LPS and cytokines, which upregulate adhesion expression on both
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the endothelium and leukocytes. Selectin molecules mainly function in leukocyte rolling, while
VCAM-1 and ICAM-1 are important for firm adhesion and transendothelial migration [308,309]. Eselectin and P-selectin relative expression was decreased in VE-cKO male ileum, but not male
duodenum, or in VE-cKO females (Figure 3.4A-D). Meanwhile, MAdCAM-1, VCAM-1, and ICAM1 relative expression was similarly elevated in the duodenum and ileum of both genotypes after
CLP (Figure 3.4E-J).
Relative expression of tight junction proteins in late sepsis
Tight junction and adherens junction proteins regulate the movement of fluids and solutes
between barrier cells, including endothelial and epithelial cells. In sepsis, when the intestine
becomes hyperpermeable, junction protein expression is altered. At 8 days post-CLP, we saw
that relative expression of Cldn5 was increased in Alplfl/fl male ileum, but not VE-cKO male ileum,
female ileum (Figure 3.5B), or duodenum tissue (Figure 3.5A). There was a genotype x sex
interaction (p=0.0171) on Cldn12 in ileum, but not duodenum (Figure 3.5C-D). There was also a
genotype x CLP x sex interaction (p=0.0492) on Ocln in duodenum, but no changes in ileum
(Figure 3.5E-F). Lastly, there was a main effect of sex (p=0.0121) on ZO-1 expression in the
duodenum, but no difference in the ileum (Figure 3.5G-H). Tight junction proteins were also
changed in the lungs post-CLP (Supplementary Figure 3.5), with a genotype x CLP interaction
for Cldn5 (Supplementary Figure 3.5A, p=0.0378).
Deletion of endothelial TNAP alters IgA and cytokine expression, while bacterial burden is
unchanged, 24 hours post-CLP
Given the differences that we saw in bacterial burden at 8 days post-CLP, we wanted to
examine bacterial burden and parameters of inflammation at an earlier timepoint. Also, we
designed the study to assess vascular and intestinal permeability post-CLP (Figure 3.6A). While
aerobic bacterial burden was similar between genotypes in the duodenum and ileum, there was
a genotype x CLP interaction (p=0.0143) in the lung (Figure 3.6B-D). There was a genotype x
CLP (p=0.0403) and genotype x sex (p=0.0331) interaction for anaerobic bacterial burden in the
duodenum, while anaerobic bacterial burden was similarly elevated in ileum and lung between
genotypes post-CLP (Figure 3.6E-G). Systemic circulation of bacteria and inflammatory
substrates can occur through both the vasculature and lymphatic systems. In order to determine
the primary route of bacterial translocation, we measured bacterial burden in the mesenteric
lymph node (MLN) and blood. While we observed an increased bacterial load in both MLN and
blood post-CLP, bacterial load, especially anaerobic bacterial load, was higher in MLN compared
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to blood (Figure 3.6H-K). Interestingly, in the blood, there was a genotype x CLP interaction
(p=0.0311) showing decreased anaerobic bacterial burden in VE-cKO mice compared to controls
(Figure 3.6K).
In the intestine, B cells produce high amounts of immunoglobulin A (IgA), which can move
into the circulation or out into the intestinal lumen to aid in the control of bacteria. There were
main effects of genotype on IgA production both in the duodenum (Figure 3.7A, p=0.0013) and
ileum (Figure 3.7B, p=0.0316). There was also a main effect of genotype in colon IgA
(Supplementary Figure 3.6A, left), but no changes in lung IgA (Supplementary Figure 3.6B,
left). Interestingly, there was reduced production of IL-6 in VE-cKO mouse ileum (Figure 3.7D),
colon (Supplementary Figure 3.6A, right), and lung (Supplementary Figure 3.6B, right), but
not duodenum (Figure 3.7C) at 24 hours post-CLP. There was a CLP x sex interaction (p=0.0188)
showing reduced production of IL-1b in male duodenum compared to female duodenum after CLP
(Figure 3.7E). There was also a main effect of genotype (p=0.0202) on IL-18 production in
duodenum, showing lower production of IL-18 in VE-cKO mice compared to controls (Figure
3.7F).
Deletion of endothelial TNAP results in exaggerated intestine hyperpermeability at 24
hours post-CLP
During sepsis, the intestine becomes more permeable, allowing the movement of bacteria
and solutes which would usually be confined to the intestinal lumen. The quantities and sizes of
solutes that gain the ability to move freely depend on the amount of tissue barrier damage. We
did not see differences in the relative expression of Plvap, an endothelial damage marker, at 8
days post-CLP in the duodenum, ileum, or lung (Supplementary Figure 3.4A-C), but this could
be due to the late timepoint. To assess vascular and intestinal permeability 24 hours post-CLP,
we injected a mixture of fluorescent molecules of differing sizes (Rhodamine 123 = 380 Da, Texas
Red = 625 Da, Cascade blue-3 kDa dextran = 3 kDa, Albumin = 69 kDa) intravenously, allowed
the molecules to circulate for 1 hour, then collected tissues and blood for analysis (Figure 3.6A).
During optimization of the permeability study design, we noticed that permeability within the
jejunum was highly variable, therefore we excluded this region from formal analysis. Initial
analysis also included sex as a variable, but we did not find any effects of sex, so we combined
sex in all groups for the permeability results.
Relative florescence of the smallest molecule injected, Rhodamine 123, showed reduced
fluorescence in whole tissue lysate from duodenum and ileum in CLP animals of both genotypes
(Supplementary Figure 3.7A-B). Frozen tissue analysis of duodenum villi and submucosa mimic
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this finding (Supplementary Figure 3.7C-E), however, there are only main effects of genotype,
with lower fluorescence in VE-cKO mice, in the ileum villi (p=0.0126) and submucosa (p=0.0445)
(Supplementary Figure 3.7F-H). P-glycoprotein is a known transporter of rhodamine 123, so we
measured its gene expression in the tissue we had collected at 8 days post-CLP, along with
another transporter gene, Glut1 (Supplementary Figure 3.4J-O). While there was a significant
effect of CLP in whole tissue lysates from both genotypes, Texas red fluorescence was increased
in the duodenum, but reduced in the ileum (Figure 3.8A-B). Frozen tissue analysis showed there
were genotype x CLP interaction for Texas red fluorescence in the villi (p=0.0145) and submucosa
(p=0.0310) of duodenum tissue (Figure 3.8C-E). Fluorescence intensity in the ileum was greatest
in Alplfl/fl sham mice, and decreased after CLP and in VE-cKO mouse tissue (Figure 3.8F-H).
Cascade blue-3 kDa dextran fluorescence was decreased after CLP treatment in VEcKO duodenum whole tissue lysate compared to Alplfl/fl duodenum (Figure 3.9A), while there was
an overall decrease in cascade blue fluorescence in VE-cKO ileum regardless of treatment
(Figure 3.9B). There were no differences in cascade blue fluorescence in the villi or submucosa
of duodenum tissue (Figure 3.9C-E). Fluorescence intensity was greatest in Alplfl/fl sham ileum,
and decreased after CLP and in VE-cKO ileum (Figure 3.9F-H). For the largest molecule,
albumin, there was a genotype x CLP interaction (p=0.0154) in the ileum, with highest albumin
fluorescence in the VE-cKO sham group (Figure 3.10B), while there were no differences in the
duodenum (Figure 3.10A). Frozen tissue analysis showed that duodenum albumin fluorescence
was highest in Alplfl/fl CLP mice, while decreased in VE-cKO CLP mice villi, and there were similar
trends in the submucosa (Figure 3.10C-E). In the ileum, albumin fluorescence intensity was
greatest in the Alplfl/fl sham group, and decreased after CLP and in VE-cKO mice (Figure 3.10FH). Using frozen tissue analysis, we assessed fluorescence in the center of villi alone and the
crypts in duodenum and ileum tissue (Supplementary Figure 3.8). Permeability, using whole
tissue lysates and frozen tissue, was assessed in the colon (Supplementary Figure 3.9). Whole
tissue lysate fluorescence was also measured in the lungs and plasma (Supplementary Figure
3.10).
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DISCUSSION
In this study, we identified two conceivable pathways in which endothelial TNAP is
protective in sepsis: (1) maintaining barrier integrity at 24 hours post-CLP to stop the passage of
harmful bacteria and substrates from extravasation into the bloodstream and (2) promoting gut
homeostasis and a reduced bacterial load at 8 days post-CLP, as shown in our summary Figure
3.11. To the best of our knowledge, this is the first study to examine the effects of endothelial
TNAP on intestinal tissue and the first to perform a rigorous permeability analysis of the intestine
by quantification of fluorescent dyes in whole tissues as well as tissue sections. Our studies
demonstrate that deciphering the contribution of endothelial TNAP at the GVB is crucial to
understand the mechanisms through which inflammation impacts intestinal function in health and
disease.
The interplay between alkaline phosphatases in the small intestine is not well understood.
Our mouse model allows us to distinguish between the TNAP-mediated effects in endothelial cells
rather than the more widely studied effects of intestinal alkaline phosphatase (IAP) in epithelial
cells. These differences, in turn, distinguish further between the effects of the well-characterized
gut-epithelial barrier compared to the lesser studied GVB. IAP is one of the best-characterized
AP isoforms and has classically been assumed to participate in nutrient absorption due to its
location on the brush border of epithelial cells. In addition to controlling lipid absorption [185], IAP
has roles in regulating intestinal homeostasis involving bicarbonate secretion [186,187],
controlling inflammation and infection [81,84,188,189], and limiting bacterial translocation across
the mucosal barrier [190–192]. In contrast, while IAP is expressed on the brush border of epithelial
cells, TNAP is expressed by leukocytes, endothelial cells, and other cell types that make up
intestinal tissue.
It has been shown in inflammatory bowel disease that an increase in colonic TNAP is due
to both an influx of leukocytes into the inflamed colon, as well as enhanced expression in epithelial
cells [199–201]. While TNAP is expressed on lymphocytes with low baseline levels, it appears to
have a role in the differentiation of B and T lymphocytes. TNAP activity is upregulated on activated
B cells and correlates with antibody secretion, which is likely part of a general mechanism that
allows TNAP to control the proliferation-differentiation ratio by dephosphorylation [202,203].
Others have shown that T cells from Alpl+/- mice exhibit a reduced response to stimuli in vitro and
in vivo, suggesting TNAP is needed for complete stimulation of T cells [148]. TNAP is also
expressed by neutrophils and macrophages, although it’s possible functions in these cells
remains unclear [199,204]. Since the role of endothelial TNAP in the intestine had not been
previously explored, we speculated that it might share redundant functions with IAP, such as
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those involved in controlling bacteria and barrier function. TNAP’s roles may also differ by small
intestine region, as we identified that its activity was greatest in duodenum and lesser activity was
measured in the ileum.
We established that, while there was a similar bacterial load between VE-cKO and Alplfl/fl
mice 24 hours post-CLP, bacterial load is retained at 8 days in VE-cKO mice, which indicates that
these bacterial clearance mechanisms are impaired in these mice. Bacterial clearance, or
bacterial killing, is usually measured by the ability of phagocytic cells, including macrophages,
neutrophils, and dendritic cells, to uptake and neutralize bacteria. However, there are other ways
that immune cells can kill bacteria without phagocytosis, such as the formation of neutrophil
extracellular traps (NETs) by neutrophils [310]. Since our mouse model contains a conditional
deletion of TNAP protein, and therefore activity, on endothelial cells, there are no direct effects of
this enzyme on phagocytic cells. This supports the hypothesis that the lack of bacterial clearance
could be due to a defect in recruitment of these phagocytic cells by the endothelial cells to the
site of infection.
It has been well-established that selectins are increased in mice after CLP [311].
Interestingly, in healthy subjects, E-selectin levels were positively associated with AP [312].
However, our data was the first to show that deletion of endothelial TNAP lead to reductions in
the expression of E- and P-selectin in mice by 8 days after CLP. Recruitment of leukocytes to the
endothelial cell surface and subsequent infiltration into the interstitium is believed to be the initial
event that leads to hyperinflammation and multi-organ dysfunction in sepsis [313,314]. This
process involves a series of well-orchestrated adhesive interactions between the endothelial cell
and leukocyte surface. This invading movement causes damage to the tissue as blocking E- and
P-selectins protect mice from sepsis-induced acute kidney injury [315,316]. Selectins play an
important role in the immune response to infection. For example, host defense to systemic
Streptococcus pneumonia infection is impaired in E- and P-selectin deficient mice [317]. This
indicates that VE-cKO mice have an impaired immune response to CLP, and the lack of selectin
expression may reduce the recruitment of leukocytes to the site of infection. Future studies will
investigate the role of endothelial cell adhesion markers to establish a more definitive basis for
defects in endothelial-mediated lymphocyte recruitment.
Our findings of positive bacterial cultures from both mesenteric lymph node (MLN) and
blood, are consistent with literature that suggests pathogens disseminate through both vascular
and lymphatic systems in response to proinflammatory triggers [11,318]. Bacterial translocation
to MLN is increased 48 hours post-intestinal ischemia/reperfusion injury [189]. In vivo imaging
shows translocation of fluorescent tracer bacteria to liver and lung is upregulated in mice with
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peritonitis [319]. IAP treatment has been shown to reduce bacterial translocation in these same
experimental models [189,319]. Bacterial translocation to the MLN, liver, blood, and abdominal
cavity was increased after CLP, but unaffected by IAP treatment (twice daily for 2 days). Similar
to our results, positive bacterial cultures were identified in MLN more often compared to blood
post-CLP [192].
In addition to demonstrating an increased bacterial load in late sepsis in VE-cKO mice, we
observed a diminished F:B ratio, enhanced expression of IgA, and a greater depletion of SCFAs.
These indices are indicative of a disruption in gut homeostasis, and by extension, an increase in
gut dysbiosis. While a pattern of increased F:B has been well-established to be associated with
worse outcomes in metabolic disease [305,306], the literature on the significance of this ratio in
sepsis is less clear. In one clinical study, four of six critically ill patients who died had a higher
abundance of Bacteroidetes compared to Firmicutes in their fecal samples [320], while another
study found a relative, though nonsignificant, increase of Bacteroidetes in 11 of 34 critically ill
patients [182]. The directionality of changes for different gut taxa in sepsis also remains unclear.
Since the F:B ratio varies widely in healthy subjects, larger sample sizes in human sepsis studies
are necessary to achieve adequate statistical power in order to assess the translatability of our
results [182,321].
Elevated tissue lysate levels of IgA observed in VE-cKO mouse duodenum are consistent
with the increased bacterial burden. IgA contributes to the development, maintenance, diversity,
and overall health of the microbiota by preferentially targeting harmful bacteria [322–324]. IgA’s
protection also extends to bacteria that have escaped the intestines, such as in sepsis [325], and
septic patients with reduced levels of IgA have increased mortality [326]. In mice, maintaining
circulating IgA after sepsis was protective even in the absence of luminal IgA [327]. Inflammation
and changes in bacterial composition also effect the amounts and types of bacterial metabolites,
including short-chain fatty acids (SCFA), that enter circulation. In general, SCFAs are thought to
be anti-inflammatory through mechanisms not yet well-understood. Locally, SCFAs maintain
intestinal barrier integrity, protect from intestinal inflammation [328], affect gastrointestinal mucus
production [329,330], and may affect gastrointestinal motility [331]. These findings are consistent
with our results that show enhanced depletion of Muc2 in female VE-cKO septic mouse
duodenum and ileum.
Proinflammatory cytokines IL-6 and IL-1b are typically elevated in both clinical and
experimental sepsis, and promote tissue damage, inflammation, and infection [192,332–334].
Importantly, IL-6 and IL-1b act on endothelial cells to increase their adherence to lymphocytes
[335]. Cytokines produced by endothelial cells, in turn, enhance the inflammatory response and
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initiate tissue damage [336–338]. Additionally, IL-6 and IL-1b production correlates with enhanced
TNAP expression. Recombinant human IL-1a and IL-1b enhance AP activity in murine
osteoblasts [339]. IL-6 induces high TNAP activity in cultured aortic and brain endothelial cells
[340]. Alpl+/- mice with acute pancreatitis displayed increased expression of Il6 and Il1b in the
pancreas [341]. Similarly to our results, which showed that VE-cKO mice produced lower levels
of IL-6 post-CLP, Alpl+/- mice express reduced levels of IL-6 following splenocyte stimulation with
LPS [148].
A previous study from our laboratory demonstrated that pharmacological inhibition of
TNAP on murine brain microvascular endothelial cells (BMECs) decreases barrier function [124].
We have also shown that in septic mice, reduced expression of TNAP activity in cerebral
microvessels of the blood-brain barrier (BBB) is coupled with reduced expression of claudin 5 and
increased IgG permeability in the brain [110]. The presumed role of endothelial TNAP at the BBB
lead us to the hypothesis that endothelial TNAP may also regulate permeability of the GVB. In
sepsis, intestinal hyperpermeability allows for the transport of bacteria, bacterial products, and
other substrates that would normally be restricted to the intestinal lumen [342]. Our permeability
results varied depending on intestinal region, size of the molecule, genotype, and physiological
state. In general, we observed increased fluorescence in the whole tissue lysate from duodenum
of both genotypes 24 hours after sepsis-induction. The duodenum revealed a decrease in
cascade blue-3 kDa dextran in VE-cKO septic mice compared to Alplfl/fl septic mice, and a
reduction in albumin specifically within the villi. Within the whole tissue lysate from ileum, Texas
red was decreased at 24 hours after sepsis, while cascade blue-3 kDa dextran was increased.
There was a reduced amount of albumin in VE-cKO mice, but an increased accumulation of
albumin in Alplfl/fl mice post-sepsis. Interestingly, ileum spatial analysis revealed a decreased
accumulation of all fluorescent molecules in VE-cKO sham mice compared to Alplfl/fl mice.
These observations lead us to believe that the reduced accumulation of fluorescent
molecules in sham (ileum) and septic (duodenum) VE-cKO mice compared to controls may
indicate an increased flux of these molecules to the intestinal lumen. We speculate that these
molecules were flushed away with saline during tissue perfusion that is necessary prior to whole
tissue lysate and frozen tissue analysis. Perfusion is necessary because intestinal fecal matter is
highly autofluorescent and is a confounding variable that must be removed for an accurate
analysis. While this is the first study to establish a role for endothelial TNAP in intestinal
permeability post-sepsis, we recognize there are several factors to consider when comparing our
our results to previously published literature. These factors primarily include: (1) the route of
fluorescent molecule administration, (2) our choice of fluorescent molecules and their respective
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characteristics, and (3) the amount of time that we allowed our molecules to circulate prior to
perfusion and tissue collection. For example, separate studies using oral gavage of a 4 kDa and
40 kDa Fluorescein isothiocyanate (FITC)-dextran in mice describe significant extravasation of
molecules into the blood post-CLP [192,319]; however, we opted to use the retro-orbital injection
of molecules directly into the circulation, which allowed us to assess permeability in multiple
organs.
Oami and Coopersmith (2021) have recently reported a novel strategy to interpret the
changes that are particularly germane to intestinal permeability pathways during sepsis. Namely,
the pore (≤6 Å), leak (<100 Å), and unrestricted pathways are the modes to which substrates,
depending on their molecular characteristics and the host’s pathological condition, are able to
penetrate a tissue barrier. The two smallest pathways are tight junction-dependent and provide
insights on paracellular permeability [343]. Tight junction proteins, which contribute to endothelial
cell permeability, are typically altered after sepsis. For example, mRNA or protein levels of Claudin
5, ZO-1, and occludin are decreased in animals post-CLP [192,344]. Our results showing that
relative expression of Cldn5 is decreased in septic male VE-cKO mice compared to Alplfl/fl mice is
consistent with our previous observation that claudin 5 protein was diminished in septic mice
following administration of a TNAP inhibitor compared to their vehicle-treated counterparts [110].
One of our most interesting observations was that VE-cKO female mice have decreased
survival post-sepsis compared to males (56% vs 100%). Therefore, we powered the study to
analyze to assess sex differences at 8 days post-sepsis. Since we did not observe any effects of
sex on permeability, and therefore, combined males and females for this analysis. This is in
contrast to the known sexual dimorphism in sepsis, wherein survival and sepsis severity are
generally more severe in males [345,346]. In humans, serum AP reference values vary by age
and sex, with values typically ranging higher in males than females [347]. Our results also suggest
a sex-dependent role for TNAP, however, a more rigorous analysis of sex differences which
includes assessment of estrous cyclicity and circulating gonadal hormone levels are needed to
identify the mechanisms behind these differences.
The results displayed here have provided us with several avenues for future analysis. For
example, cell phenotyping and quantification are necessary to confirm if there are reduced
lymphocyte and/or phagocytic cell populations recruited to the intestine of VE-cKO mice, which
may contribute to the prolonged bacterial burden post-CLP. Our previous study using a
pharmacological inhibitor of TNAP showed reduced mean fluorescence intensity of CD8+,
CD8+Foxp3+, and CD4+Foxp3+ splenocytes [124]; however, these results cannot be contributed
to any cell-specific roles of TNAP since the inhibitor targets a specific AP enzyme, TNAP, which
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is expressed in numerous cell types. It is also not clear whether the retained bacterial burden in
VE-cKO distal tissues, including liver and lung, is due to bacterial translocation or expansion of
bacteria in this model. Additional future studies will assess mechanisms of bacterial clearance
and bacterial killing in VE-cKO mice. Taken together, our results provide two potential roles for
endothelial TNAP at the GVB in infection and inflammation. Deletion of TNAP on endothelial cells
resulted in retained bacterial burden and gut dysbiosis for up to 8 days post-CLP, and
exaggerated gut permeability at 24 hours post-CLP. Deletion of TNAP resulted in several indices
of gut dysbiosis, including a decreased F:B ratio, altered levels of IgA and cytokine responses,
and reductions in fecal SCFA composition post-CLP. We have also provided information on the
how this role may differ between small intestinal regions, by post-sepsis timing, and by sex. We
believe that our studies provide novel insights into the cell-specific functions of endothelial TNAP
in the intestine, which, in turn, provides mechanistic insights into the function and regulation of
the GVB in healthy and septic individuals.
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FIGURES

Figure 3.1. Alkaline phosphatase (AP) enzyme activity in VE-cKO and Alplfl/fl intestine
(A) Representative intestine (ileum) images from VE-tdTomato reporter mice confirm that AP
enzyme activity overlaps with the vascular endothelium. Formalin-fixed mouse intestines were
gelatin-embedded, sectioned at 35 µm using a microtome, and stained for AP enzyme activity.
Representative images for tdTomato-fluorescent VE (red), AP enzyme activity (blue), and a
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merge of both were taken on a Leica microscope at 20X magnification. Scale bar in bottom right
= 25 (left, middle) or 75 (right) µm.
(B) Similar lengths of VE-cKO and Alplfl/fl mice intestine regions were collected, flushed with 0.9%
saline, and homogenized in 500 ul of saline for quantification of AP enzyme activity as previously
described [124]. AP activity was normalized to the amount of total protein per sample. TNAP was
distinguished from IAP with the addition of 50 mmol L-Phenylalanine, an intestinal IAP inhibitor,
to the assay [192]. The total amount of TNAP was reduced in VE-cKO duodenum (Genotype x
AP interaction p=0.0178), but not ileum, compared to control mice. Data were analyzed using
two-way ANOVA followed by Tukey’s multiple comparisons test (*p=0.0395); n=10 mice per
genotype.
(C) Intestine histology from VE-cKO and Alplfl/fl control mice confirm there is reduced AP protein
(black arrow) and enzyme activity (white arrows) in the intestine vasculature of VE-cKO mice.
Formalin-fixed mouse intestines were gelatin-embedded, sectioned at 35 µm using a microtome,
and stained for AP protein (brown) or enzyme activity (blue) for 3 or 6 hours. Intestines stained
for enzyme activity were also washed with 50 mM phenylalanine to reduce background activity
from IAP. Representative images (ileum) were taken on a Leica microscope at 40X magnification.
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Figure 3.2. Mortality and bacterial burden in VE-cKO and Alplfl/fl mice 8 days post-CLP
(A) Schematic of study design for 8 day CLP survival curve. Prior to surgery, fecal boli were
collected from each animal. VE-cKO and Alplfl/fl mice were assigned to undergo sham or CLP
surgery. Mice were monitored daily for survival, clinical signs of distress, and fecal boli were
collected on day 3 post-surgery. Animals were perfused, and tissues harvested on day 8 postsurgery.
(B) Percent survival in male and female VE-cKO and Alplfl/fl mice over the duration of 8 days postCLP. Comparison of survival curves was performed via the Log-rank (Mantel-Cox) test.
(C) Percent weight change in VE-cKO and Alplfl/fl mice for up to 8 days post-sepsis (CLP x time
interaction p<0.0001).
(D) Diarrhea score in VE-cKO and Alplfl/fl mice for up to 6 days post-sepsis (Genotype x CLP
interaction p=0.0019).
(E-I) Bacterial burden in intestine, liver, and lung on 8 days post-CLP, determined using CFU
quantification on BHI agar. All organs revealed a main effect of CLP (duodenum p=0.0003;
jejunum p=0.0006; ileum p=0.0036; liver p=0.0026; lung p=0.0293) and significant post-hoc
results are displayed on the graphs. For C-I, outliers were removed via the ROUT method, then
data were analyzed using three-way ANOVA (C-D factors: genotype, treatment, time; E-I factors:
genotype, treatment, sex) followed by Tukey’s multiple comparison’s post-hoc test where p≤0.05
is significant. N=3-7 mice per sex/genotype/treatment. *p≤0.05, **p≤0.01, ***p≤0.001,
****p≤0.0001.
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Figure 3.3. Parameters of gut dysbiosis are elevated in VE-cKO compared to Alplfl/fl mice at
8 days post-CLP
(A-F) Quantitative RT-PCR of Firmicutes and Bacteroidetes bacteria phyla relative to 16S rRNA
revealed a decreased F:B ratio at 8 days post-CLP.
(G-I) At 3 days post-CLP, fecal boli were collected for analysis of SCFAs.
(J-O) Relative expression of antimicrobial genes, Muc2 and Reg3g were measured using RTPCR from tissues collected 8 days post-CLP. For all graphs, outliers were removed via the ROUT
method, then data were analyzed using three-way ANOVA (factors: genotype, treatment, sex)
followed by Tukey’s multiple comparison’s post-hoc test where p≤0.05 is significant. N=3-7 mice
per sex/genotype/treatment. *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001.
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Figure 3.4. Relative expression of intestinal vascular adhesion molecules in VE-cKO and
Alplfl/fl mice 8 days post-CLP
(A-J) Relative gene expression in mouse tissue measured by Real-Time qRT-PCR. Relative
expression of (A-B) E-selectin, (C-D) P-selectin, (E-F) MAdCAM-1 (MADCAM1), (G-H) VCAM-1
(VCAM1) and (I-J) ICAM-1 (ICAM1) normalized to cyclase associated actin cytoskeleton
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regulatory protein 1 (Cap1) in duodenum and ileum tissue. For all graphs, outliers were removed
via the ROUT method, then data were analyzed using three-way ANOVA (factors: genotype,
treatment, sex) followed by Tukey’s multiple comparison’s post-hoc test where p≤0.05 is
significant. N=3-7 mice per sex/genotype/treatment. *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001.
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Figure 3.5. Relative expression of tight junction proteins in VE-cKO and Alplfl/fl mice 8 days
post-CLP
(A-H) Relative gene expression in mouse tissue measured by Real-Time qRT-PCR. Relative
expression of (A-B) claudin 5 (Cldn5), (C-D) claudin 12 (Cldn12), (E-F) occludin (Ocln), (G-H)
zonula occludens-1 (ZO-1) normalized to cyclase associated actin cytoskeleton regulatory protein
1 (Cap1) in duodenum and ileum tissue. For all graphs, outliers were removed via the ROUT
method, then data were analyzed using three-way ANOVA (factors: genotype, treatment, sex)
followed by Tukey’s multiple comparison’s post-hoc test where p≤0.05 is significant. N=3-7 mice
per sex/genotype/treatment. *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001.
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Figure 3.6. No difference in bacterial burden in VE-cKO and Alplfl/fl mice 24 hours post-CLP
(A) Schematic of basic study design for 24-hour CLP permeability study. VE-cKO and Alplfl/fl mice
received either sham or CLP surgery. Twenty-four hours later, mice were injected via retro-orbital
route with a mixture of four fluorescent molecules of varying sizes (Rhodamine 123 = 380 Da,
Texas Red = 625 Da, Cascade blue-3 kDa dextran = 3 kDa, Albumin = 69 kDa) at a concentration
of 2 mM each. After a 1-hour circulation, mice were anesthetized, blood was collected through
cardiac puncture, and mice were perfused with sterile 0.9% saline prior for organ collection.
Groups by sex are as follows: Alplfl/fl sham male n=5, Alplfl/fl sham female n=11, Alplfl/fl CLP male
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n=8, Alplfl/fl female n=15, VE-cKO sham male n=6, VE-cKO sham female n=9, VE-cKO CLP male
n=9, VE-cKO CLP female n=11.
(B-K) Bacterial burden in intestine, lung, MLN, and blood 24 hours post-CLP, determined using
CFU quantification on BHI agar placed under aerobic or anaerobic conditions. For all graphs,
outliers were removed via the ROUT method, then data were analyzed using three-way ANOVA
(factors: genotype, treatment, sex) followed by Tukey’s multiple comparison’s post-hoc test where
p≤0.05 is significant. N=3-14 mice per sex/genotype/treatment (after removal of outliers). *p≤0.05,
**p≤0.01, ***p≤0.001, ****p≤0.0001.
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Figure 3.7. Differential IgA and cytokine expression in VE-cKO intestine compared to
controls 24 hours post-CLP
(A-H) Tissues harvested 24 hours post-CLP were weighed, homogenized in 500 ul of sterile 0.9%
saline, and used for ELISA. VE-cKO and Alplfl/fl duodenum and ileum tissue were analyzed for
detection of (A-B) IgA, (C-D) IL-6, (E) IL-1b, and (F) IL-18, normalized to their tissue weights. For
all graphs, outliers were removed via the ROUT method, then data were analyzed using threeway ANOVA (factors: genotype, treatment, sex) followed by Tukey’s multiple comparison’s posthoc test where p≤0.05 is significant. N=4-15 mice per sex/genotype/treatment. *p≤0.05, **p≤0.01,
***p≤0.001, ****p≤0.0001.
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Figure 3.8. Intestinal permeability of Texas Red (625 Da) in VE-cKO and Alplfl/fl mice 24
hours post-CLP
(A-B) Relative fluorescence from small molecule, Texas red (625 Da), in whole tissue
homogenate from duodenum and ileum following a 1-hour circulation.
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(C-E) Frozen duodenum tissue analysis of mean Texas red fluorescence located in the whole villi
and submucosa regions. C is representative images from each group. D and E were analyzed
using the polygon tool in ImageJ, where mean fluorescence was normalized to area.
(F-H) Frozen ileum tissue analysis of mean Texas red fluorescence. F shows representative
images from each group. G and H were analyzed as described above. For all graphs, outliers
were removed via the ROUT method, then data were analyzed using two-way ANOVA (factors:
genotype, treatment) followed by Tukey’s multiple comparison’s post-hoc test where p≤0.05 is
significant. N=10-23 mice per genotype/treatment. *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001.
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Figure 3.9. Intestinal permeability of Cascade blue-3 kDa dextran in VE-cKO and Alplfl/fl
mice 24 hours post-CLP
(A-B) Relative fluorescence of cascade blue-3 kDa dextran in whole tissue homogenate from
duodenum and ileum following a 1-hour circulation.

103

(C-E) Frozen duodenum tissue analysis of mean cascade blue fluorescence located in the whole
villi and submucosa regions. C is representative images from each group. D and E were analyzed
using the polygon tool in ImageJ, where mean fluorescence was normalized to area.
(F-H) Frozen ileum tissue analysis of mean cascade blue fluorescence. F shows representative
images from each group. G and H were analyzed as described above. For all graphs, outliers
were removed via the ROUT method, then data were analyzed using two-way ANOVA (factors:
genotype, treatment) followed by Tukey’s multiple comparison’s post-hoc test where p≤0.05 is
significant. N=12-23 mice per genotype/treatment. *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001.
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Figure 3.10. Intestinal permeability of Albumin (69 kDa) in VE-cKO and Alplfl/fl mice 24 hours
post-CLP
(A-B) Relative fluorescence of albumin (69 kDa), in whole tissue homogenate from duodenum
and ileum following a 1-hour circulation.
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(C-E) Frozen duodenum tissue analysis of albumin fluorescence located in the whole villi and
submucosa regions. C is representative images from each group. D and E were analyzed using
the polygon tool in ImageJ, where mean fluorescence was normalized to area.
(F-H) Frozen ileum tissue analysis of mean albumin fluorescence. F shows representative images
from each group. G and H were analyzed as described above. For all graphs, outliers were
removed via the ROUT method, then data were analyzed using two-way ANOVA (factors:
genotype, treatment) followed by Tukey’s multiple comparison’s post-hoc test where p≤0.05 is
significant. N=10-23 mice per genotype/treatment. *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001.
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Figure 3.11. Summary of endothelial TNAP’s role in the ileum at the septic gut-vascular
barrier
Permeability is increased in Alplfl/fl ileum 24 hours after sepsis induction. This is accompanied by
increased expression of pro-inflammatory cytokine IL-6, and increased expression of IgA
compared to sham mice. However, when endothelial TNAP is deleted in VE-cKO mice, the septic
ileum becomes more even more permeable to molecules ranging in size from 625 Da to 69 kDa
at 24 hours post-CLP, and there is reduced IL-6 and IgA expression compared to septic controls.
At 8 days post-sepsis induction, Alplfl/fl gut dysbiosis is minimal with some bacteria still found in
intestine tissue, a reduced F:B ratio, reduced mucin and RegIII expression, increased tight
junction protein claudin 5 expression, and increased cell adhesion protein selectin expression
compared to sham. At 3 days post-CLP, mice also have reduced fecal SCFAs. In VE-cKO septic
mice, all of the above parameters are reduced compared to Alplfl/fl septic mice, indicating more
severe or more prolonged gut dysbiosis.
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Supplemental Figure 3.1. Verification of the specific targeting of the vascular
endothelium in Cdh5-Cre mouse intestine
Cadherin 5 (Cdh5)-targeting vascular endothelial (VE)-Cre mice were crossed with tdTomato
mice to breed VE-tdTomato reporter mice. Formalin-fixed mouse intestines (duodenum and
ileum) were gelatin-embedded, sectioned at 35 µm using a microtome, and stained for CD31
using fluorescence. Representative images for tdTomato (red), CD31 (green), and a merge of
both were taken on a Leica microscope at 20X magnification. Scale bar in bottom right = 25 or 75
µm.
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Supplemental Figure 3.2. Relative bacterial composition in VE-cKO and Alplfl/fl mice 8 days
post-CLP

109

Real-time qRT-PCR of Firmicutes, Bacteroidetes, and Actinobacteria phyla relative to 16S rRNA
at 8 days post-CLP. For all graphs, outliers were removed via the ROUT method, then data were
analyzed using three-way ANOVA (factors: genotype, treatment, sex) followed by Tukey’s
multiple comparison’s post-hoc test where p≤0.05 is significant. N=2-7 mice per
sex/genotype/treatment after outlier removal. *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001.

110

Supplemental Figure 3.3. Fecal short-chain fatty acids (SCFAs) measured from VE-cKO
and Alplfl/fl mice at baseline and 3 days post-CLP
Fecal boli were collected at baseline and 3 days post-CLP. For all graphs, outliers were removed
via the ROUT method. Baseline graphs were analyzed using two-way ANOVA (factors: genotype,
sex) followed by Tukey’s multiple comparison’s post-hoc test where p≤0.05 is significant. N=5-12
mice per sex/genotype. Day 3 post-CLP graphs were analyzed using three-way ANOVA (factors:
genotype, treatment, sex) followed by Tukey’s multiple comparison’s post-hoc test where p≤0.05
is significant. N=3-7 mice per sex/genotype/treatment.
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Supplemental Figure 3.4. Relative gene expression of additional dysbiosis markers in VEcKO and Alplfl/fl mice 8 days post-CLP
(A-O) Relative gene expression in mouse tissue measured by Real-Time qRT-PCR. Relative
expression of (A-C) plasmalemma vesicle-associated protein (Plvap), (D-F) mucin 4 (Muc4), (GI) regenerating islet-derived protein 3-beta (Reg3β), (J-L) glucose transporter-1 (Glut1), and (MO) P-glycoprotein (Pgp) normalized to cyclase associated actin cytoskeleton regulatory protein 1
(Cap1) in duodenum, ileum, and lung tissue. For all graphs, outliers were removed via the ROUT
method, then data were analyzed using three-way ANOVA (factors: genotype, treatment, sex)
followed by Tukey’s multiple comparison’s post-hoc test where p≤0.05 is significant. N=2-7 mice
per sex/genotype/treatment after outlier removal. *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001.
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Supplemental Figure 3.5. Relative tight junction gene expression in VE-cKO and Alplfl/fl
lung 8 days post-CLP
(A-E) Relative gene expression in mouse lung tissue measured by Real-Time qRT-PCR. Relative
expression of (A) claudin 5 (Cldn5), (B) claudin 12 (Cldn12), (C) occludin (Ocln), (D) zonula
occludens-1 (ZO-1), and (E) MAdCAM-1 (Madcam1), normalized to cyclase associated actin
cytoskeleton regulatory protein 1 (Cap1) in lung tissue. For all graphs, outliers were removed via
the ROUT method, then data were analyzed using three-way ANOVA (factors: genotype,
treatment, sex) followed by Tukey’s multiple comparison’s post-hoc test where p≤0.05 is
significant. N=3-7 mice per sex/genotype/treatment after outlier removal. *p≤0.05, **p≤0.01,
***p≤0.001, ****p≤0.0001.
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Supplemental Figure 3.6. IgA and IL-6 expression in VE-cKO and Alplfl/fl colon and lung
Tissues harvested 24 hours post-CLP were weighed, homogenized in 500 ul of sterile 0.9%
saline, and measured via ELISA. VE-cKO and Alplfl/fl (A) colon and (B) lung tissue homogenates
were analyzed for detection of IgA and IL-6, normalized to their tissue weights. For all graphs,
outliers were removed via the ROUT method, then data were analyzed using three-way ANOVA
(factors: genotype, treatment, sex) followed by Tukey’s multiple comparison’s post-hoc test where
p≤0.05 is significant. N=5-15 mice per sex/genotype/treatment. *p≤0.05, **p≤0.01, ***p≤0.001,
****p≤0.0001.

114

Supplemental Figure 3.7. Intestinal permeability of Rhodamine 123 (380 Da) in VE-cKO and
Alplfl/fl mice 24 hours post-CLP
(A-B) Relative fluorescence from small molecule, rhodamine 123 (380 Da), in whole tissue
homogenate from duodenum and ileum following a 1-hour circulation.
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(C-E) Frozen duodenum tissue analysis of mean rhodamine 123 fluorescence located in the
whole villi and submucosa regions. C is representative images from each group. D and E were
analyzed using the polygon tool in ImageJ, where mean fluorescence was normalized to area.
(F-H) Frozen ileum tissue analysis of mean rhodamine 123 fluorescence. F shows representative
images from each group. G and H were analyzed as described above. For all graphs, outliers
were removed via the ROUT method, then data were analyzed using two-way ANOVA (factors:
genotype, treatment) followed by Tukey’s multiple comparison’s post-hoc test where p≤0.05 is
significant. N=9-22 mice per genotype/treatment. *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001.
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Supplemental Figure 3.8. Duodenum and ileum frozen tissue permeability analysis 24
hours post-CLP
Frozen duodenum (left 2 columns) and ileum (right 2 columns) tissue analysis of mean rhodamine
123 (row 1), Texas red (row 2), cascade blue (row 3), and albumin (row 4) fluorescence located
in the center of the villi and crypt regions. Graphs were analyzed using the polygon tool in ImageJ,
where mean fluorescence was normalized to area. For all graphs, outliers were removed via the
ROUT method, then data were analyzed using two-way ANOVA (factors: genotype, treatment)
followed by Tukey’s multiple comparison’s post-hoc test where p≤0.05 is significant. N=9-23 mice
per genotype/treatment. *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001.
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Supplemental Figure 3.9. Colon tissue permeability in VE-cKO and Alplfl/fl mice 24 hours
post-CLP
(A) Relative fluorescence from rhodamine 123 (380 Da), Texas red (625 Da), cascade blue-3 kDa
dextran, and albumin (69 kDa) in whole colon tissue homogenate following a 1-hour circulation.
(B-E) Frozen colon tissue analysis of mean fluorescence located in the (B) whole villi, (C) villi
center, (D) crypts, and (E) submucosa regions. Graphs were analyzed using the polygon tool in
ImageJ, where mean fluorescence was normalized to area. For all graphs, outliers were removed
via the ROUT method, then data were analyzed using two-way ANOVA (factors: genotype,
treatment) followed by Tukey’s multiple comparison’s post-hoc test where p≤0.05 is significant.
N=14-23 mice per genotype/treatment. *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001.
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Supplemental Figure 3.10. Lung tissue and plasma permeability in VE-cKO and Alplfl/fl mice
24 hours post-CLP
Relative fluorescence from rhodamine 123 (380 Da), Texas red (625 Da), cascade blue-3 kDa
dextran, and albumin (69 kDa) in whole lung tissue homogenate and plasma following a 1-hour
circulation. For all graphs, outliers were removed via the ROUT method, then data were analyzed
using two-way ANOVA (factors: genotype, treatment) followed by Tukey’s multiple comparison’s
post-hoc test where p≤0.05 is significant. N=9-23 mice per genotype/treatment. *p≤0.05, **p≤0.01,
***p≤0.001, ****p≤0.0001.
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1. Discussion Overview
Despite the length of time that TNAP has been recognized to have important catalytic
activity that may contribute to health and disease, little was known about the roles of this enzyme
until recently. The majority of TNAP’s functions have focused on its role in bone health, and a
recently FDA-approved TNAP-modifying medication, asfotase alfa, is expected to greatly improve
the quality and lifespan of hypophosphatasia patients. However, the ubiquitous expression of
TNAP requires further identification of its role in the vasculature and subsequent effects on
localized tissues. Therefore, we aimed to identify a role for TNAP in blood-tissue barriers,
including the BBB and GVB. Our central hypothesis was that pharmacological or genetic
depletion of TNAP enzyme activity would result in exaggerated barrier permeability, increased
inflammation, impaired microbial homeostasis, and overall worse disease outcome in
experimental sepsis. We approached this work using the following aims: (1) determine if
pharmacological inhibition or genetic manipulation of TNAP activity was more informative for
exploring a role for TNAP in sepsis, (2) determine if endothelial TNAP activity regulates sepsisassociated bacterial load and gut dysbiosis, and (3) determine if endothelial TNAP activity
regulates gut permeability in sepsis. Ultimately, we found that using a genetic model of TNAP
deleted on endothelial cells would be most informative for our work. Using this model, we
determined that endothelial TNAP is critical for reducing bacterial burden, permeability of
molecules ranging from 625 Da to 69 kDa, and overall gut dysbiosis post-sepsis. Parameters of
gut dysbiosis measured at 8 days post-CLP include the Firmicutes:Bacteroidetes ratio,
composition of Short-Chain Fatty Acids (SCFAs), and relative antimicrobial gene expression;
while at 24 hours post-CLP we quantified Immunoglobulin-A (IgA) and levels of proinflammatory
cytokines.
2. Insights Gained from the Use of New Tools to Study Alkaline Phosphatase:
Pharmacological vs. Genetic Models
One of the many challenges to elucidating the role of TNAP in health and disease has
been the creation of appropriate genetic and pharmacological tools. The availability of isoformspecific pharmacological and genetic tools to study TNAP has recently expanded. This has
allowed us to study TNAP in the context of both nonspecific and cell-specific roles. As part of this
work, for Aim 1 we attempted to use both pharmacological and genetic models to examine the
importance of TNAP in healthy and septic states. From here, we were able to expand our findings
to examine a role for TNAP in the GVB using genetic deletion of TNAP on endothelial cells.
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2.1. What Did We Learn from Pharmacological Inhibition of TNAP in Sepsis?
In Chapter 2, we observed that pharmacological inhibition of TNAP did not influence 7day septic clinical scores, weight change, or survival. There were also no differences in astrocyte
and microglial immunoreactivity in the brains of SBI-425- vs. vehicle-treated septic mice.
Interestingly, we identified reduced mean fluorescence intensity of splenic leukocyte markers for
CD4 and CD8 T regulatory cells. TNAP has been shown to have a role in T- and B-cell activation
[148,202,203]. It is also expressed by neutrophils and macrophages, and may play a role in the
migration, generation of reactive-oxygen species (ROS), and promotion of cell apoptosis in
neutrophil-like cells [199,204,348], although a full view of its functions and mechanisms within
these cells remains unclear. Sepsis is associated with T-cell dysfunction, and our results suggest
that TNAP inhibition may enhance T-cell mediated immunosuppression in late sepsis [274,275].
The increase in CD4+Foxp3+ and CD8+Foxp3+ Tregs in vehicle- compared to SBI-425-treated
mice is consistent with previous findings which show that elevated Tregs are associated with
increased survival and improved sepsis outcomes [276]. We did not detect changes in the levels
of monocytes, including macrophages, dendritic cells, and natural killer cells (using markers
CD11b, CD11c, Ly6G, and Ly6C), though this may have something to do with the timing postCLP.
Sepsis is characterized by a hyper-inflammatory, elevated immune response during early
sepsis followed by the transition to a hypo-inflammatory, immunosuppressive period in late sepsis
prior to restoration of homeostasis [269]. While the innate immune response predominates during
early sepsis, the innate and adaptive immune responses function in parallel during later sepsis to
reduce immunosuppression and restore immune homeostasis. The immune imbalance can lead
to lessened cytokine production and reduced T cell proliferation [270,271]. In patients with acute
myeloid leukemia, overall survival was increased in patients with higher (≥12%) cellular AP activity
[349]. Likewise, human recombinant alkaline phosphatase (hrecAP) administration has been
shown to reverse platelet hyperactivity ex vivo by rapidly converting ADP to adenosine [350].
Future experiments should focus not only on how TNAP levels impact the quantities of immune
cells in sepsis, but on the expression of TNAP by those immune cells, as these may be important
clinical disease outcome indicators.
Overall, in collaboration with the developers of TNAPi and SBI-425, we demonstrated that
the SBI-425 inhibitor is unable to cross the BBB in healthy mice. Since TNAP is localized to both
the luminal and abluminal surfaces of brain endothelial cells [118], the inability of SBI-425 to cross
the BBB in health may be useful in studying the effects of brain endothelial luminal TNAP activity.
However, in diseases with an impaired BBB, like AD, MS, and sepsis, it can be used to identify
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roles on both sides of the barrier. We also established that TNAP inhibition using SBI-425 can be
achieved via intraperitoneal (IP) route, where only intravenous (half-life: 0.12 hours) and oral (halflife: 2.3 hours) routes had previously been reported [154]. Based on the reported half-lives of SBI425, we estimated that the half-life of IP administration should be approximately 4-5 hours. SBI425 was quickly metabolized by healthy brain tissue, as shown in Table 2.1, which reports the
amount of SBI-425 detected in brain tissue at 2 hours post-SBI-425 injection was 57.2 ng/g, while
by 8 hours it was 1.8 ng/g. Meanwhile, in plasma at 2 hours post-injection, the mean SBI-425
concentration was 7356.7 ng/g, while by 8 hours it was 432.0 ng/g. This indicates that little SBI425 travels to the healthy brain via IP route, and analysis of peripheral tissues, such as the spleen
or intestine, may be more suited for pharmacological inhibition of TNAP, but little information will
be gained from TNAP function in the brain using these conditions.
2.2. Preliminary Findings on Genetic Manipulation of Endothelial TNAP
In Chapter 2, by crossing the Cdh5-Cre driver, which codes for VE-cadherin, mouse with
the HprtALPL mouse described in the introduction, our lab generated a model of TNAP overexpression on endothelial cells (i.e., VE-cOE mice). While few differences were observed in septic
outcomes between SBI-425- and vehicle-treated mice, genetic over-expression of TNAP on
endothelial cells improved overall clinical scores and survival at 48 hours post-CLP. In the last 510 mins of open field testing, septic VE-cOE mice also exhibited more voluntary locomotor activity
than controls, indicating a less severe sepsis phenotype. These preliminary results lead us to
believe that the use of a genetic model to study the role of TNAP would be more useful, more
focused, and easier to interpret, than pharmacological inhibition of ubiquitously-expressed TNAP.
Therefore, the remainder of our work in Chapter 3 focused on establishing a role for geneticallydeleted endothelial TNAP in sepsis. We generated a mouse model with conditional deletion of
endothelial TNAP by crossing the Cdh5-Cre driver mouse with the Alplfl/fl mouse (i.e., VE-cKO
mice). Using primary BMEC cultures from VE-cKO mice, we observed decreased barrier integrity
compared to Alplfl/fl controls, further indicating the protective effects that TNAP activity offers to
the BBB. These observations have been reported in a preprint [351].
2.3. Endothelial TNAP Mediates Gut Dysbiosis in Sepsis
The goal of Aim 2 was to determine if endothelial TNAP activity regulates sepsisassociated gut bacterial load, inflammation, and overall gut dysbiosis in healthy and septic mice.
Recently, the gut microbiome has been implicated as an active component in a number of
inflammatory diseases. In Chapter 3, we sought to answer this using a variety of gut dysbiosis
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parameters, including the Firmicutes:Bacteroidetes ratio, composition of SCFAs, and changes in
the levels of IgA and pro-inflammatory cytokines.
2.3.1. The Gut Microbiome as a Therapeutic Target in Sepsis
The gut microbiota regulates several responses to sepsis, making it a potential therapeutic
target [352]. While the pathogenesis of sepsis is multifactorial and incompletely understood, there
is increasing evidence to support certain qualities of the gut microbiome can predispose an
individual to infection and negatively impact sepsis outcomes [353]. Colonization of the infant
intestine begins at birth; it is important for a neonate to acquire phylogenetic diversity during the
first few weeks of life to protect from domination of pathogenic species [354,355]. A recent study
of preterm neonate microbiomes found that increased bacterial diversity and anaerobic bacterial
colonization protects against sepsis [356]. Common opportunistic pathogens that dominate in the
absence of anaerobic bacteria to cause bloodstream infections include Staphylococcus species
and Escherichia coli [354,356,357]. While even less is known about how the gut microbiome
predisposes adults to sepsis, a study from nearly two decades ago showed a role for the gut
microbiome and bacterial translocation in postoperative septic patients [358]. A more recent study
indicates that patients with low fecal microbial diversity predicts risk of critical illness after
hematopoietic cell transplant [359]. Epidemiological studies also indicate gut microbiome
disruption, through use of antibiotics, may be a risk factor for sepsis [360,361]. Patients treated
for Clostridium difficile infection were 70% more likely to develop sepsis compared to other
infections [361]. Patients given high-risk antibiotics (i.e., 3rd or 4th generation cephalosporins,
carbapenems, and fluoroquinolones) or increased quantities of antibiotics during hospitalization
were at increased risk of sepsis within 90 days of discharge [360].
Similar results have been observed in animal models of experimental sepsis. Genetically
identical mice from different vendors have distinct bacterial diversity, and these baseline
differences influence septic outcome. For example, mice with lower α-diversity succumbed to CLP
more often than mice with higher α-diversity. Meanwhile, cohousing animals corrected for the
imbalance in microbial diversity and lead to similar disease outcome across mice [362]. Similarly,
the gut microbial metabolic profile between mice who are sepsis-sensitive (moribund before or by
24 hrs after CLP) was different compared to those that were sepsis-resistant (survival up to 7
days post-CLP), and mice gavaged with feces from sepsis-sensitive mice displayed more severe
liver damage [363]. Interestingly, in a small proof-of-principle intervention trial, disruption of the
gut microbiota of young men using broad-spectrum antibiotics (ciprofloxacin, vancomycin, and
metronidazole) for 7 days, did not affect innate immune responses following intravenous
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administration of LPS [364]. While the specific pathways through which the gut microbiota
increases sepsis susceptibility remain unclear, these likely involve several factors, including (1) a
pro-pathogenic gut environment that allows bacteria to disseminate systemically, (2) an altered
immune response, and (3) reduced production of beneficial microbial products [365].
Not only does gut microbiome composition predispose patients to sepsis, but changes in
the gut microbiota after sepsis can worsen and contribute to disease outcomes. One of the most
common current treatments for sepsis is the use of broad-spectrum antibiotics, which in turn
disrupt and deplete gut bacteria [366]. In addition, opioids [367], parenteral nutrition [368], and
proton-pump inhibitors [369] affect microbiome, yet improve other aspects of sepsis outcome. An
early study examining patients with severe systemic inflammatory response syndrome (SIRS)
showed they had reduced anaerobic bacterial counts and higher amounts of pathogenic
Staphylococcus and Pseudomonas bacteria compared to healthy volunteers [370]. Meanwhile,
generally beneficial bacteria, like Faecalibacterium which is associated with decreased intestinal
inflammation, is depleted during sepsis [181,182,371]. One study showed that sepsis caused by
Salmonella or E. coli can be mediated through the host mechanism of detoxification of LPS by
AP, which incapacitates neuraminidase induction. Elevated neuraminidase activity is detrimental
in sepsis, as it accelerates aging and AP clearance, which intensifies the disease [288]. Due to
the broad nature of polymicrobial sepsis, finding generalized diagnostic markers and therapeutic
targets has been challenging.
2.3.2. The Firmicutes:Bacteroidetes Ratio
The F:B ratio varies widely in healthy subjects, making a large sample size necessary to
achieve statistical power [182,321]. A recent review found that the abundance of Firmicutes in
healthy gut microbiotas varies from 11–95%, while the abundance of Bacteroidetes vary between
0.6–86.6% [372]. While the direction of movement of the ratio is likely to be multifactorial, it is also
disease-dependent. For example, in a study using piglets, coarse dietary fiber increased the F:B
ratio and reduced diarrhea induced by infection with E. coli [373]. However, a lower F:B was
observed in Mexican children with enteric parasitic infection [374]. While a pattern of increased
F:B has been well-established to be associated with worse outcome in metabolic disease
[305,306], the literature on this ratio in sepsis is less clear. In one clinical study, four of six critically
ill patients who died had higher abundance of Bacteroidetes compared to Firmicutes in their fecal
samples [320]. Another study found a relative, though nonsignificant, increase of Bacteroidetes
in 11 of 34 critically ill patients [182]. A newer study found that relative abundance of
Bacteroidetes, Proteobacteria, and Actinobacteria was higher, while Firmicutes were reduced, in
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sepsis compared to control patients [375]. Our F:B data from intestinal and peripheral tissues
correlates with these small human sample findings in that the F:B ratio is decreased after
experimental sepsis (Figure 3.3A-F). This was most obvious in the liver and lung, which may
indicate variability in the intestine is greater than in other peripheral tissues. Several murine
models have shown the existence of “gut-organ axes”, including the “gut-liver axis” and “gut-lung
axis”. The pathogen-associated molecular patterns (PAMPs) and damage-associated molecular
patterns (DAMPs) associated with communication between these axes likely modulate immune
cell to influence regulatory vs. pro-inflammatory responses [376,377].
Today, there is controversy as to whether the F:B ratio is a reliable marker of gut dysbiosis
due to several discrepancies. In many models of systemic inflammation, like obesity and sepsis,
endotoxic activity from LPS, a pro-inflammatory marker derived from Gram-negative bacteria,
passes from the gut lumen into the bloodstream [378]. Only a portion of LPS is derived from
Gram-negative Bacteroidetes as other Gram-negative bacteria, like Proteobacteria, also shed
LPS [379]. Additionally, the F:B ratio does not always correlate with production of SCFAs and
their presumed functions. Bacteroidetes mainly produce acetate and propionate, while Firmicutes
primarily produce butyrate [380]. Butyrate is considered health-promoting in metabolic disease
due to its ability to increase insulin sensitivity [381], reduce inflammation [382], regulate energy
metabolism, and increase leptin gene expression [383]. Meanwhile, acetate is generally
considered more obesogenic due to its ability to stimulate hepatic synthesis of lipids [384], and
activate brain communication with the parasympathetic nervous system to promote secretion of
insulin and ghrelin in the pancreas and gastric mucosa [385].
2.3.3. Short-Chain Fatty Acids
Increased consumption of dietary fiber has been shown to reduce systemic inflammation
and immune disorders, while low fiber is associated with increased inflammatory disease
[338,386–388]. Fermentation of carbohydrates by the intestinal microbiome produce metabolites,
like SCFAs, which affect host physiology [389–391]. For example, acetate, propionate, and
butyrate attenuate TNFα- or LPS-induced endothelial activation by the inhibition of
proinflammatory cytokines, IL-6 and IL-8 [392]. In the colon, SCFAs can either be excreted in
fecal matter, absorbed by colonocytes to generate ATP and energy for the cells, or transferred to
the portal circulation, mostly to be metabolized by the liver. A small, but measurable, portion of
SCFAs (36% acetate, 9% propionate, and 2% butyrate) are not metabolized by the liver and are
able to enter the systemic circulation and peripheral tissues, including the brain [338,393].
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In general, SCFAs are thought to be anti-inflammatory, through mechanisms not yet wellunderstood. Locally, SCFAs maintain intestinal barrier integrity, protect from intestinal
inflammation [328], affect gastrointestinal mucus production [329,330], and may affect
gastrointestinal motility [331]. The immunomodulatory properties of SCFAs are thought to occur
through the activation of certain G-protein-coupled receptors (GPRs), such as GPR41 and GPR43
[394,395]. Butyrate and propionate have also been shown to facilitate the generation of
extrathymic regulatory T cells [396]. Septic patients have fewer fecal SCFAs, and this can persist
through at least 6 weeks of hospitalization [370,397]. A recent study showed that 500 mg/kg SCFA
treatment (acetate, propionate, and butyrate at a 3:1:1 ratio administered intragastrically twice a
day for 7 days) induced neuroprotective effects against sepsis-associated encephalopathy in mice
[398].
Our results showing reduced levels of butyrate and propionate post-CLP (Figure 3.3H-I)
also

correspond

with

the

current

literature.

Butyrate

attenuates

pathogen-induced

hyperinflammation through a number of pathways. First, butyrate inhibits bacterial Infection.
Supplementation with butyrate reduced the severity of Citrobacter rodentium [399],
Corynebacterium pseudotuberculosis [400], Salmonella enterica [401], Shigella [402],
Mycobacterium tuberculosis [403,404], and Helicobacter pylori [405] infection. Indirectly, butyrate
is reported to control bacterial overgrowth by contributing to the intestinal oxygen availability [406–
408]. Propionate also attenuates Staphylococcus aureus infection by regulating bacterial growth
[409]. Second, butyrate increases mucosal barrier integrity through the secretion of mucins and
AMPs. Mucin-2 and villin production were upregulated after butyrate treatment [410,411]. In
chickens, butyrate treatment increased the number of goblet cells in the small intestine and
increased the production of mucins [412]. Increased abundance in butyrate-producing bacteria
also increases the production of mucins. For example, Bacteroides fragilis has been shown to
increase mucin production and strengthen intestinal epithelial tight junction structure [413]. AMPs,
including RegIIIγ and β-defensins, are upregulated by intestinal epithelial cells through its GPR43
following butyrate supplementation [414]. These correspond to the reductions in Muc2 in the
duodenum and ileum and reductions of Reg3g in the ileum that we observed post-CLP (Figure
3.3J-O).
2.3.4. Gut IgA and Inflammation
The lamina propria of the intestine contains large numbers of plasma cells. The duodenum
contains approximately 75% of the IgA-producing plasma cells, with increasing production as you
move down the GI tract where 90% of IgA-producing plasma cells reside in the colon. Secretion
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of IgA is dependent on the presence of the microbiota and the polymeric Ig receptor (pIgR), which
transports IgA into the lumen [157]. IgA contributes to the development, maintenance, diversity,
and overall health of the microbiota by preferentially targeting harmful bacteria [322–324].
Diabetic patients have lower levels of fecal IgA, and increased levels of liver-, macromolecular-,
and intestinal-AP [415]. Other studies have shown that glucomannan, a dietary fiber, increases
levels of IgA and mucins, modulates intestinal microflora, and elevates colonic AP activity in rats
[416,417]. An early study of AP and IgA showed that in patient serum, liver and bone AP can
attach to IgA as a result of antibody-antigen interactions, while the intestinal and placental
isoforms do not [418]. IgA’s protection also extends to bacteria that has escaped the intestines,
such as in sepsis. One study found that enriching the microbiota with Proteobacteria resulted in
T-cell dependent increases in serum IgA by IgA-secreting plasma cells in the bone marrow. The
serum IgA bound specifically to gut-derived pathogens that translocated into the circulation,
leading to increased sepsis resistance [325]. In mice, maintaining circulating IgA after sepsis was
protective even in the absence of luminal IgA [327]. In transplant patients, low serum IgA levels
increased the mortality rate due to septic shock [419]. Interestingly, our data has shown that
deletion of endothelial TNAP results in differential IgA levels along the small intestine, i.e.,
increased levels in the duodenum, but reduced levels in the ileum in both septic mice and their
controls (Figure 3.7A-B).
In sepsis, cytokines produced by endothelial and/or immune cells enhance the
inflammatory response and initiate tissue damage [336–338]. It is well-known that IL-6 and IL-1b
expression are increased in mice post-CLP [192]. These are some of the most common markers
of inflammatory disease and they correlate with enhanced TNAP expression. Recombinant
human IL-1a and IL-1b enhance AP activity in murine osteoblasts [339]. IL-6 induces high TNAP
activity in cultured aortic and brain endothelial cells [340]. TNAP+/- mice with acute pancreatitis
displayed increased expression of Il6 and Il1b in the pancreas [341]. Similarly to our results, which
showed that VE-cKO mice produced lower levels of IL-6 post-CLP (Figure 3.7C-D), TNAP+/- mice
express reduced levels of IL-6 following splenocyte stimulation with LPS [148]. IL-6 and IL-1 act
on endothelial cells to increase their adherence to lymphocytes [335], which further supports our
hypothesis on a reduced ability of VE-cKO endothelial cells to recruit cells to the site of infection.

2.4. Endothelial TNAP Regulates GVB Permeability
Data in Chapter 2 from our lab describes that inhibition of TNAP on murine brain
microvascular endothelial cells (BMECs) decreases barrier function (Figure 2.9) [124]. We have
also shown that in septic mice, reduced expression of TNAP activity is coupled with reduced
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expression of Claudin 5 and increased IgG permeability in the brain [110]. In sepsis, intestinal
hyperpermeability allows for the transport of bacteria, bacterial products, and other substrates
that would normally be restricted to the intestinal lumen [342]. For example, the relative
concentration of 4 kDa Fluorescein isothiocyanate-dextran (FITC-dextran) from the intestinal
lumen into the blood was significantly increased 48 hours post-CLP [192]. High-performance
liquid chromatography (HPLC) detection of a 40 kDa FITC-dextran in plasma following oral
gavage revealed a significant increase (p<0.0001) in permeability post-peritonitis [319]. It is also
important to note that in both of these studies exogenous treatment with IAP improved barrier
integrity [192,319]. A recent methods manuscript by Oami and Coopersmith (2021) eloquently
described the differences in intestinal permeability pathways during sepsis. Namely, the pore (≤6
Å), leak (<100 Å), and unrestricted pathways are the modes to which substrates, depending on
their molecular characteristics and the hosts pathological conditions, are able to penetrate a tissue
barrier [343].
Our permeability results varied depending on intestinal region, size of the molecule,
genotype, and pathology. In general, there was increased accumulation of fluorescent molecules
in the whole tissue lysate from duodenum of both genotypes at 24 hours after sepsis. Duodenum
revealed a decreased accumulation of cascade blue-3 kDa dextran in VE-cKO septic mice
compared to Alplfl/fl septic mice, and this finding is confirmed in plasma (Figure 3.9 and
Supplementary Figure 3.10). We also observed a reduced accumulation of albumin specifically
within the villi of duodenal tissue (Figure 3.10). Within the whole tissue lysate from ileum,
molecules meeting the size requirements for the pore pathway (Rhodamine 123 and Texas Red)
were decreased at 24 hours after sepsis, while the cascade blue-3 kDa dextran fluorescence was
increased. There was a decreased accumulation of albumin in VE-cKO mice, but an increased
accumulation of albumin in Alplfl/fl mice post-sepsis. Interestingly, ileum spatial analysis revealed
a decreased accumulation of all fluorescent molecules, in VE-cKO sham mice compared to Alplfl/fl
mice. These observations lead us to believe that the reduced accumulation of fluorescent
molecules in sham (ileum) and septic (duodenum) VE-cKO mice compared to controls may
indicate an increased flux of these molecules to the intestinal lumen, where they were flushed
away with saline before whole tissue lysate and frozen tissue analysis, as fecal matter is
autofluorescent and, therefore, excluded from our analysis. While this is the first study examining
a role for TNAP in intestinal permeability post-sepsis, we recognize additional factors to consider
in the comparison of our results to previous literature include (1) the route of fluorescent molecule
administration, (2) our choice of fluorescent molecules and their respective characteristics, and
(3) the amount of time that we allowed our molecules to circulate prior to tissue collection. For
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example, in the 4 kDa and 40 kDa study examples described above, mice were orally gavaged
with fluorescent molecules to examine extravasation of molecules into the blood [192,319], while
we opted to use the retro-orbital injection of molecules directly into the circulation since our
animals have deletion of TNAP on endothelial cells.
The two smallest permeability (pore and leak) pathways are tight junction-dependent
[343]. Tight junction proteins, which contribute to endothelial cell permeability, are typically altered
after sepsis. For example, protein levels of ZO-1 and occludin are decreased in rats post-CLP
[344]. Recently, ileal relative expression of several tight junction proteins, including Cldn5 and
Ocln were decreased post-CLP [192]. TNAP+/- and WT control mice experience similar reductions
in jejunal Cldn5 and Ocln after acute pancreatitis [341]. Our results showing that relative
expression of Cldn5 is decreased in septic male VE-cKO mice compared to Alplfl/fl mice (Figure
3.5) coincides with our previous observation that Claudin 5 protein was diminished in septic mice
following administration of a TNAP inhibitor compared to their vehicle-treated counterparts [110].
In a preprint manuscript, our lab has described that the reduced endothelial integrity is likely due
to activation of the Rho/ROCK pathway, which ultimately disrupts the actin cytoskeletal
remodeling of cells [351].
2.4.1. Bacterial Translocation
As stated above, bacterial translocation can be another sign of increased tissue
permeability. Our findings of positive bacterial cultures from both mesenteric lymph node (MLN)
and blood (Figure 3.6H-K), coincide with the literature that suggests pathogens disseminate
through both vascular and lymphatic systems in response to proinflammatory triggers [11,318].
Bacterial translocation to MLN is increased 48 hours post-intestinal ischemia/reperfusion injury
[189]. In vivo imaging shows translocation of fluorescent tracer bacteria to liver and lung is
upregulated in mice with peritonitis [319]. IAP treatment has been shown to reduce bacterial
translocation in these same experimental models [189,319]. Bacterial translocation to the MLN,
liver, blood, and abdominal cavity was increased after CLP, but unaffected by IAP treatment (twice
daily for 2 days). Similar to our results, positive bacterial cultures were identified in MLN more
often compared to blood post-CLP [192].
2.4.2. Cellular Adhesion Molecules
It has been well-established that selectins are increased in mice after CLP [311].
Interestingly, in healthy subjects, E-selectin levels were positively associated with AP [312].
However, our data was the first to show that deletion of endothelial TNAP lead to reductions in
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the expression of E- and P-selectin in mouse ileum by 8 days post-CLP (Figure 3.4A-D).
Recruitment of leukocytes to the endothelial cell surface and subsequent infiltration into the
interstitium is believed to be the initial event that leads to hyperinflammation and multi-organ
dysfunction in sepsis [313,314]. This process involves a series of well-orchestrated adhesive
interactions between the endothelial cell and leukocyte surface. The tethering and rolling of
neutrophils along the endothelium is primarily regulated by selectins, including the P-selectin and
E-selection on endothelial cells, while firm adhesion is mediated by intracellular adhesion
molecules (ICAM-1) [313]. Once neutrophils adhere firmly to the endothelial surface, they flatten
and extend pseudopodia between the endothelial cells to emigrate into the interstitium. This
invading movement causes damage to the tissue as blocking E- and P-selectins protect mice
from sepsis-induced acute kidney injury [315,316]. Selectins are not constitutively expressed, and
are dependent on stimulation. For example, P-selectin is stored in Weible-Palade bodies of
endothelial cells and are rapidly expressed within minutes of stimulation [420,421]. E-selectins
can be stimulated by LPS and cytokines, including TNF-α and IL-1ß [422,423]. Selectins play an
important role in the immune response to infection. For example, host defense to systemic
Streptococcus pneumonia infection is impaired in E- and P-selectin deficient mice [317]. This
indicates that VE-cKO mice have an impaired immune response to CLP, and the lack of selectin
expression may reduce the recruitment of leukocytes to the site of infection.
3. Impact of Dissertation Findings
The bulk of this work aimed to identify a yet-unexplored role for TNAP in the GVB.
However, we have also added important information to the fields of sepsis and TNAP on the
relevance of (1) timing, (2) small intestine segment differences, (3) age, and (4) sexual
dimorphisms.
3.1. Importance of Temporal Differences in Disease Progression
In general, the pathophysiology of sepsis is considered as an initial hyperinflammatory
phase that lasts for several days followed by a longer immunosuppressive phase [20]. The
mortality distribution peaks in both the early phase, 2-4 days after sepsis induction, and again in
the later phase, 2-3 months after sepsis induction; this late phase mortality, which occurs at a
lower magnitude, continues over the next 3 years [424,425]. In sepsis, pathogens seek an
advantage by incapacitating various aspects of host immunity [426]. Sepsis-induced
immunosuppression occurs through several mechanisms, including apoptotic depletion of
immune cells, increased expression of negative costimulatory molecules, increased Treg cell
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expression, expression of programmed cell death (PD)-1 on CD4+ T cells, and cellular exhaustion
[21,427]. For our experiments, we included timepoints within the early stage of sepsis (24-48
hours), and at the transition phase between the hyperinflammatory and immunosuppressive
stages (7-8 days). This information allows us to speculate on the role of TNAP at these various
stages of sepsis, and if its depletion is more detrimental during the early or transition phase. Our
data in Chapter 3 shows that while TNAP is important early (24 hrs) in sepsis for maintaining
barrier permeability, it is also important at the transition stage (8 days) for reducing bacterial
burden.

3.2. Appreciation of Intestinal Segment Differences
To date, the little information described on TNAP within the intestine has primarily focused
on the colon. However, in Chapter 3, we were interested in elucidating the role of endothelial
TNAP within the various segments of the small intestine. As briefly described in the introduction,
the three segments of the small intestine differ in features and functionality. Peyer’s patches are
gut-associated lymphoid tissue located throughout the intestinal wall; these are populated with
immune cells that function as an organism’s intestinal surveillance center. The ileum is recorded
to have more, and larger, Peyer’s patches than the duodenum or jejunum in humans and rodents
[428–430]. Transcriptome analysis of rat Peyer’s patches showed gene expression varied by
intestinal location. Of the 12,300 genes that were highly expressed, 18.5% were significantly
different between the duodenum and ileum [429]. Kayisoglu et al. used human and murine GI
(corpus, pylorus, duodenum, jejunum, ileum, and colon) segment epithelial organoids to
demonstrate that there is extensive spatial organization of innate immune signaling components
along this axis. The organoids show expression profiles highly specific to their gastic, small
intestinal, or large intestinal origin, and these were species-dependent. For example, human
gastric epithelium was refractory to stimulation with LPS from the basal and apical sides, while
murine gastric TLR4 could sense LPS administered on either side of the barrier. Interestingly, a
large part of this organization is determined before birth and independent of exposure to
commensal gut microbiota [431]. However, commensal bacteria may be important in shaping the
enteric nervous system, as immunolabeling revealed abnormalities in the myenteric plexi of germfree mouse jejunum and ileum, but not duodenum. This was characterized by a decrease in nerve
density, a decrease in the number of neurons per ganglion, and an increase in the proportion of
myenteric nitrergic neurons. Jejunum and ileum of germ-free mice also had significantly
decreased frequency of amplitude of muscle contractions [432].
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While there is still a lot to elucidate in the differentiation of small intestine regional functions
amongst the epithelium and microbiota, even less is understood about the intestine GVB and how
this barrier may be influencing each of the small intestine segments and vice versa. In Chapter
3, our initial findings of significantly increased bacterial load in the duodenum and ileum, but not
the jejunum, of VE-cKO mice lead us to focus on comparing the duodenum and ileum more
closely. When optimizing the permeability protocol, we also observed a greater amount of
variability along the jejunum tissue and within groups, which led us to exclude that segment from
permeability analysis in the present study. Overall, while we observed several significant
differences within both segments, the majority of our important findings were in the ileum. The
VE-cKO ileum revealed significantly depleted relative selectin expression, reduced Claudin 5
expression, and greater permeability, compared to the duodenum. Understanding small intestine
regional differences will allow us to make more-targeted therapies for diseases that cause
regional-specific dysfunction.
3.3. Age of Study Population
More than 60% of sepsis diagnoses are made in patients aged ≥65 years, and the 65+
years population is expected to more than double by 2060 [433,434]. This age effect is likely due
to the decreased immune function that occurs with aging. Immunosenescence puts older adults
at risk of developing infections, as well as experiencing more severe and protracted infections
[435,436]. While the most common sources of infections in older adults are the respiratory and
genitourinary tracts, gastrointestinal infections are associated with the highest mortality in this
group [437–439]. Sepsis management in older adults follows the same guidelines as younger
adults [45]. Preclinical murine studies have shown that CLP-induced septic shock is more severe
in aged animals. This occurs through a number of mechanisms, including a dysregulated immune
response,

excessive

pulmonary

and

systemic

inflammation,

increased

coagulation,

proinflammatory alterations of the adipose tissue, gut apoptosis, and microvascular endothelial
dysfunction and exacerbation of oxidative stress [440–443]. Although it is clear that the majority
of sepsis patients are older adults, the majority of basic research has been conducted using young
animals [444]. This disconnect creates a disadvantage for the interpretation and relevance of
sepsis data. While 3 month-old mice are comparable to a person under 20 years of age, evidence
in lacking in the group aged 50+ years [444–447]. According to information on The Jackson
Laboratory website, mouse and human equivalent ages are as follows: an adult mouse aged 3-6
months is equivalent to a mature adult human aged 20-30 years old; an adult mouse aged 10-14
months is equivalent to a middle-aged adult human aged 38-47 years old; and an adult mouse
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aged 18-24 months is equivalent to a old-aged adult human aged 56-69 years old [448]. While
the adult mice used in Chapter 2 were young (2-4 months old), in the more advanced experiments
we performed in Chapter 3, we opted to include middle-aged mice (11-12 months old) for our
sepsis studies to better address this mismatch.
Aging increases susceptibility of brain ECs to injury or toxins [449]. Preclinical studies
utilizing plasma substitution therapies from aged mice into young mice have elucidated the impact
of aging on brain EC function and zonation of the cerebrovasculature [450,451]. While a clear role
for BMEC TNAP in aging is not well-understood, recent findings suggest that brain microvascular
TNAP protein, referred to as Alpl, is decreased in the hippocampus of aged mice (20 months old)
compared to young mice (3 months) [450]. Given the observation of increased TNAP protein in
aging, we examined whether brain microvascular TNAP activity is also increased with aging. Our
lab has also demonstrated that TNAP activity is increased in cerebral microvessels of the cortex,
striatum, and hippocampus (CA3 shown) in 14-month-old mice compared to 4-month-old mice.
These results suggest a dichotomy in brain microvascular TNAP function whereby TNAP activity
is decreased in acute injuries like sepsis and ischemic stroke, while TNAP activity is increased in
aging. The implications of the increased brain microvascular TNAP protein were further explored
in a new report, which showed that intraperitoneal injection of TNAPi, i.e., MLS-0038949, in aged
mice enhanced transcytosis of plasma proteins into the brain parenchyma [452]. To our
knowledge, these are the only studies that have investigated a functional role for brain
microvascular TNAP in aging. Importantly, transcriptomic profiling has shown that vessel
segments, i.e., arteries, capillaries, or venules, exhibit different changes in their transcriptomic
profiles during aging [450]. Overall, these findings emphasize the need to consider the impact of
zonation, differential functions of the vascular tree, and as well as regional differences when
studying EC TNAP function in normal health and in disease.
These brain EC results likely also occur in the EC of the gut, as age disproportionately
increases sepsis-induced apoptosis in the gut [453]. New studies have shown that
supplementation with IAP slows the effects of aging on the epithelial barrier [194,454]. The gut
microbiota is also impacted by age and sepsis. A study published this year demonstrated that
young adult mice generally maintain their microbiome stability 7 days after CLP + daily chronic
stress (induced by placing mice in weighted plexiglass animal restraint holders for two hours daily
starting the day after CLP) compared to old adult mice [455]. Louise McCullough and colleagues
have shown the importance of gut microbiota age in stroke, and have demonstrated that ischemic
stroke increases gut permeability and bacterial translocation, leading to sepsis in aged mice [456].
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3.4. Sexual Dimorphisms in Study Population
Clinical studies of septic patients show that female patients have better clinical outcome,
including reduced mortality and length of hospital, compared to male patients male [346,457]. A
small clinical study revealed that during endotoxemia, females had a more pronounced
proinflammatory innate immune response associated with less attenuation of norepinephrine
sensitivity [458]. Specifically, sexual dimorphism in susceptibility to Gram-negative sepsis has
been reported; women exhibit significantly less morbidity and mortality following E. coli
bacteremia despite similar exposure rates to men [459]. Zeng et al. showed that sex-hormonedriven innate antibodies facilitate the clearance of enteropathogenic E. coli from the bloodstream
by Kupffer cells in females [460]. A sexual dimorphism has also been observed within the small
intestine and gut microbiome, and these differences are evident at different stages of the lifespan
[461,462]. For example, P-glycoprotein expression of the GI tract of male and female rats is
influenced differentially by food [463]. Snipe and Costa reported no differences in intestine
permeability between male and eumenorrheic (regular menstruation) female endurance runners,
while IL-1b increased in males only post-exercise [464].
One of our most interesting observations in Chapter 3 was that VE-cKO female mice have
decreased survival post-sepsis compared to males (56% vs 100%). This led us to analyze male
and female 8-day results separately. However, we did not observe any effects of sex on
permeability, and therefore, combined males and females for analysis. In humans, serum AP
reference values vary by age and sex, and values typically range higher in males than females
[347]. TNAP is shown to play redundant roles to enzymes CD39 and CD73 in the conversion of
ATP to adenosine [297]. CD73 knockout female mice were revealed to show a reduced ability to
produce spontaneous adenosine compared to males. mRNA analysis revealed the adenosine
maintenance in males may be due to an upregulation of TNAP [465]. Relative expression of TNAP
protein from left ventricle myocardium tissue showed increased levels of TNAP in female mice
compared to males. However, TNAP activity was localized to the sarcoplasmic reticulum (SR)
and more visible in myocardium of males compared to females. In parallel, phospholamban, a
muscle-specific SR calcium-ATPase inhibitor, phosphorylation was reduced in male myocardium
compared to females after treatment with zinc acetate, suggesting TNAP has a role in
phosphorylation of calcium handling proteins, and this regulation is sex-dependent [466]. Our
results also suggest sex-dependent role for TNAP, but further analysis is needed to identify the
mechanism behind these differences. TNAP levels may be influenced by hormone levels. A study
published this year showed that mean serum AP levels were increased following orchiectomy
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(both testes removed) in rats, but reduced to control levels following testosterone and estrogen
replacement therapies [467].
3.5. Limitations
These studies have sought to identify a critical role for TNAP in the GVB, but also have
several limitations. Due to limited time and resources, we did not always analyze each intestine
segment for each assay. For example, the jejunum intestinal segment was excluded from the
permeability experiments because of the amount of variability within groups while optimizing the
assay. However, perhaps a more thorough analysis of the jejunal segment where the jejunum is
broken into 3-4 sections would be more informative. Given the differences that we’ve identified
with cytokine signaling and IgA production in VE-cKO vs Alplfl/fl animals, there is likely some
immune-related dysfunction occurring that requires intestinal cell-specific quantifying and
phenotyping. While we have identified some potential avenues for the basis of a protective role
for TNAP at the GVB, further investigation is required to elucidate the complete mechanisms.
Additionally, we showed that IP administration of TNAP pharmacological inhibitor, SBI-425, is not
informative for identification of TNAP’s role in the healthy brain, but may be used for analysis of
peripheral TNAP functions. Overall, these studies add positive data to the prospective use of
TNAP as a therapeutic in inflammatory conditions.
4. Next Steps: Emerging Insights and Future Directions
In this work, we demonstrated a protective role for TNAP in experimental sepsis, which is
primarily observed using genetically-modified mouse models. However, the specific mechanisms
through which this protection is elicited needs further clarification. Work from our lab, as well as
many others, have described a therapeutic role in inflammatory diseases via manipulation of
TNAP enzyme activity. We suggest two potential avenues for this protection include modification
of the immune response, and promotion of bacterial clearance. Additional questions that remain
include whether the increased levels of bacteria observed in VE-cKO mice were due to defects in
bacterial translocation or bacterial expansion within peripheral tissue to the intestine post-CLP.
Lastly, we have yet to answer if TNAP at the GVB and/or the microbiome can be targeted as a
potential therapeutic in sepsis.
4.1. Therapeutic Applications of Alkaline Phosphatase
Currently, there are no FDA-approved therapies for sepsis and the majority of treatments
focus on alleviating sepsis-associated symptoms, rather than targeting the disease. Therapeutic
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manipulation of AP is a viable option for a number of inflammatory diseases, including sepsis.
Preclinical and clinical trials targeting AP have shown promising results, and warrant further
investigation. Exogenous administration of AP has been shown to have beneficial effects on the
outcome of numerous inflammatory disorders in humans and animal models of the associated
disease, including sepsis [137,138,468,469], ulcerative colitis [141,470], necrotizing enterocolitis
[471], and multiple sclerosis [12]. These studies and a number of others which have shown
positive disease outcomes following AP administration are described in Table 4.1. Intravenous
administration of AP decreased plasma creatinine levels in patients with renal complications from
severe sepsis or septic shock [137,140]. Phase II clinical trials have already shown the benefits
of using bovine-derived intestinal AP in a subset of critically ill patients [137]. Administration of a
human recombinant AP (recAP) consisting of a placental/intestinal AP hybrid resulted in positive
phase I clinical trial outcome in a subset of septic patients [13,15], that is supported by effective
recAP therapeutic efficacy from preclinical models [142,472].
On the other hand, therapeutic inhibition of AP has been beneficial in other vascularrelated conditions, such as stroke. Research from Pratibha and colleagues suggests that
administration of AP inhibitors could be used to prevent cerebral ischemia in high-risk populations
[473]. TNAP inhibition has also been shown to reduce aortic calcification and prolong life in TNAPoverexpressing mice [154]. These examples showcase the multifactorial nature of inflammatory
diseases and how a greater understanding of the role of TNAP in each pathological state is
imperative for determining its use as a therapeutic. The ability to modulate TNAP activity easily
using inhibitors or through exogenous administration of the enzyme will also provide insights on
AP’s mechanism(s) of action in disease.
Table 4.1. Positive Therapeutic Outcomes in Preclinical and Clinical AP Studies
Type of AP
Therapy

Study
Population

Injury or Disease
Model

Mouse

LPS

PLAP

Mouse

LPS

IAP

Mouse & pig

LPS

IAP

Mouse

Sepsis

Outcome

Ref.

AP Administration
PLAP

PLAP administration improved
sepsis survival, possibly by
halting its’ development
PLAP treatment improved
survival and lowered NO levels
in septic mice
IAP administration attenuates
LPS toxicity up to 80%, resulting
in increased survival and inhibits
differentiation of white blood cell
and thrombocyte counts
IAP treatment reduced local and
systemic inflammatory
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[474]
[468]

[475]

[476]

responses, as well as distant
damage in the liver and lungs
Administration of IAP in fecal
peritonitis-induced septic shock
improved gas exchange,
decreased blood IL-6 levels, and
increased survival time
Infusion of IAP in severe sepsis
and septic shock patients
inhibits the upregulation of renal
iNOS, leading to reduction of
NO metabolite production and
attenuated tubular enzymuria,
resulting in overall improved
renal function

IAP

Sheep

Sepsis

IAP

Phase IIa
clinical trial

Sepsis

IAP

Randomized,
double-blind,
placebocontrolled
clinical study

Sepsis

IAP

Rat

Inflammatory
bowel disease

IAP

Open-label,
first-in-patient
exploratory trial

Ulcerative colitis

IAP

Rat

NEC

IAP

Mouse

Antibiotic
treatment

IAP

Mouse

Sepsis

IAP

Phase IIa
prospective
randomized,
double-blind,
placebocontrolled
clinical trial

IAP

Rat

IAP administration significantly
improved renal function in septic
patients
IAP treatment alleviates
epithelial layer damage
associated with DSS in rat
intestines
IAP administration was
associated with short-term
improvement in UC disease
activity
Supplemental IAP has a
protective role in experimental
NEC
IAP supplementation increased
growth of commensal bacteria
leading to restored gut
microbiota lost to antibiotic
treatment
IAP treatment enhanced survival
and reduced organ damage in
septic mice

[477]

[137]

[138]

[470]

[141]

[471]

[84]

[469]

Sepsis and AKI

Overall, IAP treatment improves
renal function in patients with
severe sepsis or sepsis shock
with AKI

[140]

Inflammatory
bowel disease

Intrarectally administered IAP in
models of rat colitis resulted in a
lower colonic weight and tissue
damage score; normalized
expression of neutrophil markers
and IL-1b; and counteracted
bacterial translocation

[201]
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IAP

Mouse

Multiple Sclerosis

IAP

Rat

NEC

IAP

Mouse

Metabolic
syndrome

IAP

Rat

NEC

IAP

Rat

NEC

IAP

Mouse

Antibioticassociated
infections

recAP

Rat

LPS

recAP

Rat

Renal ischemia
and reperfusion;
LPS

Pre-symptomatic treatment of
EAE with IAP reduces
neurological symptoms
IAP supplementation decreased
histologic injury scores and
barrier permeability in the ileum
of rat pups with NEC
IAP supplementation inhibited
absorption of endotoxins and
improved the lipid profile in
mice, resulting in prevention or
reversal of metabolic syndrome
IAP treatment decreased iNOS
and TNF-a expression, and
decreased LPS translocation
into the serum of infant rats
IAP supplementation decreased
intestinal injury and
inflammation, including TNF-a,
IL-6 and iNOS by LPS in
preterm rat intestine
Antibiotics+IAP oral
supplementation resulted in
weight maintenance, reduced
clinical severity, reduced gut
inflammation, and improved
survival following infection
recAP treatment has renal
protective effects from LPSinduced damage
recAP exerted a clear renal
protective anti-inflammatory
effect

[12]

[478]

[479]

[480]

[481]

[482]

[85]
[142]

AP Inhibition
Levamisole

Prospective
clinical trial

Colon cancer

L-Phen

Rat

LPS

SBI-425

Mouse

Medial vascular
calcification

SBI-425

Mouse

Hypophosphatasia

SBI-425

Mouse

Pseudoxanthoma
elasticum (PXE)
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The addition of levamisole to
5FU-adjuvant therapy improved
survival in stage II and III colon
cancer patients
Suggest that IAPs in the
gastrointestinal tract reduce LPS
content in serum
TNAP inhibition significantly
reduced aortic calcification and
cardiac hypertrophy, and
extended lifespan over vehicletreated controls
TNAP inhibition reduces calcium
and lipid levels to improve the
course of coronary
atherosclerosis
TNAP inhibition attenuated
calcification, altering disease
development and progression in
vivo

[483]

[484]

[154]

[156]

[485]

4.2. Insight into TNAP Mechanisms of Action: TNAP Modification of the Host Immune
System
Our earlier work in Chapter 2 examining the effect of a TNAP inhibitor on the splenic cell
immune response one week following sepsis-induction revealed T-cell impairment at that
timepoint. After determining that genetic manipulation of TNAP on endothelial cells would prove
more insightful for our studies, we observed several differential septic outcomes. In both animals
that over-express or have deleted endothelial TNAP, sepsis outcome was either improved or
reduced, respectively. However, immune cell quantification and phenotyping in these mice is not
an experiment that we have had the resources to perform so far. Flow cytometry of both the
immune cell populations, as well as their surface expression of alkaline phosphatase activity, will
be important to determine a more pronounced role for endothelial TNAP in the immune response
and its ability to allow for communication between cells. In Chapter 3, we observed that selectin
relative expression was impaired in VE-cKO ileum. We hypothesize that the reduced selectin
expression would modify the ability of leukocytes to participate in endothelial cell rolling in
inflammation, leading to impaired cellular recruitment to the site of infection during sepsis, as
shown in Figure 4.1.
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Figure 4.1. Proposed Mechanisms for TNAP Modification of the Host Immune Response
In Chapter 3, we observed that selectin relative expression was impaired in VE-cKO ileum. We
hypothesize that the reduced selectin expression would modify the ability of leukocytes to
participate in endothelial cell rolling in inflammation, leading to impaired cellular recruitment to the
site of infection during sepsis. This reduced recruitment of cells may include phagocytic cells,
which are responsible for the uptake of bacteria and debris in the tissue and blood. If the number
of phagocytic cells is reduced in the intestine tissue, bacterial burden would be increased for a
prolonged amount of time.
4.3. Does TNAP Activity Regulate Bacterial Clearance?
In Chapter 3, we observed increased levels of bacteria in VE-cKO mice at 8 days post
CLP, but no differences in early sepsis compared to Alplfl/fl controls. This indicates to us that there
may be a delayed or impaired ability for VE-cKO mice to rid themselves of the infection. To
determine a role for endothelial TNAP on bacterial clearance, functional assays should be
employed with the consideration of several factors. For example, is the late-term elevation in
bacteria post-CLP due to reduced membrane-bound TNAP activity, reduced soluble TNAP
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activity, or both? APs have been shown to have a general anti-inflammatory effect through the
detoxification of LPS, which impairs its ability to bind TLR4 [486,487]. In our VE-cKO septic mice,
it is not clear whether their impaired ability to clear bacteria is due to the inability to recruit cells to
the site of infection, or a more general defect in the function in those immune cells brought on by
improper cell signaling. In sepsis, phagocytic cells of the innate immune response, including
monocytes and neutrophils, initiate bacterial clearance [488]. Phagocytosis is a prime cellular
mechanism crucial for the elimination of pathogen and damaged or infected cells. During this
process, material >0.5 µm are recognized via surface receptors and engulfed by the phagocytic
cell within a vesicle, called the phagosome. Once fully internalized, the phagosome fuses with the
lysosome to digest its contents [489–491]. Phagocytosis has four main steps: (1) activation, (2)
chemotaxis, (3) attachment, and (4) ingestion [492]. In sepsis, some pathogens have developed
methods to block phagocytic activity [493–495], and reduced phagocytosis has been associated
with worse sepsis outcome. For example, one study showed that murine knock-out of CD11b, a
component of the CR3 integrin receptor commonly expressed on macrophages, resulted in
increased bacterial load, systemic inflammation, and splenic apoptosis compared to controls
[496]. However, a contrasting study observed that sepsis response was improved by blocking
phagocytic receptors and thereby preventing intracellular bacterial proliferation [497]. IgA immune
complexes are formed to promote the opsonization of pathogens, and also influence the
generation of ROS and NETosis [498,499]. Therefore, the reduced levels of IgA observed in VEcKO ileum tissue may lead to reduced IgA-promoted uptake of pathogenic bacteria.
In sepsis, the presence of systemic pathogens and enhanced inflammatory cytokine
responses result in changes in leukocyte proportions in the bloodstream [500]. In the blood,
neutrophils are the most common phagocytic cells, accounting for 60–80% of leukocytes, and
their production can increase up to 10-fold during infection [501,502]. Preclinical and clinical
models of lethal sepsis have shown that bacterial and pro-inflammatory signals can induce rigidity
of the neutrophil membrane and reduce its ability to migrate into the inflamed tissue [503–505].
To decipher which immune cells in VE-cKO mice may have an impaired response to sepsis,
isolation of various phagocytic cell types should be employed, and their ability to uptake bacteria
should be observed.
4.4. Does Endothelial TNAP Modify Bacterial Translocation or Expansion?
The effect of sepsis on the microbiota extends beyond the intestine, and can influence
additional microbiota environments, including those of the skin and lungs [170]. While we have
established a basis for increased intestinal permeability in VE-cKO mice in early (24 hours) and
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late (8 days) sepsis, we have not directly determined whether the increased lung bacterial burden
at 8 days post-CLP is due to bacterial translocation or expansion. Our lab is currently optimizing
methods that can be used to answer this question. We have obtained a luminescent E. coli that
we plan to orally gavage into VE-cKO and control animals and monitor the movement of the
luminescent bacteria in real-time using the In Vivo Imaging System (IVIS). Unfortunately, this
system requires high levels of luminescence in order to be detected by the device and maintaining
these levels has been challenging.
4.5. GVB TNAP Manipulation of the Gut Microbiome
Our results indicate that deletion of endothelial TNAP has enhanced gut dysbiosis,
including further reducing the F:B ratio, expression of SCFAs, and modulating production of IgA
and cytokine responses. In order to determine if differences in the microbiome composition or its
components between VE-cKO and control mice directly affected our sepsis outcomes, we would
need to use microbiome manipulating techniques, such as use of antibiotics, prebiotics or
probiotics, and fecal microbiota transplants following infection. For example, recolonization of
murine gut microbiota following influenza infection decreased the inflammatory response,
including promotion to an anti-inflammatory phenotype [506].
5. Summary
In conclusion, this body of work has sought to answer several important questions within
the scientific community on the role of TNAP at the GVB in sepsis. Our results have shown that
endothelial TNAP is protective from sepsis via two potential mechanisms: (1) decreasing bacterial
burden and gut dysbiosis by 8 days post-CLP, and (2) decreasing intestinal permeability at 24
hours post-CLP. Regardless of the TNAP-related findings, this work has also contributed valuable
information to the cross-sections of age, sex, sepsis timing, and small intestinal region specificity.
These studies further validate the potential use of TNAP as a therapeutic in inflammatory disease.
Nevertheless, further investigation is crucial to identify the specific mechanisms and pathways in
which TNAP acts at the GVB.
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